US20090164239A1 - Dynamic Display Of Glucose Information - Google Patents

Dynamic Display Of Glucose Information Download PDF

Info

Publication number
US20090164239A1
US20090164239A1 US12/242,799 US24279908A US2009164239A1 US 20090164239 A1 US20090164239 A1 US 20090164239A1 US 24279908 A US24279908 A US 24279908A US 2009164239 A1 US2009164239 A1 US 2009164239A1
Authority
US
United States
Prior art keywords
profile
representation
physiological
treatment parameter
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/242,799
Inventor
Gary Hayter
Timothy Christian Dunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Diabetes Care Inc
Original Assignee
Abbott Diabetes Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/024,082 external-priority patent/US20090164251A1/en
Application filed by Abbott Diabetes Care Inc filed Critical Abbott Diabetes Care Inc
Priority to US12/242,799 priority Critical patent/US20090164239A1/en
Assigned to ABBOTT DIABETES CARE, INC. reassignment ABBOTT DIABETES CARE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DUNN, TIMOTHY CHRISTIAN, HAYTER, GARY
Publication of US20090164239A1 publication Critical patent/US20090164239A1/en
Priority to PCT/US2009/058894 priority patent/WO2010039743A1/en
Priority to US14/981,863 priority patent/US10685749B2/en
Priority to US15/468,156 priority patent/US11749410B2/en
Priority to US18/156,212 priority patent/US20230154625A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/01Input arrangements or combined input and output arrangements for interaction between user and computer
    • G06F3/048Interaction techniques based on graphical user interfaces [GUI]
    • G06F3/0484Interaction techniques based on graphical user interfaces [GUI] for the control of specific functions or operations, e.g. selecting or manipulating an object, an image or a displayed text element, setting a parameter value or selecting a range
    • G06F3/04847Interaction techniques to control parameter settings, e.g. interaction with sliders or dials
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/60ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W4/00Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/80Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M2005/14208Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/18General characteristics of the apparatus with alarm
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3576Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3584Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502User interfaces, e.g. screens or keyboards
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/005Parameter used as control input for the apparatus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/20Blood composition characteristics
    • A61M2230/201Glucose concentration
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F2218/00Aspects of pattern recognition specially adapted for signal processing
    • G06F2218/12Classification; Matching
    • G06F2218/16Classification; Matching by matching signal segments

Definitions

  • Analyte e.g., glucose
  • monitoring systems including continuous and discrete monitoring systems generally include a small, lightweight battery powered and microprocessor controlled system which is configured to detect signals proportional to the corresponding measured glucose levels using an electrometer, and RF signals to transmit the collected data.
  • One aspect of certain analyte monitoring systems include a transcutaneous or subcutaneous analyte sensor configuration which is, for example, partially mounted on the skin of a subject whose analyte level is to be monitored.
  • the sensor cell may use a two or three-electrode (work, reference and counter electrodes) configuration driven by a controlled potential (potentiostat) analog circuit connected through a contact system.
  • external infusion devices typically include an input mechanism such as buttons through which the patient may program and control the infusion device.
  • Such infusion devices also typically include a user interface such as a display which is configured to display information relevant to the patient's infusion progress, status of the various components of the infusion device, as well as other programmable information such as patient specific basal profiles.
  • data associated with a patient's physiological condition such as monitored analyte levels, insulin dosage information, for example, may be stored and processed.
  • data associated with a patient's physiological condition such as monitored analyte levels, insulin dosage information, for example, may be stored and processed.
  • method system including displaying a first representation of a medication treatment parameter profile, displaying a first representation of a physiological profile associated with the medication treatment parameter profile, detecting a modification to a segment of the medication treatment parameter profile, displaying a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modifying an attribute of the first representation of the medication treatment parameter profile, and modifying an attribute of the first representation of the physiological profile are provided.
  • FIG. 1 is a block diagram illustrating a therapy management system for practicing one embodiment of the present disclosure
  • FIG. 2 is a block diagram of a fluid delivery device of FIG. 1 in one embodiment of the present disclosure
  • FIG. 3 is a flow chart illustrating therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure
  • FIG. 4 is a flowchart illustrating analyte trend information updating procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure
  • FIG. 5 is a flowchart illustrating modified therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure
  • FIG. 6 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment of the present disclosure
  • FIG. 7 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment of the present disclosure.
  • FIG. 8 illustrates dynamic medication level determination in accordance with one embodiment of the present disclosure
  • FIG. 9 illustrates dynamic medication level determination in accordance with another embodiment of the present disclosure.
  • FIG. 10 illustrates metric analysis in accordance with one embodiment of the present disclosure
  • FIG. 11 illustrates metric analysis in accordance with another embodiment of the present disclosure
  • FIG. 12 is illustrates metric analysis in accordance with yet another embodiment of the present disclosure.
  • FIG. 13 illustrates metric analysis in accordance with a further embodiment of the present disclosure
  • FIG. 14 illustrates condition detection or notification analysis in accordance with one embodiment of the present disclosure
  • FIG. 15 illustrates condition detection or notification analysis in accordance with another embodiment of the present disclosure
  • FIG. 16 illustrates therapy parameter analysis in accordance with one embodiment of the present disclosure
  • FIG. 17 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with one embodiment of the present disclosure.
  • FIG. 18 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with another embodiment of the present disclosure.
  • FIG. 19 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with still another embodiment of the present disclosure.
  • FIG. 20 is a flowchart illustrating visual medication delivery profile programming in accordance with one embodiment of the present disclosure
  • FIG. 21 is a flowchart illustrating visual medication delivery profile programming in accordance with another embodiment of the present disclosure.
  • FIG. 22 is an exemplary screen display of a medication delivery profile
  • FIG. 23 is an exemplary screen display illustrating vertical modification of the medication delivery profile
  • FIG. 24 is an exemplary screen display illustrating horizontal modification of the medication delivery profile
  • FIG. 25 is an exemplary screen display illustrating addition of a transition in the medication delivery profile
  • FIG. 26 is an exemplary screen display illustrating deletion of a transition in the medication delivery profile
  • FIG. 27 is an exemplary display illustrating an initial glucose level and a corresponding parameter value as a function of time in one embodiment
  • FIG. 28 is an exemplary display illustrating response to the manipulation of the initial parameter value of FIG. 27 and corresponding modification to the displayed glucose profile as a function of time in one embodiment
  • FIG. 29 is an exemplary display illustrating response to the manipulation of the initial parameter value of FIG. 27 and corresponding modification to the displayed glucose profile as a function of time in another embodiment.
  • FIG. 1 is a block diagram illustrating an insulin therapy management system for practicing one embodiment of the present disclosure.
  • the therapy management system 100 includes an analyte monitoring system 110 operatively coupled to an fluid delivery device 120 , which may be in turn, operatively coupled to a remote terminal 140 .
  • the analyte monitoring system 110 is, in one embodiment, coupled to the patient 130 so as to monitor or measure the analyte levels of the patient.
  • the fluid delivery device 120 is coupled to the patient using, for example, and infusion set and tubing connected to a cannula (not shown) that is placed transcutaneously through the skin of the patient so as to infuse medication such as, for example, insulin, to the patient.
  • the analyte monitoring system 110 may include one or more analyte sensors subcutaneously positioned such that at least a portion of the analyte sensors are maintained in fluid contact with the patient's analytes.
  • the analyte sensors may include, but not limited to short term subcutaneous analyte sensors or transdermal analyte sensors, for example, which are configured to detect analyte levels of a patient over a predetermined time period, and after which, a replacement of the sensors is necessary.
  • the one or more analyte sensors of the analyte monitoring system 110 is coupled to a respective one or more of a data transmitter unit which is configured to receive one or more signals from the respective analyte sensors corresponding to the detected analyte levels of the patient, and to transmit the information corresponding to the detected analyte levels to a receiver device, and/or fluid delivery device 120 . That is, over a communication link, the transmitter units may be configured to transmit data associated with the detected analyte levels periodically, and/or intermittently and repeatedly to one or more other devices such as the insulin delivery device and/or the remote terminal 140 for further data processing and analysis.
  • the transmitter units of the analyte monitoring system 110 may in one embodiment configured to transmit the analyte related data substantially in real time to the fluid delivery device 120 and/or the remote terminal 140 after receiving it from the corresponding analyte sensors such that the analyte level such as glucose level of the patient 130 may be monitored in real time.
  • the analyte levels of the patient may be obtained using one or more of a discrete blood glucose testing devices such as blood glucose meters, or a continuous analyte monitoring systems such as continuous glucose monitoring systems.
  • Additional analytes that may be monitored, determined or detected the analyte monitoring system 110 include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin.
  • concentration of drugs such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be determined.
  • the transmitter units of the analyte monitoring system 110 may be configured to directly communicate with one or more of the remote terminal 140 or the fluid delivery device 120 .
  • additional devices may be provided for communication in the analyte monitoring system 110 including additional receiver/data processing unit, remote terminals, such as a physician's terminal and/or a bedside terminal in a hospital environment, for example.
  • one or more of the analyte monitoring system 110 , the fluid delivery device 120 and the remote terminal 140 may be configured to communicate over a wireless data communication link such as, but not limited to RF communication link, Bluetooth communication link, infrared communication link, or any other type of suitable wireless communication connection between two or more electronic devices, which may further be unidirectional or bi-directional communication between the two or more devices.
  • the data communication link may include wired cable connection such as, for example, but not limited to RS232 connection, USB connection, or serial cable connection.
  • the analyte monitoring system 100 includes a strip port configured to receive a test strip for capillary blood glucose testing.
  • the glucose level measured using the test strip may in addition, be configured to provide periodic calibration of the analyte sensors of the analyte monitoring system 110 to assure and improve the accuracy of the analyte levels detected by the analyte sensors.
  • the fluid delivery device 120 may include in one embodiment, but not limited to, an external infusion device such as an external insulin infusion pump, an implantable pump, a pen-type insulin injector device, an on-body patch pump, an inhalable infusion device for nasal insulin delivery, or any other type of suitable delivery system.
  • the remote terminal 140 in one embodiment may include for example, a desktop computer terminal, a data communication enabled kiosk, a laptop computer, a handheld computing device such as a personal digital assistant (PDAs), or a data communication enabled mobile telephone.
  • PDAs personal digital assistant
  • FIG. 2 is a block diagram of an insulin delivery device of FIG. 1 in one embodiment of the present disclosure.
  • the fluid delivery device 120 in one embodiment includes a processor 210 operatively coupled to a memory unit 240 , an input unit 220 , a display unit 230 , an output unit 260 , and a fluid delivery unit 250 .
  • the processor 210 includes a microprocessor that is configured to and capable of controlling the functions of the fluid delivery device 120 by controlling and/or accessing each of the various components of the fluid delivery device 120 .
  • multiple processors may be provided as safety measure and to provide redundancy in case of a single processor failure.
  • processing capabilities may be shared between multiple processor units within the insulin delivery device 120 such that pump functions and/or control maybe performed faster and more accurately.
  • the input unit 220 operatively coupled to the processor 210 may include a jog dial, a key pad buttons, a touch pad screen, or any other suitable input mechanism for providing input commands to the fluid delivery device 120 . More specifically, in case of a jog dial input device, or a touch pad screen, for example, the patient or user of the fluid delivery device 120 will manipulate the respective jog dial or touch pad in conjunction with the display unit 230 which performs as both a data input and output units.
  • the display unit 230 may include a touch sensitive screen, an LCD screen, or any other types of suitable display unit for the fluid delivery device 120 that is configured to display alphanumeric data as well as pictorial information such as icons associated with one or more predefined states of the fluid delivery device 120 , or graphical representation of data such as trend charts and graphs associated with the insulin infusion rates, trend data of monitored glucose levels over a period of time, or textual notification to the patients.
  • the output unit 260 operatively coupled to the processor 210 may include audible alarm including one or more tones and/or preprogrammed or programmable tunes or audio clips, or vibratory alert features having one or more pre-programmed or programmable vibratory alert levels.
  • the vibratory alert may also assist in priming the infusion tubing to minimize the potential for air or other undesirable material in the infusion tubing. Also shown in FIG.
  • the fluid delivery unit 250 which is operatively coupled to the processor 210 and configured to deliver the insulin doses or amounts to the patient from the insulin reservoir or any other types of suitable containment for insulin to be delivered (not shown) in the fluid delivery device 120 via an infusion set coupled to a subcutaneously positioned cannula under the skin of the patient.
  • the memory unit 240 may include one or more of a random access memory (RAM), read only memory (ROM), or any other types of data storage units that is configured to store data as well as program instructions for access by the processor 210 and execution to control the fluid delivery device 120 and/or to perform data processing based on data received from the analyte monitoring system 110 , the remote terminal 140 , the patient 130 or any other data input source.
  • RAM random access memory
  • ROM read only memory
  • data storage units that is configured to store data as well as program instructions for access by the processor 210 and execution to control the fluid delivery device 120 and/or to perform data processing based on data received from the analyte monitoring system 110 , the remote terminal 140 , the patient 130 or any other data input source.
  • FIG. 3 is a flow chart illustrating insulin therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure.
  • a predetermined number of consecutive glucose levels are received or detected over a predetermined or defined time period.
  • the monitored glucose levels of a patient is substantially continuously received or detected substantially in real time for a predetermined time period.
  • the predefined time period may include one or more time periods, the data within which may provide a therapeutically meaningful basis for associated data analysis.
  • the predefined time period of the real time monitored glucose data in one embodiment may include one or more time periods sufficient to provide glucose trend information or sufficient to provide analysis of glucose levels to adjust insulin therapy on an on-going, and substantially real time basis.
  • the predefined time period in one embodiment may include one or more of a 15 minute time period, a 30 minute time period, a 45 minute time period, a one hour time period, a two hour time period and a 6 hour time period. While exemplary predefined time periods are provided herein, within the scope of the present disclosure, any suitable predefined time period may be employed as may be sufficient to be used for glucose trend determination and/or therapy related determinations (such as, for example, modification of existing basal profiles, calculation of temporary basal profile, or determination of a bolus amount).
  • the consecutive glucose levels received over the predefined time period in one embodiment may not be entirely consecutive due to, for example, data transmission errors and/or one or more of potential failure modes associated with data transmission or processing.
  • a predetermined margin of error for the received real time glucose data such that, a given number of data points associated with glucose levels which are erroneous or alternatively, not received from the glucose sensor, may be ignored or discarded.
  • the glucose trend information based on the received glucose levels is updated.
  • the glucose trend information estimating the rate of change of the glucose levels may be determined, and based upon which the projecting the level of glucose may be calculated.
  • the glucose trend information may be configured to provide extrapolated glucose level information associated with the glucose level movement based on the real time glucose data received from the glucose sensor. That is, in one embodiment, the real time glucose levels monitored are used to determine the rate at which the glucose levels is either increasing or decreasing (or remaining substantially stable at a given level). Based on such information and over a predetermined time period, a glucose projected information may be determined.
  • the therapy related parameters associated with the monitored real time glucose levels is updated. That is, in one embodiment, one or more insulin therapy related parameters of an insulin pump such as including, but not limited to, insulin on board information associated with the fluid delivery device 120 ( FIG. 1 ), insulin sensitivity level of the patient 130 ( FIG. 1 ), insulin to carbohydrate ratio, and insulin absorption rate. Thereafter, in one embodiment, one or more modifications to the current therapy profile are determined. That is, in one embodiment of the present disclosure, one or more current basal profiles, calculated bolus levels, temporary basal profiles, and/or any other suitable pre-programmed insulin delivery profiles stored in the fluid delivery device 120 ( FIG. 1 ) for example, are retrieved and analyzed based on one or more of the received real time glucose levels, the updated glucose trend information, and the updated therapy related parameters.
  • insulin therapy related parameters of an insulin pump such as including, but not limited to, insulin on board information associated with the fluid delivery device 120 ( FIG. 1 ), insulin sensitivity level of the patient 130 ( FIG. 1 ), insulin to carbohydrate ratio
  • the modified one or more therapy profiles is generated and output to the patient 130 ( FIG. 1 ) so that the patient 130 may select, store and/or ignore the one or more modified therapy profiles based on one or more of the monitored real time glucose values, updated glucose trend information, and updated therapy related parameters.
  • the patient 130 may be provided with a recommended temporary basal profile based on the monitored real time glucose levels over a predetermined time period as well as the current basal profile which is executed by the fluid delivery device 120 ( FIG. 1 ) to deliver a predetermined level of insulin to the patient 130 ( FIG. 1 ).
  • the patient 130 in a further embodiment may be provided with one or more additional recommended actions for selection as the patient sees suitable to enhance the insulin therapy based on the real time monitored glucose levels.
  • the patient may be provided with a recommended correction bolus level based on the real time monitored glucose levels and the current basal profile in conjunction with, for example, the patient's insulin sensitivity and/or insulin on board information.
  • the patient may be provided with an on-going, real time insulin therapy options and modifications to the pre-programmed insulin delivery basal profiles so as to improve upon the initially programmed therapy profiles based on the monitored real time glucose data.
  • FIG. 4 is a flowchart illustrating analyte trend information updating procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure.
  • real time data associated with monitored analyte levels is received. Thereafter it is determined whether the real time data has been received for a predetermined time period. If it is determined that the real time data has not been received for at least the predetermined time period, then the routine continues to receive the real time data associated with the monitored analyte levels such as glucose levels.
  • the received real time data associated with the monitored analyte levels is stored. Thereafter, analyte level trend information is determined based on the received real time data associated with the monitored analyte levels.
  • the real time data associated with the monitored analyte levels is analyzed and an extrapolation of the data based on the rate of change of the monitored analyte levels is determined. That is, the real time data associated with the monitored analyte levels is used to determined the rate at which the monitored analyte level changed over the predetermined time period, and accordingly, a trend information is determined based on, for example, the determined rate at which the monitored analyte level changed over the predetermined time period.
  • the trend information based on the real time data associated with the monitored analyte levels may be dynamically modified and continuously updated based on the received real time data associated with the monitored analyte levels for one or more predetermined time periods.
  • the trend information may be configured to dynamically change and be updated continuously based on the received real time data associated with the monitored analyte levels.
  • FIG. 5 is a flowchart illustrating modified therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure.
  • the current therapy parameters are retrieved and, the retrieved current therapy parameters are analyzed based on the received real time data associated with the monitored analyte levels and/or updated analyte trend information.
  • one or more preprogrammed basal profiles, correction bolus, carbohydrate bolus, temporary basal and associated parameters are retrieved and analyzed based on, for example, the received real time data associated with the monitored analyte levels and/or updated analyte trend information, and further, factoring in the insulin sensitivity of the patient as well as insulin on board information.
  • one or more modified therapy profiles are calculated. That is, based upon the real time glucose levels monitored by the analyte monitoring system 110 ( FIG. 1 ), a modification or adjustment to the pre-programmed basal profiles of the fluid delivery device 120 ( FIG. 1 ) may be determined, and the modified therapy profiles is output to the patient 130 ( FIG. 1 ). That is, the modification or adjustment to the pre-programmed basal profiles may be provided to the patient for review and/or execution to implement the recommended modification or adjustment to the pre-programmed basal profiles.
  • the patient may be provided with one or more adjustments to the existing or current basal profiles or any other pre-programmed therapy profiles based on continuously monitored physiological levels of the patient such as analyte levels of the patient.
  • continuously monitored glucose levels of the patient modification or adjustment to the pre-programmed basal profiles may be calculated and provided to the patient for review and implementation as desired by the patient.
  • a diabetic patient may improve the insulin therapy management and control.
  • FIG. 6 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment of the present disclosure.
  • one or more user input parameters is received such as, for example, the amount of carbohydrate to ingest, type of exercise to perform, current time of day information, or any other appropriate information that may potentially impact the determination of the suitable medication level.
  • one or more database is queried.
  • the database may be provided in the analyte monitoring system 110 .
  • the one or more database may be provided in the fluid delivery device 120 and/or remote terminal 140 .
  • the database query in one embodiment may be configured to search or query for medication dosage levels that are associated with similar parameters as the received one or more user input parameters. Thereafter, the queried result is generated and provided to the user which may be acted upon by the user, for example, to administer the medication dosage level based on the queried result.
  • the user selection of the administered medication dosage level is stored in the database with the associated one or more user input parameters as well as the time and date information of when the user has administered the medication dosage level.
  • insulin dosages and associated contextual information may be stored and tracked in one or more databases.
  • a bolus amount for a diabetic patient may be determined in the manner described above using historical information without performing a mathematical calculation which takes into account of variables such as sensitivity factors vary with time and/or user's physiological conditions, and which may need to be estimated.
  • insulin dependent users may determine their appropriate insulin dosages by, for example, using historical dosage information as well as associated physiological condition information.
  • the historical data may be stored in one or more databases to allow search or query based on one or more parameters such as the user's physiological condition and other contextual information associated with each prior bolus dosage calculated and administered.
  • the user may be advised on the proper amount of insulin under the particular circumstances, the user may be provided with descriptive statistical information of insulin dosages under the various conditions, and the overall system may be configured to learn and customize the dosage determination for the particular user over an extended time period.
  • contextual information may be stored with the insulin bolus value.
  • the contextual data in one aspect may include one or more of blood glucose concentration, basal rate, type of insulin, exercise information, meal information, carbohydrate content estimate, insulin on board information, and any other parameters that may be used to determine the suitable or appropriate medication dosage level.
  • Some or all of the contextual information may be provided by the user or may be received from another device or devices in the overall therapy management system such as receiving the basal rate information from the fluid delivery device 120 ( FIG. 1 ), or receiving the blood glucose concentration from the analyte monitoring system 110 ( FIG. 1 ).
  • a contextually determined medication dosage level in one embodiment may be provided to the user along with a suitable or appropriate notification or message to the user that after a predetermined time period since the prior administration of the medication dosage level, the blood glucose level was still above a target level. That is, the queried result providing the suitable medication dosage level based on user input or other input parameters may be accompanied by other relevant physiological condition information associated with the administration of the prior medication dosage administration.
  • the user when the user is provided with the contextually determined medication dosage level, the user is further provided with information associated with the effects of the determined medication dosage level to the user's physiological condition (for example, one hour after the administration of the particular medication dosage level determined, the user's blood glucose level changed by a given amount). Accordingly, the user may be better able to adjust or modify, as desired or needed, the contextually determined medication dosage level to the current physiological conditions.
  • the present or current context including the patient's current physiological condition (such as current blood glucose level, current glucose trend information, insulin on board information, the current basal profile, and so on) is considered and the database is queried for one or more medication dosage levels which correlate (for example, within a predetermined range of closeness or similarity) to the one or more current contextual information associated with the user's physiological condition, among others.
  • the patient's current physiological condition such as current blood glucose level, current glucose trend information, insulin on board information, the current basal profile, and so on
  • the database is queried for one or more medication dosage levels which correlate (for example, within a predetermined range of closeness or similarity) to the one or more current contextual information associated with the user's physiological condition, among others.
  • statistical determination of the suitable medication dosage based on contextual information may be determined using, one or more of mean dosage determination, using a standard deviation or other appropriate statistical analysis of the contextual information for medication dosages which the user has administered in the past. Further, in one aspect, in the case where no close match is found in the contextual query for the desired medication dosage level, the medication dosage level with the most similar contextual information may be used to interpolate an estimated medication dosage level.
  • the database query may be configured to provide time based weighing of prior medication dosage level determinations such that, for example, more recent dosage level determination which similar contextual information may be weighed heavier than aged dosage level determination under similar conditions. For example, older or more aged bolus amounts determined may be weighed less heavily than the more recent bolus amounts. Also, over an extended period of time, in one aspect, the older or aged bolus amounts may be aged out or weighed with a value parameter that minimally impacts the current contextual based bolus determination. In this manner, in one aspect, a highly personalized and individualistic profile for medication dosage determination may be developed and stored in the database with the corresponding contextual information associated therewith.
  • FIG. 7 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment.
  • the current infusion profile of the user's insulin pump is determined at step 720 .
  • the database is queried based on the input parameters and the current infusion profile at step 730 , and which results in one or more contextually determined bolus amount associated with the input parameters and the current infusion profile at step 740 that is provided to the user.
  • the determined bolus amount is then stored in the database with the associated input parameters and the current infusion profile and any other contextual information associated with the determined bolus amount.
  • other relevant contextual information may be retrieved (for example, the current infusion profile such as basal rate from the insulin pump, the current blood glucose level and/or glucose trend information from the analyte monitoring system, and the like) prior to the database query to determine the suitable bolus amount.
  • the current infusion profile such as basal rate from the insulin pump, the current blood glucose level and/or glucose trend information from the analyte monitoring system, and the like
  • the contextual information including the user input parameters and other relevant information may be queried to determine the suitable medication dosage level based on one or more statistical analysis such as, for example, but not limited to, descriptive statistics with the use of numerical descriptors such as mean and standard deviation, or inferential statistics including, for example, estimation or forecasting, correlation of parameters, modeling of relationships between parameters (for example, regression), as well as other modeling approaches such as time series analysis (for example, autoregressive modeling, integrated modeling and moving average modeling), data mining, and probability.
  • descriptive statistics with the use of numerical descriptors such as mean and standard deviation
  • inferential statistics including, for example, estimation or forecasting, correlation of parameters, modeling of relationships between parameters (for example, regression), as well as other modeling approaches such as time series analysis (for example, autoregressive modeling, integrated modeling and moving average modeling), data mining, and probability.
  • the patient when a diabetic patient plans to ingest insulin of a particular type, the patient enters contextual information such as that the patient has moderately exercised and is planning to consume a meal with a predetermined estimated carbohydrate content.
  • the database in one embodiment may be queried for insulin dosages determined under similar circumstances in the past for the patient, and further, statistical information associated with the determined insulin dosage is provided to the user.
  • the displayed statistical information associated with the determined insulin dosage may include, for example, an average amount of insulin dosage, a standard deviation or a median amount and the 25 th and the 75 th percentile values of the determined insulin dosage.
  • the patient may consider the displayed statistical information associated with the determined insulin dosage, and determines the most suitable or desired insulin amount based on the information received.
  • the patient programs the insulin pump to administer the desired insulin amount (or otherwise administer the desired insulin amount using other medication administration procedures such as injection (using a pen-type injection device or a syringe), intaking inhalable or ingestable insulin, and the like, the administered dosage level is stored in the database along with the associated contextual information and parameters.
  • the database for use in the contextual based query may be continuously updated with each administration of the insulin dosage such that, each subsequent determination of appropriate insulin dosage level may be determined with more accuracy and is further customized to the physiological profile of the particular patient.
  • the database queried may be used for other purposes, such as, for example, but not limited to tracking medication information, providing electronic history of the patient related medical information, and the like.
  • other medication dosage may be determined based on the contextual based database query approaches described herein.
  • the contextual based medication dosage query and determination may be used in conjunction with the standard or available medication dosage determination (for example, standard bolus calculation algorithms) as a supplement to provide additional information or provide a double checking ability to insure that the estimated or calculated bolus or medication dosage level is appropriate for the particular patient under the physiological condition at the time of the dosage level determination.
  • standard or available medication dosage determination for example, standard bolus calculation algorithms
  • the processes and routines described in conjunction with FIGS. 3-7 may be performed by the analyte monitoring system 110 ( FIG. 1 ) and/or the fluid delivery device 120 ( FIG. 1 ).
  • the output of information associated with the context based database query for medication dosage determination may be displayed on a display unit of the receiver of the analyte monitoring system 110 ( FIG. 1 ), or the infusion device display of the fluid delivery device 120 ( FIG. 1 ), the display unit of the remote terminal 140 ( FIG. 1 ), or any other suitable output device that is configured to receive the results of the database query associated with the medication dosage level determination.
  • one or more such information may be output to the patient audibly as sound signal output.
  • statistical analysis may be performed based on the database query and factored into generating the medication dosage amount for the user.
  • analyte e.g., glucose
  • bolus or basal rate change recommendations for comparing expected glucose level changes to actual real time glucose level changes to update, for example, insulin sensitivity factor in an ongoing basis, and for automatically confirming the monitored glucose values within a preset time period (e.g., 30 minutes) after insulin therapy initiation to determine whether the initiated therapy is having the intended therapeutic effect.
  • glucose trend information in insulin delivery rate determinations provides for a more accurate insulin dosing and may lead to a decrease in hypoglycemic events and improved HbAlCs.
  • a method in one embodiment of the present disclosure includes receiving data associated with monitored analyte related levels for a predetermined time period substantially in real time, retrieving one or more therapy profiles associated with the monitored analyte related levels, generating one or more modifications to the retrieved one or more therapy profiles based on the data associated with the monitored analyte related levels.
  • the method may further include displaying the generated one or more modifications to the retrieved one or more therapy profiles.
  • the generated one or more modifications to the retrieved one or more therapy profiles may be displayed as one or more of an alphanumeric output display, a graphical output display, an icon display, a video output display, a color display or an illumination display.
  • the predetermined time period may include one of a time period between 15 minutes and six hours.
  • the one or more therapy profiles in yet another aspect may include a basal profile, a correction bolus, a temporary basal profile, an insulin sensitivity, an insulin on board level, and an insulin absorption rate.
  • retrieving the one or more therapy profiles associated with the monitored analyte related levels may include retrieving a current analyte rate of change information.
  • generating the one or more modifications to the retrieved one or more therapy profiles may include determining a modified analyte rate of change information based on the received data associated with monitored analyte related levels.
  • the method may further include generating an output alert based on the modified analyte rate of change information.
  • the method may also include determining an analyte level projection information based on the modified analyte rate of change information.
  • a system for providing diabetes management in accordance with another embodiment of the present disclosure includes an interface unit, one or more processors coupled to the interface unit, a memory for storing instructions which, when executed by the one or more processors, causes the one or more processors to receive data associated with monitored analyte related levels for a predetermined time period substantially in real time, retrieve one or more therapy profiles associated with the monitored analyte related levels, and generate one or more modifications to the retrieved one or more therapy profiles based on the data associated with the monitored analyte related levels.
  • the interface unit may include an input unit and an output unit, the input unit configured to receive the one or more analyte related data, and the output unit configured to output the one or more of the generated modifications to he retrieved one or more therapy profiles.
  • the interface unit and the one or more processors in a further embodiment may be operatively coupled to one or more of a housing of an infusion device or a housing of an analyte monitoring system.
  • the infusion device may include one of an external insulin pump, an implantable insulin pump, an on-body patch pump, a pen-type injection device, an inhalable insulin delivery system, and a transdermal insulin delivery system.
  • the memory in a further aspect me ye configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to display the generated one or more modifications to the retrieved one or more therapy profiles.
  • the memory may be configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to display the generated one or more modifications to the retrieved one or more therapy profiles as one or more of an alphanumeric output display, a graphical output display, an icon display, a video output display, a color display or an illumination display.
  • the predetermined time period may include one of a time period between 15 minutes and six hours.
  • the one or more therapy profiles may include a basal profile, a correction bolus, a temporary basal profile, an insulin sensitivity, an insulin on board level, and an insulin absorption rate.
  • the memory may be further configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to retrieve a current analyte rate of change information.
  • the memory may be further configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to determine a modified analyte rate of change information based on the received data associated with monitored analyte related levels.
  • the memory may be further configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to generate an output alert based on the modified analyte rate of change information.
  • the memory may be further configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to determine an analyte level projection information based on the modified analyte rate of change information.
  • a system for providing diabetes management in accordance with yet another embodiment of the present disclosure includes an analyte monitoring system configured to monitor analyte related levels of a patient substantially in real time, a medication delivery unit operatively for wirelessly receiving data associated with the monitored analyte level of the patient substantially in real time from the analyte monitoring system, a data processing unit operatively coupled to the one or more of the analyte monitoring system or the medication delivery unit, the data processing unit configured to retrieve one or more therapy profiles associated with the monitored analyte related levels, and generate one or more modifications to the retrieved one or more therapy profiles based on the data associated with the monitored analyte related levels.
  • the analyte monitoring system may be configured to wirelessly communicate with one or more of the medication delivery unit or the remote terminal such as a computer terminal (PC) or a server terminal over a radio frequency (RF) communication link, a Bluetooth communication link, an Infrared communication link, or a wireless local area network (WLAN).
  • PC computer terminal
  • RF radio frequency
  • Bluetooth Bluetooth communication link
  • Infrared Infrared
  • WLAN wireless local area network
  • FIG. 8 illustrates dynamic medication level determination in accordance with one embodiment of the present disclosure.
  • the analyte monitoring system 110 may be configured to receive and store available and/or valid analyte sensor data including continuous glucose level measurement data ( 8100 ) which are indicative of the user or patient's current and past glucose levels.
  • continuous glucose level measurement data 8100
  • the patient or the user may activate or call a bolus determination function ( 8110 ) using, for example, a user interface input/output unit of the analyte monitoring system 110 ( FIG. 1 ) or that of the fluid delivery unit 120 ( FIG. 1 ).
  • the patient enters the anticipated carbohydrate intake amount, or other form of meal selection or one or more other parameters as desired for bolus determination function.
  • the retrieved glucose level information ( 8010 ) it is not necessary for the patient or the user to manually enter the glucose level information.
  • the glucose level information may be manually entered by the patient or the user.
  • blood glucose level may be provided to the system based on a finger stick test using a blood glucose meter device.
  • the patient or the user may enter anticipated carbohydrate information based on a pre-programmed food library stored, for example, in the analyte monitoring system 110 or the fluid delivery device 120 ( FIG. 1 ).
  • a pre-programmed food library stored, for example, in the analyte monitoring system 110 or the fluid delivery device 120 ( FIG. 1 ).
  • Such stored information may include, for example, serving size and associated carbohydrate value for different types of food, or other relevant food information related to the physiology of food update (such as fat content, for example) which may be preloaded into the analyte monitoring system 110 or the fluid delivery device 120 , or alternatively, personalized by the patient or the user using custom settings and stored in the memory device of the analyte monitoring system 110 or the fluid delivery device 120 .
  • the bolus level determination is performed in one embodiment ( 8110 ) upon patient or user activation of a user input button or component, or alternatively, in an automatic manner upon user entry of the meal information ( 8120 ).
  • the bolus determination may include glucose level information from the analyte monitoring system 110 ( FIG. 1 ) and the meal information received from the patient or the user, in conjunction with one or more of other relevant parameters described below, to propose an insulin dosage or level information to attain an anticipated blood glucose level or the future or target glucose profile ( 8190 ).
  • the future or target glucose profile may be preset or alternatively, may be adjusted or modified based, for example, on the patient or user's physiological condition or profile.
  • the future or target glucose profile may include a single glucose target value, or a range of desired glucose levels.
  • Other parameters may be included in the target or future glucose profile such as, for example, maximum peak glucose value, minimum glucose value, time to achieve within 5% of the target glucose value, or other dynamic parameters.
  • the future or target glucose profile may be specified as a cost function to minimize, such as, the area defined by the accumulation in time of deviations from a target value and control sensitivity parameters, such as overshoot and undershoot.
  • cost function to minimize, such as, the area defined by the accumulation in time of deviations from a target value and control sensitivity parameters, such as overshoot and undershoot.
  • other glucose target profiles and/or cost functions may be contemplated.
  • the determination of required insulin infusion to achieve the target glucose profile may include other parameters which may be predefined or patient adjustable, and/or automatically adjusted using, for example, an adaptive learning algorithm or routine that may be configured to tune the particular parameter based on a particular patient/user's physiological condition or therapy profile.
  • one input parameter may be associated with the patient's physiological glucose response to meal intake and/or insulin intake ( 8160 ). Factors such as carbohydrate ratio and insulin sensitivity are contemplated. In one aspect, this parameter may be configured to be responsive to the various meal types or components, response time parameters and the like, such that it is updated, real time or semi real-time, based on the change to the patient's physiological condition related to the glucose level monitored by, for example, the analyte monitoring system 110 ( FIG. 1 ).
  • Another input parameter may include factors associated with the meal—meal dynamics parameters ( 8170 ).
  • the meal dynamics parameters may include the timing of the meal (for example, meal event starts immediately), and the full carbohydrate intake is an impulse function—that is, the meal is substantially ingested in a short amount of time.
  • factors associated with the meal dynamics parameters may be specified or programmed such as, for example, time to meal intake onset (relative to the start time of the bolus delivery), carbohydrate intake profile over time (for example, carbohydrate intake may be configured to remain substantially constant over a predetermined time period).
  • time to meal intake onset relative to the start time of the bolus delivery
  • carbohydrate intake profile over time for example, carbohydrate intake may be configured to remain substantially constant over a predetermined time period.
  • other elaborate intake models are contemplated.
  • a further input parameter may include insulin dynamic response parameters ( 8180 ) which may include physiological dynamic glucose response associated with the different types of insulin that may be delivered by, for example, fluid delivery device 120 ( FIG. 1 ).
  • insulin dynamic response parameters may include time to peak effect of the relevant insulin formulation, or a time constant associated with the glucose response which may be established by the type of insulin for delivery.
  • the calculation of the required insulin to attain the targeted glucose profile ( 8130 ) may be configured in different manner.
  • the determination may be configured as a lookup table, with input values as described above, and associated outputs of insulin profiles.
  • the dynamic functional relationship that defines the physiological glucose response to the measurement inputs and parameters described above may be incorporated for determination of the desired insulin amount.
  • the calculation or determination function may be incorporated in a regulator control algorithm that may be configured to model functional relationships and measured input values or parameters to define a control signal to drive the therapy system 100 ( FIG. 1 ) to achieve the desired response. That is, in one aspect, the dynamic functional relationship may be defined by the physiological relationships and/or the parameter inputs.
  • the measured input values may include the current and prior glucose values, for example, received from the analyte sensor in the analyte monitoring system 110 ( FIG. 1 ) and the user or patient specified meal related information.
  • the control signal discussed above may include determined or calculated insulin amount to be delivered, while the desired response includes the target or desired future glucose profile.
  • the determined insulin level may be displayed optionally with other relevant information, to the patient or the user ( 8140 ).
  • the patient or the user may modify the determined insulin level to personalize or customize the dosage based on the user's knowledge of her own physiological conditions, for example.
  • the patient or the user may be also provided with a function or a user input command to execute the delivery of the determined bolus amount ( 8150 ), which, upon activation is configured to control the fluid delivery device 120 (FIG, 1 ) to deliver the determined amount of insulin to the patient.
  • a further embodiment may not permit the patient modification of the determined bolus amount, and/or include automatic delivery of the determined insulin amount without patient or user intervention.
  • the determined insulin amount may be displayed to the user with a recommendation to defer the activation or administration of the determined insulin amount for a predetermined time period.
  • FIG. 9 illustrates dynamic medication level determination in accordance with another embodiment of the present disclosure.
  • the bolus determination function may include additional data from the analyte monitoring system 110 ( FIG. 1 ), the fluid delivery device 120 ( FIG. 1 ), and/or the remote terminal 140 ( FIG. 1 ). More specifically, in one aspect, one or more blood glucose measurement data ( 9110 ) and/or the current and previous insulin administration profiles or measurements ( 9120 ) may be retrieved from one or more of the analyte monitoring system 110 , the fluid delivery device 120 and/or the remote terminal 140 of the therapy management system 100 ( FIG. 1 ).
  • Each of the measured or monitoring data or information such as analyte sensor data, blood glucose measurements, insulin delivery information and the like, in one aspect, are associated with a time stamp and stored in the one or more memory devices of the therapy management system 100 .
  • this information may be retrieved for therapy related determination such as bolus dosage calculation, or further data analysis for therapy management for the patient.
  • Kalman filter may be used to provide for multiple measurements of the same measurable quantity.
  • the Kalman filter may be configured to use the input parameters and/or factors discussed above, to generate an optimal estimate of the measured quantity.
  • the Kalman filter may be configured to validate the analyte sensor data based on the blood glucose measurements, where one or more sensor data may be disqualified if the blood glucose data in the relevant time period deviates from the analyte sensor data by a predetermined level or threshold.
  • the blood glucose measurements may be used to validate the analyte sensor data or otherwise, calibrate the sensor data.
  • the bolus determination function may include a subroutine to indicate unacceptable error in one or more measured data values.
  • analyte sensor data include attenuations (or “dropouts”)
  • a retrospective analysis may be performed to detect the incidence of such signal attenuation in the analyte sensor data, and upon detection, the bolus determination function may be configured to ignore or invalidate this portion of data in its calculation of the desired insulin amount.
  • the therapy management system 100 may be configured such that insulin dosage or level calculation or determination includes a validation of analyte sensor data and/or verification of the sensor data for use in conjunction with the bolus determination (or any other therapy related determination) function.
  • various metrics may be determined to summarize a patient's monitored glucose data and related information such as, but not limited to insulin delivery data, exercise events, meal events, and the like, to provide indication of the degree or status of the management and control of the patient's diabetic conditions.
  • Metrics may be determined or calculated for a specified period of time (up to current time), and include, but not limited to, average glucose level, standard deviation, percentage above/below a target threshold, number of low glucose alarms, for example.
  • the metrics may be based on elapsed time, for example, since the time of the patient's last reset of particular metric(s), or based on a fixed time period prior to the current time.
  • Such determined metrics may be visually or otherwise provided to the patient in an easy to understand and navigate manner to provide the progression of the therapy management to the user and also, with the option to adjust or modify the related settings or parameters.
  • the output of the determined metrics may be presented to the user on the output unit 260 ( FIG. 2 ) of the fluid delivery device 120 ( FIG. 1 ), a display deice on the analyte monitoring system 110 , a user interface, and/or an output device coupled to the remote terminal 140 ( FIG. 1 ).
  • the metrics may be configured to provide a visual indication, tactile indication, audible indication or in other manner in which the patient or the user of the therapy management system 100 ( FIG. 1 ) is informed of the condition or status related to the therapy management.
  • Each metric may be user configurable to allow the patient or the user to obtain additional information related to the metric and associated physiological condition or the operational state of the devices used in the therapy management system 100 .
  • the metric may be associated with indicators or readings other than glucose, such as, for example, the amount and/or time of insulin delivered, percentage of bolus amount as compared to the total insulin delivered, carbohydrate intake, alarm events, analyte sensor replacement time periods, and in one aspect, the user or the patient may associate one or more alarms, alerts or notification with one or more of the metrics as may be desired.
  • FIG. 10 illustrates metric analysis in accordance with one embodiment of the present disclosure.
  • the desired metric information is determined ( 1020 ), for example, based on the current available information (e.g., the insulin delivery information for the past 2 hours).
  • the determined metric information is displayed on the main or home screen or display of the user interface device ( 1030 ).
  • the displayed metric may be selected, for example, based on user activation on a display element ( 1040 ).
  • additional detail information related to the selected metric as well as, optionally, other related information are determined or calculated ( 1050 ), and thereafter provided to the user or the patient on the user interface device ( 1060 ).
  • the user interface device may be configured with layered menu hierarchy architecture for providing current information associated with a particular metric or condition associated with the therapy management system. The patient or the user may configure the user interface device to display or output the desired metrics at a customizable levels of detail based on the particular patient or the user's settings.
  • the metrics may be provided on other devices that may be configured to receive periodic updates from the user interface device of the therapy management system.
  • such other devices may include mobile telephones, personal digital assistants, pager devices, Blackberry devices, remote care giver devices, remote health monitoring system or device, which may be configured for communication with the therapy management system 100 , and that may be configured to process the data from the therapy management system 100 to determine and output the metrics. This may be based on real time or substantially real time data communication with the therapy management system 1 00 .
  • the therapy management system 100 may be configured to process and determine the various metrics, and transmit the determined metrics to the other devices asynchronously, or based on a polling request received from the other devices by the therapy management system 100 .
  • the user interface device in the therapy management system 100 may be configurable such that the patient or the user may customize which metric they would like to view on the home screen (in the case of visual indication device such as a display unit). Moreover, other parameters associated with the metrics determination, such as, for example, but not limited to the relevant time period for the particular metric, the number of metrics to be output or displayed on a screen, and the like may be configured by the user or the patient.
  • the metric determination processing may include routines to account for device anomalies (for example, in the therapy management system 100 ), such as signal attenuation (ESA) or dropouts, analyte sensor calibration, or other physiological conditions associated with the patient as well as operational condition of the devices in the therapy management system such as the fluid delivery device 120 ( FIG. 1 ) or the analyte monitoring system 110 ( FIG. 1 ).
  • device anomalies for example, in the therapy management system 100
  • ESA signal attenuation
  • dropouts analyte sensor calibration
  • other physiological conditions associated with the patient as well as operational condition of the devices in the therapy management system
  • operational condition of the devices in the therapy management system such as the fluid delivery device 120 ( FIG. 1 ) or the analyte monitoring system 110 ( FIG. 1 ).
  • Some glucose measurement anomalies may not be detected in real time and thus require retrospective detection and/or compensation.
  • anomalies such as signal attenuation, dropouts, noise burse, calibration errors or other anomalies may be detected and/or compensated.
  • a signal dropout detector may be used to invalidate a portion of the prior glucose related data, to invalidate an entire data set, or to notify the patient or the user of the corresponding variation or uncertainly in accuracy in a predetermined one or more metrics or calculations.
  • FIG. 11 illustrates metric analysis in accordance with another embodiment of the present disclosure
  • retrospective validation of data used in metric calculation is performed ( 1120 ), which includes one or more metric calculation parameters ( 1130 ).
  • the metric calculation parameters ( 1130 ) may be used in the metric calculation ( 1140 ) which, as shown, may be performed after the data to be used in the metric calculation are retrospectively validated.
  • the metrics may be determined or recalculated after each received analyte sensor data and thereafter, displayed or provided to the user or the patient upon request, or alternatively, automatically, for example, by refreshing the display screen of the user interface device in the therapy management system 100 ( FIG. 1 ), or otherwise providing an audible or vibratory indication to the patient or the user.
  • FIG. 12 is illustrates metric analysis in accordance with yet another embodiment of the present disclosure.
  • the user interface device may be configured to activate a home screen or main menu configuration or setup function based on detected display element selection ( 1220 ). That is, in one aspect, the user or the patient may call a configuration function to customize the displayed menu associated with the display or output indication of the metrics.
  • the user or patient selection of one or more metrics to be displayed or output on the main menu or home screen on the user interface device is detected ( 1230 ).
  • the user interface device is configured to display or output the selected one or more metrics on the home screen or the main menu each time the user interface device is activated ( 1240 ).
  • the user or the patient may be provided with an option to display or output a particular subset of available metrics on the main display screen of the user interface device.
  • the user interface device in the therapy management system 100 may be configured to include a default set of metrics to displayed and/or updated, either in real time, or substantially in real time, or based in response to another related event such as an alarm condition, or a monitored glucose level.
  • the system may be configured to not output any metrics.
  • FIG. 13 illustrates metric analysis in accordance with a further embodiment of the present disclosure.
  • metric calculation setup function is called based on detection of a display selection to activate the same ( 1320 ), and detection of a selection from a list of metrics that allow the calculations to be modified (or alarms associated) ( 1330 ).
  • the configuration options including metric calculation parameters, for example, are displayed ( 1340 ) in one embodiment, and the selected metric may be calculated, with one or more parameters modified or otherwise programmed, and optionally with one or more alarm conditions or settings associated with the selected metric ( 1 350 ).
  • therapy related information may be configured for output to the user to, among others, provide the patient or the user of the associated physiological condition and the related therapy compliance state.
  • the therapy management system 100 may be configured to monitor potential adverse conditions related to the patient's physiological conditions. For example, a prevalence of glucose levels for a predetermined time period, pre-prandial, may be analyzed to determine if the prevalence exceeds a predefined threshold, with some consistency.
  • the user interface device may be configured to provide a notification (visual or otherwise) to the patient or the user, and varying degrees of detailed information associated with the detected adverse condition may be provided to the patient or the user.
  • Such notification may include text information such as, for example “Your pre-meal glucose tends to be high”, or graphically by use of an arrow icon or other suitable visual indication, or a combination of text and graphics.
  • Adverse conditions that are not related to the monitored analyte level such as insulin delivery data that is consistent with insulin stacking may be detected.
  • Other examples include mean bolus event that appear to occur too late relative to the meal related glucose increases may be detected, or excessive use of temporary basal or bolus dosage or other modes of enhanced insulin delivery beyond the basal delivery profiles.
  • device problems such as excessive signal dropouts from the analyte sensor may be detected and reported to the user.
  • the user interface device may be configured to customize or program the visual output indication such as icon appearance, such as enabling or disabling the icon appearance or one or more alarms associated with the detection of the adverse conditions.
  • the notification to the user may be real time, active or passive, such that portions of the user interface device is updated to provide real time detection of the adverse conditions.
  • the adverse condition detection thresholds may be configured to be more or less sensitive to the triggering event, and further, parameters associated with the adverse condition detection determination may be adjusted—for example, the time period for calculating a metric.
  • the user interface device may provide indication of a single adverse detection condition, based on a priority list of possible adverse conditions, a list of detected adverse conditions, optionally sorted by priority, or prior detection of adverse conditions. Also, the user interface device may provide treatment recommendation related to the detected adverse condition, displayed concurrently, or options to resolve the detected adverse condition along with the detected adverse condition.
  • the notification of the detected adverse condition may be transmitted to another device, for example, that the user or the patient is carrying or using such as, for example, mobile telephone, a pager device, a personal digital assistant, or to a remote device over a data network such as a personal computer, server terminal or the like.
  • some or all aspects of the adverse condition detection and analysis may be performed by a data management system, for example, by the remote terminal 140 ( FIG. 1 ) or a server terminal coupled to the therapy management system 100 .
  • the analysis, detection and display of the adverse condition may be initiated upon the initial upload of data from the one or more analyte monitoring system 110 or the fluid delivery device 120 , or both.
  • the adverse condition process may also account for potential measurement anomalies such as analyte sensor attenuation conditions or dropouts, or sensor calibration failures.
  • FIG. 14 illustrates condition detection or notification analysis in accordance with one embodiment of the present disclosure.
  • user interface device activation detection such as activation of a display device in the therapy management system 100 ( FIG. 1 )
  • preprogrammed or predefined adverse condition is detected ( 1420 ), and displayed ( 1430 ) on the home screen of the user interface device using, for example, a problem icon.
  • the icon display element associated with the adverse condition is detected ( 1440 ), for example, indicating that the patient or the user desires additional information associated with the detected adverse condition, additional detailed information associated with the adverse condition is determined, as appropriate ( 1450 ), and thereafter, the additional detailed information is displayed to the user ( 1460 ).
  • FIG. 15 illustrates condition detection or notification analysis in accordance with another embodiment of the present disclosure.
  • current and prior stored analyte sensor data and blood glucose data are retrieved ( 1510 ) and retrospective validation of the data for use in the adverse condition detection process is performed ( 1530 ), based also, at least in part, on the detection calculation parameters ( 1520 ) which may be user input or preprogrammed and stored.
  • the adverse condition detection process is performed ( 1540 ), for example, the parameters associated with the programmed adverse conditions are monitored and upon detection, notified to the patient or the user.
  • FIG. 16 illustrates therapy parameter analysis in accordance with one embodiment of the present disclosure.
  • data from a continuous glucose monitoring system (CGM) such as an analyte monitoring system 110 ( FIG. 1 ) and an insulin pump such as, for example, fluid delivery device 120 ( FIG. 1 ) are collected or stored over a predetermined time period.
  • CGM continuous glucose monitoring system
  • an insulin pump such as, for example, fluid delivery device 120 ( FIG. 1 )
  • meal intake information may be stored, along with other relevant data such as, exercise information, and other health related information. All data are stored with a corresponding date and time stamp and are synchronized.
  • the stored data including, for example, time synchronized analyte sensor data (CGM), blood glucose (BG) data, insulin delivery information, meal intake information and pump therapy settings, among others, are uploaded to a personal computer, for example, such as the remote terminal 140 ( FIG. 1 ) for further analysis ( 1601 ).
  • the received data are used as input data including, for example, actual glucose data (CGM), actual blood glucose data (BG), actual insulin amount delivered, actual pump settings including carbohydrate ratio, insulin sensitivity, and basal rate, among other ( 1607 ), as well as actual meal information ( 1608 ), to perform a system identification process ( 1602 ).
  • system identification process ( 1602 ) in one embodiment is configured to fit the received input data to a generic physiological model that dynamically describes the interrelationship between the glucose levels and the delivered insulin level as well as meal intake. In this manner, in one aspect, the system identification process ( 1602 ) is configured to predict or determine glucose levels that closely matches the actual glucose level (CGM) received as one of the input parameters.
  • CGM actual glucose level
  • the parameters of the generic physiological model are adjusted so that the model output (glucose level) closely matches the actual monitored glucose level when the measured inputs are applied ( 1610 ). That is, a newly identified model is generated based, at least in part, on meal dynamics, insulin absorption dynamics, and glucose response dynamics. Thereafter, based on the newly identified model ( 1610 ), actual meal information representing carbohydrate intake data ( 1608 ), and the glucose profile target(s) as well as any other constraints such as insulin delivery limits, low glucose limits, for example ( 1609 ), to determine the optimal pump setting to obtain the target glucose profile(s) ( 1603 ). That is, in one aspect, based on a predefined cost function such as minimizing the area about a preferred glucose level, or some other boundaries, predicted glucose levels are determined based on optimal pump therapy settings, and optimal insulin delivery information ( 1611 ).
  • a predefined cost function such as minimizing the area about a preferred glucose level, or some other boundaries
  • a report may be generated which show modal day results, with median and quartile traces, and illustrating the actual glucose levels and glucose levels predicted based on the identified model parameters, actual insulin delivery information and optimal insulin delivery information, actual mean intake information, and actual and optimal insulin therapy settings ( 1604 ).
  • Other report types can be generated as desired.
  • a physician or a treatment provider may modify one or more parameters to view a corresponding change in the predicted glucose values, for example, that may be more conservative to reduce the possibility of hypoglycemia.
  • a new predicted glucose and insulin delivery information based on the adjusted setting are determined ( 1605 ).
  • the predicted glucose values and insulin delivery information are added to the plot displayed and in one aspect, configured to dynamically change, in real time, in response to the parameter adjustments.
  • the settings and/or parameters associated with the insulin delivery including, for example, modified basal profiles, for the insulin pump, may be downloaded ( 1606 ) to the pump controller from the computer terminal (for example, the remote terminal 140 ) for execution by the insulin pump, for example, the fluid delivery device 120 ( FIG. 1 ).
  • FIG. 17 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with one embodiment of the present disclosure.
  • the physiological profile of a patient or user based on data collected or received from one or more of the analyte monitoring system 110 ( FIG. 1 ) or the fluid delivery device ( 120 ) for example, are retrieved ( 1710 ).
  • the profile of a patient which represents the physiological condition of the patient is retrieved ( 1720 ).
  • Other relevant data could be collected, for example, but not limited to, the patient's physical activities, meal consumption information including the particular content of the consumed meal, medication intake including programmed and executed basal and/or bolus profiles, other medication ingested during the relevant time period of interest.
  • the generated physiological model includes one or more parameters associated with the patient's physiological condition including, for example, insulin sensitivity, carbohydrate ratio and basal insulin needs.
  • the relevant time period of interest for physiological simulation may be selected by the patient, physician or the care provider as may be desired.
  • there may be a threshold time period which is necessary to generate the physiological model, and thus a selection of a time period shorter than the threshold time period may not result in accurate physiological modeling.
  • the data processing system or device may be configured to establish a seven day period as the minimum number of days based on which, the physiological modeling may be achieved.
  • one or more patient condition parameters may be modified ( 1730 ).
  • the basal profile for the infusion device of the patient may be modified and entered into the simulation module.
  • the patient's profile may be modified.
  • the type or amount of food to be ingested may be provided into the simulation module.
  • the patient, the physician or the care provider may modify one or more of the condition parameters to determine the simulated effect of the modified condition parameter or profile component to the physiological model generated. More specifically, referring back to FIG. 17 , when one or more patient condition parameters or one or more profiles components is modified, the simulated physiological model is modified or altered in response to the modified condition parameter(s) ( 1740 ).
  • the simulation of the initial physiological profile of a patient may be generated based on collected/monitored data. Thereafter, one or more parameters may be modified to show the resulting effect of such modified one or more patient condition parameters on the simulation of the patient's physiological model.
  • the patient, physician or the healthcare provider may be provided with a simulation tool to assist in the therapy management of the patient, where a model based on the patient's condition is first built, and thereafter, with adjustment or modification of one or more parameters, the simulation model provides the resulting effect of the adjustment or modification so as to allow the patient, physician or the healthcare provider to take appropriate actions to improve the therapy management of the patient's physiological condition.
  • FIG. 18 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with another embodiment of the present disclosure.
  • a user selects, using one or more user input devices of a personal computer or other computing or data processing device, the desired physiological profile ( 1810 ), and thereafter, one or more condition parameters displayed to the user may be selected as desired. For example, the user may be prompted to select an insulin level adjustment setting, to view a simulation of the physiological profile model responding to such insulin level adjustment setting.
  • the user may select an activity adjustment setting to view the effect of the selected activity on the physiological profile model. For example, the user may select to exercise for 30 minutes before dinner every day.
  • the physiological profile model simulation module may be configured to modify the generated physiological model to show the resulting effect of the exercise to the glucose level of the patient in view of the existing insulin delivery profile, for example.
  • one or more parameters associated with the patient's physiological condition may be modified as a condition parameter and provided to the model simulation module to determine the resulting effect of such modified condition parameter ( 1820 ). Indeed, referring back to FIG.
  • the simulation module in one aspect may be configured to generate a modified physiological profile model which is received or output to the user, patient, physician or the healthcare provider, visually, graphically, in text form, or one or more combinations thereof ( 1830 ).
  • FIG. 19 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with still another embodiment of the present disclosure.
  • the simulation module may prompt the patient, the user, physician or the healthcare provider to either enter additional or different condition parameters to view the resulting effect on the simulated physiological model, or alternatively, select the option to indicate the completion of the modification to the condition parameters ( 1940 ).
  • an iteration may be provided such that the patient, user, physician or the healthcare provider may modify one or more conditions associated with the patient's physiological condition, and in response, view or receive in real time, the resulting effect of the modified one or more conditions to the modeled physiological condition simulation.
  • the modified as well as the initial physiological profile model (and including any intermediate modification to the physiological profile model based on one or more parameter inputs) may be stored in the memory or storage unit of the data processing terminal or computer ( 1950 ).
  • the simulation module when the simulation module has sufficient data associated with the patient's physiological condition or state to define the simulation model parameters, the patient, healthcare provider, physician or the user may model different treatment scenarios to determine strategies for managing the patient's condition such as the diabetic condition in an interactive manner, for example.
  • changes to the resulting physiological model may be displayed or provided to the patient, physician or the healthcare provider based on one or more potential changes to the treatment regimen.
  • FIG. 20 is a flowchart illustrating visual medication delivery profile programming in accordance with one embodiment of the present disclosure.
  • medication delivery profile such as a basal rate profile is retrieved ( 2010 ), for example, from memory of the remote terminal 140 ( FIG. 1 ) or received from the fluid delivery device 120 ( FIG. 1 ) such as an insulin pump.
  • a graphical representation of the medication delivery profile is generated and displayed ( 2020 ) on the display unit of the remote terminal 140 .
  • the graphical representation of the medication delivery profile may include a line graph of the insulin level over a predetermined time period for the corresponding medication delivery profile.
  • the graphically displayed medication delivery profile may be configured to be manipulated using an input device for the remote terminal 140 such as, for example, a computer mouse, a pen type pointing device, or any other types of user input device that is configured for manipulation of the displayed objects on the display unit of the remote terminal 140 .
  • an input device for the remote terminal 140 such as, for example, a computer mouse, a pen type pointing device, or any other types of user input device that is configured for manipulation of the displayed objects on the display unit of the remote terminal 140 .
  • one or more of a corresponding therapy or physiological profile for a particular patient or user may be displayed.
  • the remote terminal 140 may be configured to display the basal profile programmed in the fluid delivery device 120 indicating the amount of insulin that has been programmed to administer to the patient, and the corresponding monitored analyte level of the patient, insulin sensitivity, insulin to carbohydrate ratio, and any other therapy or physiological related parameters.
  • the patient or the user including a physician or the healthcare provider may manipulate the user input device such as the computer mouse coupled to the remote terminal 140 to select and modify one or more segments of the graphically displayed medication delivery profile ( 2030 ).
  • the corresponding displayed therapy/physiological profile may be dynamically updated ( 2040 ).
  • the user or the patient may select a portion or segment of the basal profile line graph, and either move the selected portion or segment of the line graph in vertical or horizontal direction (or at an angle), to correspondingly modify the level of the medication segment for a given time period as graphically displayed by the line graph.
  • the medication delivery profile in one aspect may be displayed as a line graph with time of day represented along the X-axis and the value or level of the medication on the Y-axis.
  • the cursor displayed on the remote terminal 140 display unit may be configured to change to indicate that the portion of the line graph may be selected and dragged on the displayed screen.
  • the horizontal portions of the line graph may be dragged in a vertical direction to increase or decrease the setting or the medication level for that selected time period, while the vertical portions of the line graph may be dragged in the horizontal direction to adjust the time associated with the particular medication level selected.
  • the modified medication delivery profile and the updated therapy/physiological profile are stored ( 2050 ) in a storage unit such as a memory of the remote terminal 140 , and thereafter, may be transmitted to one or more of the fluid delivery device 120 or the analyte monitoring system 110 ( 2060 ).
  • the patient or the user may be provided with an intuitive and graphical therapy management tool which allows manipulation of one or more parameters associated with the patient's condition such as diabetes, and receive real time visual feedback of based on the manipulation of the one or more parameters to determine the appropriate therapy regimen.
  • the user may manipulate the line graph associated with the insulin delivery rate, for example, to receive feedback on the effect of the change to the insulin amount on the blood glucose level.
  • the modeling of the physiological parameters associated with the patient in one aspect may be generated using computer algorithms that provide simulated model of the patient's physiological condition based on the monitored physiological condition, medication delivery rate, patient specific conditions such as exercise and meal events (and the types of exercise and meal for the particular times), which may be stored and later retrieved for constructing or modeling the patient's physiological conditions.
  • FIG. 21 is a flowchart illustrating visual medication delivery profile programming in accordance with another embodiment of the present disclosure.
  • medication delivery profile for a particular patient may be graphically displayed ( 2110 ), and thereafter, upon detection of an input command to modify the displayed medication delivery profile ( 2120 ), the corresponding displayed therapy physiological profile is modified ( 2130 ).
  • the input command may be received from an input device such as a computer mouse executing select and drag functions, for example, on the display screen of the remote terminal 140 .
  • the displayed medication delivery profile as well as the corresponding displayed therapy/physiological profile may be graphically updated to provide visual feedback to the patient or the user of the effect resulting from the input command modifying the medication delivery profile.
  • the modified medication delivery profile when the confirmation of the modified medication delivery profile is received ( 2140 ), for example, via the user input device, the modified medication delivery profile may be transmitted ( 2150 ) and, the modified medication delivery profile and the updated therapy/physiological profile are stored ( 2160 ). That is, when the user or the patient confirms or accepts the modification or update to the medication delivery profile based, for example, on the visual feedback received corresponding to the change to the therapy/physiological profile, in one aspect, the modified medication delivery profile may be transmitted to the fluid delivery device 120 to program the device for execution, for example.
  • the transmission may be wireless using RF communication, infrared communication or any other suitable wireless communication techniques, or alternatively, may include cabled connection using, for example, USB or serial connection.
  • an intuitive and easy to use visual feedback mechanism to improve treatment of a medical condition such as diabetes by providing visual modeling of the therapy regimen that can be dynamically adjusted to show the effect of such adjustment to the physiological condition.
  • FIG. 22 is an exemplary screen display of a medication delivery profile.
  • the basal rate, insulin sensitivity and the insulin to carbohydrate ratio (CHO) are shown on the Y-axis, while the X-axis represents the corresponding time of day.
  • the existing profile is shown 2320 and the optimal profile proposed by the therapy calculator is shown 2330 .
  • FIG. 23 is an exemplary screen display illustrating vertical modification of the proposed medication delivery profile as shown by the directional arrow 2310
  • FIG. 24 illustrates an exemplary screen display with horizontal modification of the proposed medication delivery profile shown by the directional arrow 2410 .
  • FIG. 25 illustrates addition of a transition 2510 in the medication delivery profile
  • FIG. 26 illustrates deletion 2610 of a transition in the medication delivery profile.
  • the visual modeling and dynamic feedback in therapy management provides immediate feedback on the anticipated results or effect of a proposed modification to the therapy profile such as increase or decrease of insulin administration to the patient.
  • a proposed modification to the therapy profile such as increase or decrease of insulin administration to the patient.
  • the patient, the physician or the healthcare provider may be provided with a graphical treatment tool to assist in the treatment of the patient's condition.
  • the visual modeling and dynamic feedback in the therapy management includes illustration of a current physiological profile such as the glucose level and one or more time corresponding parameter values associated with the current physiological profile such that, when the user, patient or healthcare provider modifies the displayed one or more parameter values (such as, but not limited to, the corresponding medication level including basal profile, insulin sensitivity, and/or insulin to carbohydrate ratio), the corresponding current physiological profile is responsively modified and displayed in real time, while leaving a trace (referring to herein as a phantom plot) of the current physiological profile and the time corresponding one or more parameter values associated with the current physiological profile.
  • a current physiological profile such as the glucose level
  • one or more time corresponding parameter values associated with the current physiological profile such that, when the user, patient or healthcare provider modifies the displayed one or more parameter values (such as, but not limited to, the corresponding medication level including basal profile, insulin sensitivity, and/or insulin to carbohydrate ratio)
  • the corresponding current physiological profile is responsively modified and displayed in real time, while leaving a trace (referring
  • the display or screen is configured to represent both the initial profile and the modified profile so that the user, patient or healthcare provider can readily see the change to the plotted physiological profile in response to the modification to the one or more parameter values, for example, the initial profile or plot shown as a lighter trace (phantom plot) or of a different color or representation), while maintaining a darker color or thickness of the plot for the modified profile/plot.
  • the initial position of the glucose level remains displayed as a trace (phantom plot), while displaying the new or modified glucose level.
  • both the initial and the modified basal profile of the time corresponding basal profile are displayed on the same chart or plot. In this manner, in one aspect, the display of the remote terminal 140 ( FIG.
  • the display of the analyte monitoring system 110 or the display of the fluid delivery device 120 may be manipulated using, for example, user interface capabilities such as input device (computer mouse for use with the remote terminal 140 , input/select buttons on the analyte monitoring system 110 or the fluid delivery device 120 to provide visual indications of the extent of adjustment to one or more parameters from the initial or recommended settings or profiles and the corresponding modification to the associated physiological or other monitored profile such as glucose levels in addition to the initial displayed profile.
  • input device computer mouse for use with the remote terminal 140
  • input/select buttons on the analyte monitoring system 110 or the fluid delivery device 120 to provide visual indications of the extent of adjustment to one or more parameters from the initial or recommended settings or profiles and the corresponding modification to the associated physiological or other monitored profile such as glucose levels in addition to the initial displayed profile.
  • FIG. 27 is an exemplary display illustrating an initial glucose level and a corresponding parameter value
  • FIGS. 28-29 are exemplary displays illustrating response to the manipulation of the parameter plot or value segment of FIG. 27 and corresponding modification to the displayed glucose profile as a function of time in one embodiment.
  • an initial display of one parameter value 2720 ( FIG. 27 ) is plotted along with a time corresponding plot of the glucose level 2710 ( FIG. 27 ).
  • the user, patient or the healthcare provider may move the computer mouse to position the cursor over and select a segment of the plotted parameter value 2720 (for example, between two displayed dots at each transition point in the displayed plot). With the selected segment of the plotted parameter, the user, patient or the healthcare provider may move the selected segment in a vertical direction as shown in FIG. 28 , in a horizontal direction, or in both a horizontal and vertical direction as shown in FIG. 29 .
  • the corresponding initial glucose profile 2810 is updated to the modified glucose profile 2820 .
  • FIG. 28 it can be seen that both the initial position and the modified position of the parameter plot and those of the glucose levels are shown.
  • the segment of the initial position or plot of the parameter value (and the corresponding initial display of the glucose level) is displayed as a lighter trace or of a different color (for example, the initial parameter segment 2840 and the initial glucose profile 2810 ) to be distinguishable with the modified parameter segment 2830 and the corresponding modified glucose profile 2820 .
  • the particular type of display modes may be user definable or configurable.
  • the corresponding displayed initial glucose level display 2910 is updated to a modified profile 2920 in the direction shown by the arrow illustrating a movement from the initial display 2910 to the modified display 2920 in addition to the display of the initial glucose profile 2910 and the initial parameter value 2940 .
  • proposed or recommended modification to therapy profiles such as basal profiles may be displayed including the initial and modified profiles, and the corresponding initial and modified physiological profiles recalculated or determined in response to the proposed or recommended modification to the therapy profiles may be visually output to the user, patient or the healthcare provider to enhance visual representation of the proposed or recommended modification to the therapy profiles in the course of the treatment and therapy of physiological conditions such as diabetes.
  • the user, patient or the healthcare provider may easily and visually understand the degree of parameter change and effect of the change on the output values such as insulin delivery and glucose level.
  • the phantom plots may be associated with the plots that are adjusted rather than the plots that stay in the same position.
  • the phantom plots may be represented other than as a thinner line (compared to the non-phantom or the modified profile), including, such as, for example, with different colors, line types, icon indication, legends, labels and the like.
  • the modification to the initial profile or parameter may be represented in tabular form with numeric value entries, with some table elements associated with the original or initial values and other table elements representing the adjusted/modified values.
  • the phantom (original) plot may be updated or modified after each adjustment, relative to the immediately prior modification position.
  • multiple phantom plots may be displayed (using different indications such as gradually increasing thickness of the plotted line, or different color or legend, for example) such that the modifications may be visually represented in a graphically sweeping manner, illustrating each modification to the parameter(s) and the corresponding modification to the physiological profile in, for example, a single chart or display.
  • a table may be provided and displayed with numeric values associated with parameter segments, and the user, patient or the healthcare provider may edit the numeric values in the table.
  • the corresponding plots may be modified as described above, in a similar manner as when the graphical segment is modified using, for example, the computer mouse by click and drag operation.
  • segments of the parameter plots may be predefined, for instance, at a segment of 15 minutes or other time periods.
  • the segments may be defined by changes in time for the original parameter value.
  • new segments may be defined by the user using for example, the computer mouse by clicking the mouse button with a cursor near a point on the parameter plot, where the selected or clicked point representing the end of a segment with the beginning of a segment already defined on the plot (as indicated by a dot on the plot).
  • a segment may be defined by the user with a mouse click once near one point on a plot and again near a second point, where the points define a segment.
  • the segment may be visually highlighted (for example, made thicker) to indicate to the user that it can be dragged or otherwise adjusted or modified.
  • these defined segments may be limited to a predefined time resolution as defined by the insulin delivery device, for example. That is, fluid delivery device 120 ( FIG. 1 ) may be limited to a 15 minute resolution of parameter changes, in which case, the plotting routine may locate the 15 minute point on the plot closest to where the user selected with the mouse.
  • the display discussed above may include one or more error indication.
  • the glucose display may show, along with the median glucose profile, the upper and lower glucose quartiles. This information may be useful to the user when making corresponding adjustments to the therapy profile. For example, if the user, patient or the healthcare provider desires to make parameter adjustments in order to lower the median glucose profile, they may understand from the lower quartile plot that there is a high degree of glucose variation and that it may not be safe or desirable to lower the median profile as much as they intended or desired.
  • the phantom plots discussed above may be associated with these types of displayed error indications.
  • the profile modification and the corresponding displays may be based on data organized around time-of-day information.
  • the modifications or determinations and the corresponding display plots may be based on meals markers or meal bolus events recorded in time. These events may be entered into the system manually (for instance a meal event may be entered into the system by the user) or automatically (the system may record a meal bolus when it is delivered, using, for example, the fluid delivery device 120 ).
  • the parameter, insulin delivery and glucose data may be organized in data sets, with time relative to the meal bolus event.
  • a resulting data set for each may be generated using a median calculation or average calculation, or other appropriate calculation, to generate a profile in time relative to the meal bolus event.
  • each data set may be defined one hour prior to and 5 hours after when meals bolus event occurs. Adjustments, as described above for plots over time-of-day, may be made similarly for plots over time-relative-to-meal-events. Also, determination and display of parameters, insulin delivery and glucose profiles may be made for data sets generated relative to correction bolus events.
  • the user may select from a list of possible parameters to adjust or modify based on one or more indications presenting the parameters available for modification. For example, if the basal parameter adjustment is selected, then the determination or modification and display may be associated with time-of-day. In this case, when the user adjusts the glucose values, the basal profile parameter may be adjusted to correlate with glucose level adjustments. As a further example, if the carbohydrate ratio parameter is selected, the modification and display may be associated with time relative to meal bolus or meal events. As yet a further example, when the insulin sensitivity parameter adjustment is selected, the modification and display may be associated with time relative to a correction bolus.
  • modifications and displays when modifications and displays are associated with time relative to an event, they may be restricted to time of day periods.
  • the profile modification determination may be restricted to one or more meal bolus that occur in a morning period, for instance, between 6 am and 11 am. This restriction may be used to associate a single carbohydrate ratio parameter for this time period.
  • the resulting modified parameters may be constrained by resolution restrictions imposed by the insulin delivery device 120 discussed above.
  • the parameter and/or physiological profile display may include both actual and recommended glucose traces, insulin traces and therapy parameter traces, in addition to the modified traces, and further, user definable or configurable.
  • data mining techniques may be used to generate and/or modify the physiological profile models based on the patient's data as well as data from other patient's that have similar physiological characteristics. Such data mining techniques may be used to filter and extract physiological profile models that meet a predetermined number of criteria and ranked in a hierarchy of relevance or applicability to the particular patient's physiological condition.
  • the simulation module may be implemented by computer software with algorithm that defines the parameters associated with the patient's physiological conditions, and may be configured to model the various different conditions of the patient's physiology.
  • the therapy analysis system described above may be implemented in a database management system and used for treatment of diabetic patients by general practitioner. Additionally, the therapy analysis system may be implemented based on multiple daily doses of insulin (using, for example, syringe type insulin injector, or inhalable insulin dispenser) rather than based on an insulin pump, where the insulin related information may be recorded by the patient and uploaded or transferred to the data management system (for example, the remote terminal 140 ( FIG. 1 )). Also, some or all of the data analysis and display described above may be performed by the analyte monitoring system 110 ( FIG. 1 ) or the fluid delivery device ( 120 ), or by a separate controller configured for communication with the therapy management system 100 .
  • a method may comprise displaying a first representation of a medication treatment parameter profile, displaying a first representation of a physiological profile associated with the medication treatment parameter profile, detecting a modification to a segment of the medication treatment parameter profile, displaying a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modifying an attribute of the first representation of the medication treatment parameter profile, and modifying an attribute of the first representation of the physiological profile.
  • modifying the attribute of the first representation of the medication treatment parameter profile may include modifying a visual attribute without modifying the underlying value associated with the profile.
  • the visual attribute may include one or more of a color representation, a line representation, visual contrast representation.
  • the modified representation and the first representation of the medication treatment parameter profile may include at least an overlapping displayed segment.
  • modified representation and the first representation of the physiological profile may be substantially non-overlapping.
  • the medication treatment parameter profile may include one or more of a basal rate profile, an insulin sensitivity profile, an insulin to carbohydrate ratio, an meal event, a bolus event, or an insulin type profile.
  • the physiological profile may include a glucose level profile, an oxygen level profile, or a blood pressure level profile.
  • modifying the attribute of the first representation of the physiological profile may include modifying a visual attribute without modifying the underlying value associated with the profile.
  • the displayed position of the first representation of the medication treatment parameter profile is not changed.
  • the displayed position of the first representation of the physiological profile is not changed.
  • the displayed first representation of the medication treatment parameter profile and the physiological profile respectively may include one or more of a line graph, a bar graph, a 2-dimensional graph, or a 3-dimensional graph.
  • an apparatus may comprise, a display unit, one or more processing units coupled to the display unit, and a memory for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to display a first representation of a medication treatment parameter profile, display a first representation of a physiological profile associated with the medication treatment parameter profile, detect a modification to a segment of the medication treatment parameter profile, display a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modify an attribute of the first representation of the medication treatment parameter profile, and modify an attribute of the first representation of the physiological profile.
  • the memory for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to modify a visual attribute associated with the physiological profile without modifying the underlying value associated with the first representation of the physiological profile, and to modify a visual attribute associated with the first representation of the medication treatment parameter profile without modifying the underlying value associated with the medication treatment parameter profile.
  • the visual attribute may include one or more of a color representation, a line representation, visual contrast representation.
  • the modified representation and the first representation of the medication treatment parameter profile may include at least an overlapping displayed segment.
  • modified representation and the first representation of the physiological profile may be substantially non-overlapping.
  • the medication treatment parameter profile may include one or more of a basal rate profile, an insulin sensitivity profile, an insulin to carbohydrate ratio, an meal event, a bolus event, or an insulin type profile.
  • the physiological profile may include a glucose level profile, an oxygen level profile, or a blood pressure level profile.
  • the displayed position of the first representation of the medication treatment parameter profile may not be changed, and further, when the attribute of the first representation of the physiological profile is modified, the displayed position of the first representation of the physiological profile may not be changed.
  • the software required to carry out the inventive process which may be stored in the memory unit 240 (or similar storage devices in the analyte monitoring system 110 and the remote terminal 140 ) and executed by the processor 210 , may be developed by a person of ordinary skill in the art and may include one or more computer program products.

Abstract

Method and system including displaying a first representation of a medication treatment parameter profile, displaying a first representation of a physiological profile associated with the medication treatment parameter profile, detecting a modification to a segment of the medication treatment parameter profile, displaying a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modifying an attribute of the first representation of the medication treatment parameter profile, and modifying an attribute of the first representation of the physiological profile are provided.

Description

    RELATED APPLICATIONS
  • The present application is a continuation in part of pending application Ser. No. 12/024,082 filed Jan. 31, 2008 entitled “Method and Apparatus for Providing Treatment Profile Management” which claims priority to provisional application No. 61/015,185 filed Dec. 19, 2007, entitled “Medical Devices and Methods” assigned to the Assignee of the present application, Abbott Diabetes Care, Inc., of Alameda, Calif., the disclosure of each of which are incorporated herein by reference for all purposes.
  • BACKGROUND
  • Analyte, e.g., glucose, monitoring systems including continuous and discrete monitoring systems generally include a small, lightweight battery powered and microprocessor controlled system which is configured to detect signals proportional to the corresponding measured glucose levels using an electrometer, and RF signals to transmit the collected data. One aspect of certain analyte monitoring systems include a transcutaneous or subcutaneous analyte sensor configuration which is, for example, partially mounted on the skin of a subject whose analyte level is to be monitored. The sensor cell may use a two or three-electrode (work, reference and counter electrodes) configuration driven by a controlled potential (potentiostat) analog circuit connected through a contact system.
  • With increasing use of pump therapy for Type 1 diabetic patients, young and old alike, the importance of controlling the infusion device such as external infusion pumps is evident. Indeed, presently available external infusion devices typically include an input mechanism such as buttons through which the patient may program and control the infusion device. Such infusion devices also typically include a user interface such as a display which is configured to display information relevant to the patient's infusion progress, status of the various components of the infusion device, as well as other programmable information such as patient specific basal profiles.
  • In the course of using the analyte monitoring system and the infusion device, data associated with a patient's physiological condition such as monitored analyte levels, insulin dosage information, for example, may be stored and processed. As the complexity of these systems and devices increase, so do the amount of data and information associated with the system/device.
  • SUMMARY
  • In accordance with the various embodiments of the present disclosure, there are provided method system including displaying a first representation of a medication treatment parameter profile, displaying a first representation of a physiological profile associated with the medication treatment parameter profile, detecting a modification to a segment of the medication treatment parameter profile, displaying a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modifying an attribute of the first representation of the medication treatment parameter profile, and modifying an attribute of the first representation of the physiological profile are provided.
  • These and other objects, features and advantages of the present disclosure will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a block diagram illustrating a therapy management system for practicing one embodiment of the present disclosure;
  • FIG. 2 is a block diagram of a fluid delivery device of FIG. 1 in one embodiment of the present disclosure;
  • FIG. 3 is a flow chart illustrating therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure;
  • FIG. 4 is a flowchart illustrating analyte trend information updating procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure;
  • FIG. 5 is a flowchart illustrating modified therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure;
  • FIG. 6 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment of the present disclosure;
  • FIG. 7 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment of the present disclosure;
  • FIG. 8 illustrates dynamic medication level determination in accordance with one embodiment of the present disclosure;
  • FIG. 9 illustrates dynamic medication level determination in accordance with another embodiment of the present disclosure;
  • FIG. 10 illustrates metric analysis in accordance with one embodiment of the present disclosure;
  • FIG. 11 illustrates metric analysis in accordance with another embodiment of the present disclosure;
  • FIG. 12 is illustrates metric analysis in accordance with yet another embodiment of the present disclosure;
  • FIG. 13 illustrates metric analysis in accordance with a further embodiment of the present disclosure;
  • FIG. 14 illustrates condition detection or notification analysis in accordance with one embodiment of the present disclosure;
  • FIG. 15 illustrates condition detection or notification analysis in accordance with another embodiment of the present disclosure;
  • FIG. 16 illustrates therapy parameter analysis in accordance with one embodiment of the present disclosure;
  • FIG. 17 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with one embodiment of the present disclosure;
  • FIG. 18 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with another embodiment of the present disclosure;
  • FIG. 19 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with still another embodiment of the present disclosure;
  • FIG. 20 is a flowchart illustrating visual medication delivery profile programming in accordance with one embodiment of the present disclosure;
  • FIG. 21 is a flowchart illustrating visual medication delivery profile programming in accordance with another embodiment of the present disclosure;
  • FIG. 22 is an exemplary screen display of a medication delivery profile;
  • FIG. 23 is an exemplary screen display illustrating vertical modification of the medication delivery profile;
  • FIG. 24 is an exemplary screen display illustrating horizontal modification of the medication delivery profile;
  • FIG. 25 is an exemplary screen display illustrating addition of a transition in the medication delivery profile;
  • FIG. 26 is an exemplary screen display illustrating deletion of a transition in the medication delivery profile;
  • FIG. 27 is an exemplary display illustrating an initial glucose level and a corresponding parameter value as a function of time in one embodiment;
  • FIG. 28 is an exemplary display illustrating response to the manipulation of the initial parameter value of FIG. 27 and corresponding modification to the displayed glucose profile as a function of time in one embodiment; and
  • FIG. 29 is an exemplary display illustrating response to the manipulation of the initial parameter value of FIG. 27 and corresponding modification to the displayed glucose profile as a function of time in another embodiment.
  • DETAILED DESCRIPTION
  • FIG. 1 is a block diagram illustrating an insulin therapy management system for practicing one embodiment of the present disclosure. Referring to FIG. 1, the therapy management system 100 includes an analyte monitoring system 110 operatively coupled to an fluid delivery device 120, which may be in turn, operatively coupled to a remote terminal 140. As shown the Figure, the analyte monitoring system 110 is, in one embodiment, coupled to the patient 130 so as to monitor or measure the analyte levels of the patient. Moreover, the fluid delivery device 120 is coupled to the patient using, for example, and infusion set and tubing connected to a cannula (not shown) that is placed transcutaneously through the skin of the patient so as to infuse medication such as, for example, insulin, to the patient.
  • Referring to FIG. 1, in one embodiment the analyte monitoring system 110 may include one or more analyte sensors subcutaneously positioned such that at least a portion of the analyte sensors are maintained in fluid contact with the patient's analytes. The analyte sensors may include, but not limited to short term subcutaneous analyte sensors or transdermal analyte sensors, for example, which are configured to detect analyte levels of a patient over a predetermined time period, and after which, a replacement of the sensors is necessary.
  • The one or more analyte sensors of the analyte monitoring system 110 is coupled to a respective one or more of a data transmitter unit which is configured to receive one or more signals from the respective analyte sensors corresponding to the detected analyte levels of the patient, and to transmit the information corresponding to the detected analyte levels to a receiver device, and/or fluid delivery device 120. That is, over a communication link, the transmitter units may be configured to transmit data associated with the detected analyte levels periodically, and/or intermittently and repeatedly to one or more other devices such as the insulin delivery device and/or the remote terminal 140 for further data processing and analysis.
  • The transmitter units of the analyte monitoring system 110 may in one embodiment configured to transmit the analyte related data substantially in real time to the fluid delivery device 120 and/or the remote terminal 140 after receiving it from the corresponding analyte sensors such that the analyte level such as glucose level of the patient 130 may be monitored in real time. In one aspect, the analyte levels of the patient may be obtained using one or more of a discrete blood glucose testing devices such as blood glucose meters, or a continuous analyte monitoring systems such as continuous glucose monitoring systems.
  • Additional analytes that may be monitored, determined or detected the analyte monitoring system 110 include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be determined.
  • Moreover, within the scope of the present disclosure, the transmitter units of the analyte monitoring system 110 may be configured to directly communicate with one or more of the remote terminal 140 or the fluid delivery device 120. Furthermore, within the scope of the present disclosure, additional devices may be provided for communication in the analyte monitoring system 110 including additional receiver/data processing unit, remote terminals, such as a physician's terminal and/or a bedside terminal in a hospital environment, for example. In addition, within the scope of the present disclosure, one or more of the analyte monitoring system 110, the fluid delivery device 120 and the remote terminal 140 may be configured to communicate over a wireless data communication link such as, but not limited to RF communication link, Bluetooth communication link, infrared communication link, or any other type of suitable wireless communication connection between two or more electronic devices, which may further be unidirectional or bi-directional communication between the two or more devices. Alternatively, the data communication link may include wired cable connection such as, for example, but not limited to RS232 connection, USB connection, or serial cable connection.
  • Referring back to FIG. 1, in one embodiment, the analyte monitoring system 100 includes a strip port configured to receive a test strip for capillary blood glucose testing. In one aspect, the glucose level measured using the test strip may in addition, be configured to provide periodic calibration of the analyte sensors of the analyte monitoring system 110 to assure and improve the accuracy of the analyte levels detected by the analyte sensors.
  • Exemplary analyte systems that may be employed are described in, for example, U.S. Pat. Nos. 6,134,461, 6,175,752, 6,121,611, 6,560,471, 6,746,582, and elsewhere, the disclosures of which are herein incorporated by reference.
  • Referring again to FIG. 1, the fluid delivery device 120 may include in one embodiment, but not limited to, an external infusion device such as an external insulin infusion pump, an implantable pump, a pen-type insulin injector device, an on-body patch pump, an inhalable infusion device for nasal insulin delivery, or any other type of suitable delivery system. In addition, the remote terminal 140 in one embodiment may include for example, a desktop computer terminal, a data communication enabled kiosk, a laptop computer, a handheld computing device such as a personal digital assistant (PDAs), or a data communication enabled mobile telephone.
  • FIG. 2 is a block diagram of an insulin delivery device of FIG. 1 in one embodiment of the present disclosure. Referring to FIG. 2, the fluid delivery device 120 in one embodiment includes a processor 210 operatively coupled to a memory unit 240, an input unit 220, a display unit 230, an output unit 260, and a fluid delivery unit 250. In one embodiment, the processor 210 includes a microprocessor that is configured to and capable of controlling the functions of the fluid delivery device 120 by controlling and/or accessing each of the various components of the fluid delivery device 120. In one embodiment, multiple processors may be provided as safety measure and to provide redundancy in case of a single processor failure. Moreover, processing capabilities may be shared between multiple processor units within the insulin delivery device 120 such that pump functions and/or control maybe performed faster and more accurately.
  • Referring back to FIG. 2, the input unit 220 operatively coupled to the processor 210 may include a jog dial, a key pad buttons, a touch pad screen, or any other suitable input mechanism for providing input commands to the fluid delivery device 120. More specifically, in case of a jog dial input device, or a touch pad screen, for example, the patient or user of the fluid delivery device 120 will manipulate the respective jog dial or touch pad in conjunction with the display unit 230 which performs as both a data input and output units. The display unit 230 may include a touch sensitive screen, an LCD screen, or any other types of suitable display unit for the fluid delivery device 120 that is configured to display alphanumeric data as well as pictorial information such as icons associated with one or more predefined states of the fluid delivery device 120, or graphical representation of data such as trend charts and graphs associated with the insulin infusion rates, trend data of monitored glucose levels over a period of time, or textual notification to the patients.
  • Referring to FIG. 2, the output unit 260 operatively coupled to the processor 210 may include audible alarm including one or more tones and/or preprogrammed or programmable tunes or audio clips, or vibratory alert features having one or more pre-programmed or programmable vibratory alert levels. In one embodiment, the vibratory alert may also assist in priming the infusion tubing to minimize the potential for air or other undesirable material in the infusion tubing. Also shown in FIG. 2 is the fluid delivery unit 250 which is operatively coupled to the processor 210 and configured to deliver the insulin doses or amounts to the patient from the insulin reservoir or any other types of suitable containment for insulin to be delivered (not shown) in the fluid delivery device 120 via an infusion set coupled to a subcutaneously positioned cannula under the skin of the patient.
  • Referring yet again to FIG. 2, the memory unit 240 may include one or more of a random access memory (RAM), read only memory (ROM), or any other types of data storage units that is configured to store data as well as program instructions for access by the processor 210 and execution to control the fluid delivery device 120 and/or to perform data processing based on data received from the analyte monitoring system 110, the remote terminal 140, the patient 130 or any other data input source.
  • FIG. 3 is a flow chart illustrating insulin therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure. Referring to FIG. 3, in one embodiment of the present disclosure, a predetermined number of consecutive glucose levels are received or detected over a predetermined or defined time period. For example, in one embodiment, referring to FIG. 1, the monitored glucose levels of a patient is substantially continuously received or detected substantially in real time for a predetermined time period. In one embodiment, the predefined time period may include one or more time periods, the data within which may provide a therapeutically meaningful basis for associated data analysis.
  • That is, the predefined time period of the real time monitored glucose data in one embodiment may include one or more time periods sufficient to provide glucose trend information or sufficient to provide analysis of glucose levels to adjust insulin therapy on an on-going, and substantially real time basis. For example, the predefined time period in one embodiment may include one or more of a 15 minute time period, a 30 minute time period, a 45 minute time period, a one hour time period, a two hour time period and a 6 hour time period. While exemplary predefined time periods are provided herein, within the scope of the present disclosure, any suitable predefined time period may be employed as may be sufficient to be used for glucose trend determination and/or therapy related determinations (such as, for example, modification of existing basal profiles, calculation of temporary basal profile, or determination of a bolus amount).
  • Referring back to FIG. 3, the consecutive glucose levels received over the predefined time period in one embodiment may not be entirely consecutive due to, for example, data transmission errors and/or one or more of potential failure modes associated with data transmission or processing. As such, in one embodiment of the present disclosure, there is provided a predetermined margin of error for the received real time glucose data such that, a given number of data points associated with glucose levels which are erroneous or alternatively, not received from the glucose sensor, may be ignored or discarded.
  • Referring back to FIG. 3, upon receiving the predetermined number of glucose levels over a predefined time period, the glucose trend information based on the received glucose levels is updated. For example, in one embodiment, the glucose trend information estimating the rate of change of the glucose levels may be determined, and based upon which the projecting the level of glucose may be calculated. Indeed, in one embodiment, the glucose trend information may be configured to provide extrapolated glucose level information associated with the glucose level movement based on the real time glucose data received from the glucose sensor. That is, in one embodiment, the real time glucose levels monitored are used to determine the rate at which the glucose levels is either increasing or decreasing (or remaining substantially stable at a given level). Based on such information and over a predetermined time period, a glucose projected information may be determined.
  • Referring again to FIG. 3, the therapy related parameters associated with the monitored real time glucose levels is updated. That is, in one embodiment, one or more insulin therapy related parameters of an insulin pump such as including, but not limited to, insulin on board information associated with the fluid delivery device 120 (FIG. 1), insulin sensitivity level of the patient 130 (FIG. 1), insulin to carbohydrate ratio, and insulin absorption rate. Thereafter, in one embodiment, one or more modifications to the current therapy profile are determined. That is, in one embodiment of the present disclosure, one or more current basal profiles, calculated bolus levels, temporary basal profiles, and/or any other suitable pre-programmed insulin delivery profiles stored in the fluid delivery device 120 (FIG. 1) for example, are retrieved and analyzed based on one or more of the received real time glucose levels, the updated glucose trend information, and the updated therapy related parameters.
  • Referring back to FIG. 3, after determining one or more modifications to the therapy profiles, the modified one or more therapy profiles is generated and output to the patient 130 (FIG. 1) so that the patient 130 may select, store and/or ignore the one or more modified therapy profiles based on one or more of the monitored real time glucose values, updated glucose trend information, and updated therapy related parameters.
  • For example, in one embodiment, the patient 130 may be provided with a recommended temporary basal profile based on the monitored real time glucose levels over a predetermined time period as well as the current basal profile which is executed by the fluid delivery device 120 (FIG. 1) to deliver a predetermined level of insulin to the patient 130 (FIG. 1). Alternatively, the patient 130 in a further embodiment may be provided with one or more additional recommended actions for selection as the patient sees suitable to enhance the insulin therapy based on the real time monitored glucose levels. For example, the patient may be provided with a recommended correction bolus level based on the real time monitored glucose levels and the current basal profile in conjunction with, for example, the patient's insulin sensitivity and/or insulin on board information.
  • In this manner, in one embodiment of the present disclosure, based on real time monitored glucose levels, the patient may be provided with an on-going, real time insulin therapy options and modifications to the pre-programmed insulin delivery basal profiles so as to improve upon the initially programmed therapy profiles based on the monitored real time glucose data.
  • FIG. 4 is a flowchart illustrating analyte trend information updating procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure. Referring to FIG. 4, in one embodiment, real time data associated with monitored analyte levels is received. Thereafter it is determined whether the real time data has been received for a predetermined time period. If it is determined that the real time data has not been received for at least the predetermined time period, then the routine continues to receive the real time data associated with the monitored analyte levels such as glucose levels.
  • On the other hand, referring back to FIG. 4, if it is determined that the real time data associated with the monitored analyte levels has been received for the predetermined time period (for example, as described above in conjunction with FIG. 3), then the received real time data associated with the monitored analyte levels is stored. Thereafter, analyte level trend information is determined based on the received real time data associated with the monitored analyte levels.
  • For example, in one embodiment, the real time data associated with the monitored analyte levels is analyzed and an extrapolation of the data based on the rate of change of the monitored analyte levels is determined. That is, the real time data associated with the monitored analyte levels is used to determined the rate at which the monitored analyte level changed over the predetermined time period, and accordingly, a trend information is determined based on, for example, the determined rate at which the monitored analyte level changed over the predetermined time period.
  • In a further embodiment, the trend information based on the real time data associated with the monitored analyte levels may be dynamically modified and continuously updated based on the received real time data associated with the monitored analyte levels for one or more predetermined time periods. As such, in one embodiment, the trend information may be configured to dynamically change and be updated continuously based on the received real time data associated with the monitored analyte levels.
  • FIG. 5 is a flowchart illustrating modified therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure. Referring to FIG. 5, in one embodiment, the current therapy parameters are retrieved and, the retrieved current therapy parameters are analyzed based on the received real time data associated with the monitored analyte levels and/or updated analyte trend information. For example, one or more preprogrammed basal profiles, correction bolus, carbohydrate bolus, temporary basal and associated parameters are retrieved and analyzed based on, for example, the received real time data associated with the monitored analyte levels and/or updated analyte trend information, and further, factoring in the insulin sensitivity of the patient as well as insulin on board information.
  • Referring to FIG. 5, based upon the analysis of the current therapy parameters, one or more modified therapy profiles are calculated. That is, based upon the real time glucose levels monitored by the analyte monitoring system 110 (FIG. 1), a modification or adjustment to the pre-programmed basal profiles of the fluid delivery device 120 (FIG. 1) may be determined, and the modified therapy profiles is output to the patient 130 (FIG. 1). That is, the modification or adjustment to the pre-programmed basal profiles may be provided to the patient for review and/or execution to implement the recommended modification or adjustment to the pre-programmed basal profiles.
  • In this manner, the patient may be provided with one or more adjustments to the existing or current basal profiles or any other pre-programmed therapy profiles based on continuously monitored physiological levels of the patient such as analyte levels of the patient. Indeed, in one embodiment of the present disclosure, using continuously monitored glucose levels of the patient, modification or adjustment to the pre-programmed basal profiles may be calculated and provided to the patient for review and implementation as desired by the patient. In this manner, for example, a diabetic patient may improve the insulin therapy management and control.
  • FIG. 6 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment of the present disclosure. Referring to the Figure, one or more user input parameters is received such as, for example, the amount of carbohydrate to ingest, type of exercise to perform, current time of day information, or any other appropriate information that may potentially impact the determination of the suitable medication level. Based on the one or more user input parameters, one or more database is queried. In one embodiment, the database may be provided in the analyte monitoring system 110. Alternatively or in addition, the one or more database may be provided in the fluid delivery device 120 and/or remote terminal 140.
  • Referring back to FIG. 6, the database query in one embodiment may be configured to search or query for medication dosage levels that are associated with similar parameters as the received one or more user input parameters. Thereafter, the queried result is generated and provided to the user which may be acted upon by the user, for example, to administer the medication dosage level based on the queried result. The user selection of the administered medication dosage level is stored in the database with the associated one or more user input parameters as well as the time and date information of when the user has administered the medication dosage level.
  • In this manner, in one embodiment, insulin dosages and associated contextual information (e.g., user input parameters) may be stored and tracked in one or more databases. For example, a bolus amount for a diabetic patient may be determined in the manner described above using historical information without performing a mathematical calculation which takes into account of variables such as sensitivity factors vary with time and/or user's physiological conditions, and which may need to be estimated.
  • In particular, in one embodiment of the present disclosure, insulin dependent users may determine their appropriate insulin dosages by, for example, using historical dosage information as well as associated physiological condition information. For example, the historical data may be stored in one or more databases to allow search or query based on one or more parameters such as the user's physiological condition and other contextual information associated with each prior bolus dosage calculated and administered. In this manner, the user may be advised on the proper amount of insulin under the particular circumstances, the user may be provided with descriptive statistical information of insulin dosages under the various conditions, and the overall system may be configured to learn and customize the dosage determination for the particular user over an extended time period.
  • For example, in one aspect, contextual information may be stored with the insulin bolus value. The contextual data in one aspect may include one or more of blood glucose concentration, basal rate, type of insulin, exercise information, meal information, carbohydrate content estimate, insulin on board information, and any other parameters that may be used to determine the suitable or appropriate medication dosage level. Some or all of the contextual information may be provided by the user or may be received from another device or devices in the overall therapy management system such as receiving the basal rate information from the fluid delivery device 120 (FIG. 1), or receiving the blood glucose concentration from the analyte monitoring system 110 (FIG. 1).
  • By way of an example, a contextually determined medication dosage level in one embodiment may be provided to the user along with a suitable or appropriate notification or message to the user that after a predetermined time period since the prior administration of the medication dosage level, the blood glucose level was still above a target level. That is, the queried result providing the suitable medication dosage level based on user input or other input parameters may be accompanied by other relevant physiological condition information associated with the administration of the prior medication dosage administration. In this manner, when the user is provided with the contextually determined medication dosage level, the user is further provided with information associated with the effects of the determined medication dosage level to the user's physiological condition (for example, one hour after the administration of the particular medication dosage level determined, the user's blood glucose level changed by a given amount). Accordingly, the user may be better able to adjust or modify, as desired or needed, the contextually determined medication dosage level to the current physiological conditions.
  • In this manner, in one embodiment, to determine and provide the user with proper medication dosage levels, the present or current context including the patient's current physiological condition (such as current blood glucose level, current glucose trend information, insulin on board information, the current basal profile, and so on) is considered and the database is queried for one or more medication dosage levels which correlate (for example, within a predetermined range of closeness or similarity) to the one or more current contextual information associated with the user's physiological condition, among others.
  • Accordingly, in one embodiment, statistical determination of the suitable medication dosage based on contextual information may be determined using, one or more of mean dosage determination, using a standard deviation or other appropriate statistical analysis of the contextual information for medication dosages which the user has administered in the past. Further, in one aspect, in the case where no close match is found in the contextual query for the desired medication dosage level, the medication dosage level with the most similar contextual information may be used to interpolate an estimated medication dosage level.
  • In still another aspect, the database query may be configured to provide time based weighing of prior medication dosage level determinations such that, for example, more recent dosage level determination which similar contextual information may be weighed heavier than aged dosage level determination under similar conditions. For example, older or more aged bolus amounts determined may be weighed less heavily than the more recent bolus amounts. Also, over an extended period of time, in one aspect, the older or aged bolus amounts may be aged out or weighed with a value parameter that minimally impacts the current contextual based bolus determination. In this manner, in one aspect, a highly personalized and individualistic profile for medication dosage determination may be developed and stored in the database with the corresponding contextual information associated therewith.
  • FIG. 7 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment. Referring to FIG. 7, in one aspect, when the user input parameters are received at step 710, the current infusion profile of the user's insulin pump is determined at step 720. Thereafter, the database is queried based on the input parameters and the current infusion profile at step 730, and which results in one or more contextually determined bolus amount associated with the input parameters and the current infusion profile at step 740 that is provided to the user. The determined bolus amount is then stored in the database with the associated input parameters and the current infusion profile and any other contextual information associated with the determined bolus amount.
  • In this manner, in one aspect, in addition to the user provided input parameters, other relevant contextual information may be retrieved (for example, the current infusion profile such as basal rate from the insulin pump, the current blood glucose level and/or glucose trend information from the analyte monitoring system, and the like) prior to the database query to determine the suitable bolus amount.
  • As discussed above, optionally, the contextual information including the user input parameters and other relevant information may be queried to determine the suitable medication dosage level based on one or more statistical analysis such as, for example, but not limited to, descriptive statistics with the use of numerical descriptors such as mean and standard deviation, or inferential statistics including, for example, estimation or forecasting, correlation of parameters, modeling of relationships between parameters (for example, regression), as well as other modeling approaches such as time series analysis (for example, autoregressive modeling, integrated modeling and moving average modeling), data mining, and probability.
  • By way of a further non-limiting example, when a diabetic patient plans to ingest insulin of a particular type, the patient enters contextual information such as that the patient has moderately exercised and is planning to consume a meal with a predetermined estimated carbohydrate content. The database in one embodiment may be queried for insulin dosages determined under similar circumstances in the past for the patient, and further, statistical information associated with the determined insulin dosage is provided to the user. In one aspect, the displayed statistical information associated with the determined insulin dosage may include, for example, an average amount of insulin dosage, a standard deviation or a median amount and the 25th and the 75th percentile values of the determined insulin dosage.
  • The patient may consider the displayed statistical information associated with the determined insulin dosage, and determines the most suitable or desired insulin amount based on the information received. When the patient programs the insulin pump to administer the desired insulin amount (or otherwise administer the desired insulin amount using other medication administration procedures such as injection (using a pen-type injection device or a syringe), intaking inhalable or ingestable insulin, and the like, the administered dosage level is stored in the database along with the associated contextual information and parameters.
  • In this manner, the database for use in the contextual based query may be continuously updated with each administration of the insulin dosage such that, each subsequent determination of appropriate insulin dosage level may be determined with more accuracy and is further customized to the physiological profile of the particular patient. Additionally, the database queried may be used for other purposes, such as, for example, but not limited to tracking medication information, providing electronic history of the patient related medical information, and the like. Further, while the above example is provided in the context of determining an insulin level determination, within the scope of the present disclosure, other medication dosage may be determined based on the contextual based database query approaches described herein.
  • In a further aspect, the contextual based medication dosage query and determination may be used in conjunction with the standard or available medication dosage determination (for example, standard bolus calculation algorithms) as a supplement to provide additional information or provide a double checking ability to insure that the estimated or calculated bolus or medication dosage level is appropriate for the particular patient under the physiological condition at the time of the dosage level determination.
  • Within the scope of the present disclosure, the processes and routines described in conjunction with FIGS. 3-7 may be performed by the analyte monitoring system 110 (FIG. 1) and/or the fluid delivery device 120 (FIG. 1). Furthermore, the output of information associated with the context based database query for medication dosage determination may be displayed on a display unit of the receiver of the analyte monitoring system 110 (FIG. 1), or the infusion device display of the fluid delivery device 120 (FIG. 1), the display unit of the remote terminal 140 (FIG. 1), or any other suitable output device that is configured to receive the results of the database query associated with the medication dosage level determination. Alternatively, one or more such information may be output to the patient audibly as sound signal output.
  • In this manner, there are provided methods and system for receiving one or more parameters associated with a user physiological condition, querying a database based on the one or more parameters associated with the user physiological condition, generating a medication dosage amount based on the database query, and outputting the medication dosage amount to the user.
  • Optionally, statistical analysis may be performed based on the database query and factored into generating the medication dosage amount for the user.
  • In other aspects, there are provided methods and system for providing information associated with the direction and rate of change of analyte (e.g., glucose) levels changes for determination of, for example, bolus or basal rate change recommendations, for comparing expected glucose level changes to actual real time glucose level changes to update, for example, insulin sensitivity factor in an ongoing basis, and for automatically confirming the monitored glucose values within a preset time period (e.g., 30 minutes) after insulin therapy initiation to determine whether the initiated therapy is having the intended therapeutic effect.
  • Indeed, in accordance with the various embodiments of the present disclosure, the use of glucose trend information in insulin delivery rate determinations provides for a more accurate insulin dosing and may lead to a decrease in hypoglycemic events and improved HbAlCs.
  • Accordingly, a method in one embodiment of the present disclosure includes receiving data associated with monitored analyte related levels for a predetermined time period substantially in real time, retrieving one or more therapy profiles associated with the monitored analyte related levels, generating one or more modifications to the retrieved one or more therapy profiles based on the data associated with the monitored analyte related levels.
  • The method may further include displaying the generated one or more modifications to the retrieved one or more therapy profiles.
  • In one aspect, the generated one or more modifications to the retrieved one or more therapy profiles may be displayed as one or more of an alphanumeric output display, a graphical output display, an icon display, a video output display, a color display or an illumination display.
  • In a further aspect, the predetermined time period may include one of a time period between 15 minutes and six hours.
  • The one or more therapy profiles in yet another aspect may include a basal profile, a correction bolus, a temporary basal profile, an insulin sensitivity, an insulin on board level, and an insulin absorption rate.
  • In still another aspect, retrieving the one or more therapy profiles associated with the monitored analyte related levels may include retrieving a current analyte rate of change information.
  • In yet still another aspect, generating the one or more modifications to the retrieved one or more therapy profiles may include determining a modified analyte rate of change information based on the received data associated with monitored analyte related levels.
  • Moreover, the method may further include generating an output alert based on the modified analyte rate of change information.
  • Still, the method may also include determining an analyte level projection information based on the modified analyte rate of change information.
  • A system for providing diabetes management in accordance with another embodiment of the present disclosure includes an interface unit, one or more processors coupled to the interface unit, a memory for storing instructions which, when executed by the one or more processors, causes the one or more processors to receive data associated with monitored analyte related levels for a predetermined time period substantially in real time, retrieve one or more therapy profiles associated with the monitored analyte related levels, and generate one or more modifications to the retrieved one or more therapy profiles based on the data associated with the monitored analyte related levels.
  • The interface unit may include an input unit and an output unit, the input unit configured to receive the one or more analyte related data, and the output unit configured to output the one or more of the generated modifications to he retrieved one or more therapy profiles.
  • The interface unit and the one or more processors in a further embodiment may be operatively coupled to one or more of a housing of an infusion device or a housing of an analyte monitoring system.
  • The infusion device may include one of an external insulin pump, an implantable insulin pump, an on-body patch pump, a pen-type injection device, an inhalable insulin delivery system, and a transdermal insulin delivery system.
  • The memory in a further aspect me ye configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to display the generated one or more modifications to the retrieved one or more therapy profiles.
  • Further, the memory may be configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to display the generated one or more modifications to the retrieved one or more therapy profiles as one or more of an alphanumeric output display, a graphical output display, an icon display, a video output display, a color display or an illumination display.
  • In one aspect, the predetermined time period may include one of a time period between 15 minutes and six hours.
  • The one or more therapy profiles may include a basal profile, a correction bolus, a temporary basal profile, an insulin sensitivity, an insulin on board level, and an insulin absorption rate.
  • In another aspect, the memory may be further configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to retrieve a current analyte rate of change information.
  • In still another aspect, the memory may be further configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to determine a modified analyte rate of change information based on the received data associated with monitored analyte related levels.
  • Additionally, in yet still another aspect, the memory may be further configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to generate an output alert based on the modified analyte rate of change information.
  • Further, the memory may be further configured for storing instructions which, when executed by the one or more processors, causes the one or more processors to determine an analyte level projection information based on the modified analyte rate of change information.
  • A system for providing diabetes management in accordance with yet another embodiment of the present disclosure includes an analyte monitoring system configured to monitor analyte related levels of a patient substantially in real time, a medication delivery unit operatively for wirelessly receiving data associated with the monitored analyte level of the patient substantially in real time from the analyte monitoring system, a data processing unit operatively coupled to the one or more of the analyte monitoring system or the medication delivery unit, the data processing unit configured to retrieve one or more therapy profiles associated with the monitored analyte related levels, and generate one or more modifications to the retrieved one or more therapy profiles based on the data associated with the monitored analyte related levels.
  • In one aspect, the analyte monitoring system may be configured to wirelessly communicate with one or more of the medication delivery unit or the remote terminal such as a computer terminal (PC) or a server terminal over a radio frequency (RF) communication link, a Bluetooth communication link, an Infrared communication link, or a wireless local area network (WLAN).
  • FIG. 8 illustrates dynamic medication level determination in accordance with one embodiment of the present disclosure. In one aspect, the analyte monitoring system 110 (FIG. 1) may be configured to receive and store available and/or valid analyte sensor data including continuous glucose level measurement data (8100) which are indicative of the user or patient's current and past glucose levels. When the patient or the user is anticipating a meal event or any other event which may likely impact the glucose level, the patient or the user may activate or call a bolus determination function (8110) using, for example, a user interface input/output unit of the analyte monitoring system 110 (FIG. 1) or that of the fluid delivery unit 120 (FIG. 1).
  • Referring to FIG. 8, in one aspect the patient enters the anticipated carbohydrate intake amount, or other form of meal selection or one or more other parameters as desired for bolus determination function. With the retrieved glucose level information (8010) it is not necessary for the patient or the user to manually enter the glucose level information. In alternate embodiment, the glucose level information may be manually entered by the patient or the user. Optionally, blood glucose level may be provided to the system based on a finger stick test using a blood glucose meter device.
  • In one aspect, the patient or the user may enter anticipated carbohydrate information based on a pre-programmed food library stored, for example, in the analyte monitoring system 110 or the fluid delivery device 120 (FIG. 1). Such stored information may include, for example, serving size and associated carbohydrate value for different types of food, or other relevant food information related to the physiology of food update (such as fat content, for example) which may be preloaded into the analyte monitoring system 110 or the fluid delivery device 120, or alternatively, personalized by the patient or the user using custom settings and stored in the memory device of the analyte monitoring system 110 or the fluid delivery device 120.
  • Referring again to FIG. 8, the bolus level determination is performed in one embodiment (8110) upon patient or user activation of a user input button or component, or alternatively, in an automatic manner upon user entry of the meal information (8120). In one aspect, the bolus determination may include glucose level information from the analyte monitoring system 110 (FIG. 1) and the meal information received from the patient or the user, in conjunction with one or more of other relevant parameters described below, to propose an insulin dosage or level information to attain an anticipated blood glucose level or the future or target glucose profile (8190). In one aspect, the future or target glucose profile may be preset or alternatively, may be adjusted or modified based, for example, on the patient or user's physiological condition or profile. I none aspect, the future or target glucose profile may include a single glucose target value, or a range of desired glucose levels. Other parameters may be included in the target or future glucose profile such as, for example, maximum peak glucose value, minimum glucose value, time to achieve within 5% of the target glucose value, or other dynamic parameters. In a further aspect, the future or target glucose profile may be specified as a cost function to minimize, such as, the area defined by the accumulation in time of deviations from a target value and control sensitivity parameters, such as overshoot and undershoot. Within the scope of the present disclosure, other glucose target profiles and/or cost functions may be contemplated.
  • Referring back to FIG. 8, the determination of required insulin infusion to achieve the target glucose profile (8130) may include other parameters which may be predefined or patient adjustable, and/or automatically adjusted using, for example, an adaptive learning algorithm or routine that may be configured to tune the particular parameter based on a particular patient/user's physiological condition or therapy profile.
  • For example, one input parameter may be associated with the patient's physiological glucose response to meal intake and/or insulin intake (8160). Factors such as carbohydrate ratio and insulin sensitivity are contemplated. In one aspect, this parameter may be configured to be responsive to the various meal types or components, response time parameters and the like, such that it is updated, real time or semi real-time, based on the change to the patient's physiological condition related to the glucose level monitored by, for example, the analyte monitoring system 110 (FIG. 1).
  • Another input parameter may include factors associated with the meal—meal dynamics parameters (8170). In one aspect, the meal dynamics parameters may include the timing of the meal (for example, meal event starts immediately), and the full carbohydrate intake is an impulse function—that is, the meal is substantially ingested in a short amount of time. Alternatively, factors associated with the meal dynamics parameters may be specified or programmed such as, for example, time to meal intake onset (relative to the start time of the bolus delivery), carbohydrate intake profile over time (for example, carbohydrate intake may be configured to remain substantially constant over a predetermined time period). Within the scope of the present disclosure, other elaborate intake models are contemplated.
  • Referring again to FIG. 8, a further input parameter may include insulin dynamic response parameters (8180) which may include physiological dynamic glucose response associated with the different types of insulin that may be delivered by, for example, fluid delivery device 120 (FIG. 1). For example, a factor associated with the insulin dynamic response parameters may include time to peak effect of the relevant insulin formulation, or a time constant associated with the glucose response which may be established by the type of insulin for delivery.
  • In one aspect, the calculation of the required insulin to attain the targeted glucose profile (8130) may be configured in different manner. For example, the determination may be configured as a lookup table, with input values as described above, and associated outputs of insulin profiles. In one aspect, the dynamic functional relationship that defines the physiological glucose response to the measurement inputs and parameters described above may be incorporated for determination of the desired insulin amount. The calculation or determination function may be incorporated in a regulator control algorithm that may be configured to model functional relationships and measured input values or parameters to define a control signal to drive the therapy system 100 (FIG. 1) to achieve the desired response. That is, in one aspect, the dynamic functional relationship may be defined by the physiological relationships and/or the parameter inputs. The measured input values may include the current and prior glucose values, for example, received from the analyte sensor in the analyte monitoring system 110 (FIG. 1) and the user or patient specified meal related information. The control signal discussed above may include determined or calculated insulin amount to be delivered, while the desired response includes the target or desired future glucose profile.
  • Referring yet again to FIG. 8, the determined insulin level, based on the calculation described above, may be displayed optionally with other relevant information, to the patient or the user (8140). In one aspect, the patient or the user may modify the determined insulin level to personalize or customize the dosage based on the user's knowledge of her own physiological conditions, for example. The patient or the user may be also provided with a function or a user input command to execute the delivery of the determined bolus amount (8150), which, upon activation is configured to control the fluid delivery device 120 (FIG, 1) to deliver the determined amount of insulin to the patient. A further embodiment may not permit the patient modification of the determined bolus amount, and/or include automatic delivery of the determined insulin amount without patient or user intervention. In still a further embodiment, based on the monitored analyte levels of the patient, the determined insulin amount may be displayed to the user with a recommendation to defer the activation or administration of the determined insulin amount for a predetermined time period.
  • FIG. 9 illustrates dynamic medication level determination in accordance with another embodiment of the present disclosure. Referring to FIG. 9, in another embodiment, the bolus determination function may include additional data from the analyte monitoring system 110 (FIG. 1), the fluid delivery device 120 (FIG. 1), and/or the remote terminal 140 (FIG. 1). More specifically, in one aspect, one or more blood glucose measurement data (9110) and/or the current and previous insulin administration profiles or measurements (9120) may be retrieved from one or more of the analyte monitoring system 110, the fluid delivery device 120 and/or the remote terminal 140 of the therapy management system 100 (FIG. 1).
  • Each of the measured or monitoring data or information such as analyte sensor data, blood glucose measurements, insulin delivery information and the like, in one aspect, are associated with a time stamp and stored in the one or more memory devices of the therapy management system 100. Thus, this information may be retrieved for therapy related determination such as bolus dosage calculation, or further data analysis for therapy management for the patient.
  • In accordance with aspect of the present disclosure, the various sources of glucose level determination (in some instances redundant), in several different ways. For example, Kalman filter may be used to provide for multiple measurements of the same measurable quantity. The Kalman filter may be configured to use the input parameters and/or factors discussed above, to generate an optimal estimate of the measured quantity. In a further configuration, the Kalman filter may be configured to validate the analyte sensor data based on the blood glucose measurements, where one or more sensor data may be disqualified if the blood glucose data in the relevant time period deviates from the analyte sensor data by a predetermined level or threshold. Alternatively, the blood glucose measurements may be used to validate the analyte sensor data or otherwise, calibrate the sensor data.
  • In a further aspect, the bolus determination function may include a subroutine to indicate unacceptable error in one or more measured data values. For example, in the case where analyte sensor data include attenuations (or “dropouts”), in one aspect, a retrospective analysis may be performed to detect the incidence of such signal attenuation in the analyte sensor data, and upon detection, the bolus determination function may be configured to ignore or invalidate this portion of data in its calculation of the desired insulin amount. Additionally, the therapy management system 100 may be configured such that insulin dosage or level calculation or determination includes a validation of analyte sensor data and/or verification of the sensor data for use in conjunction with the bolus determination (or any other therapy related determination) function.
  • In a further aspect of the present disclosure, various metrics may be determined to summarize a patient's monitored glucose data and related information such as, but not limited to insulin delivery data, exercise events, meal events, and the like, to provide indication of the degree or status of the management and control of the patient's diabetic conditions. Metrics may be determined or calculated for a specified period of time (up to current time), and include, but not limited to, average glucose level, standard deviation, percentage above/below a target threshold, number of low glucose alarms, for example. The metrics may be based on elapsed time, for example, since the time of the patient's last reset of particular metric(s), or based on a fixed time period prior to the current time. Such determined metrics may be visually or otherwise provided to the patient in an easy to understand and navigate manner to provide the progression of the therapy management to the user and also, with the option to adjust or modify the related settings or parameters.
  • In one aspect, the output of the determined metrics may be presented to the user on the output unit 260 (FIG. 2) of the fluid delivery device 120 (FIG. 1), a display deice on the analyte monitoring system 110, a user interface, and/or an output device coupled to the remote terminal 140 (FIG. 1). In one aspect, the metrics may be configured to provide a visual indication, tactile indication, audible indication or in other manner in which the patient or the user of the therapy management system 100 (FIG. 1) is informed of the condition or status related to the therapy management. Each metric may be user configurable to allow the patient or the user to obtain additional information related to the metric and associated physiological condition or the operational state of the devices used in the therapy management system 100. The metric may be associated with indicators or readings other than glucose, such as, for example, the amount and/or time of insulin delivered, percentage of bolus amount as compared to the total insulin delivered, carbohydrate intake, alarm events, analyte sensor replacement time periods, and in one aspect, the user or the patient may associate one or more alarms, alerts or notification with one or more of the metrics as may be desired.
  • FIG. 10 illustrates metric analysis in accordance with one embodiment of the present disclosure. Referring to FIG. 10, upon activation of the display (1010) or a user interface device coupled to the one or more devices in the therapy management system 100 (FIG. 1), the desired metric information is determined (1020), for example, based on the current available information (e.g., the insulin delivery information for the past 2 hours). After determining the metric information, the determined metric information is displayed on the main or home screen or display of the user interface device (1030).
  • In one aspect, as shown in FIG. 10, the displayed metric may be selected, for example, based on user activation on a display element (1040). Upon detecting the selection of the particular metric displayed, additional detail information related to the selected metric as well as, optionally, other related information are determined or calculated (1050), and thereafter provided to the user or the patient on the user interface device (1060). In this manner, in one aspect, the user interface device may be configured with layered menu hierarchy architecture for providing current information associated with a particular metric or condition associated with the therapy management system. The patient or the user may configure the user interface device to display or output the desired metrics at a customizable levels of detail based on the particular patient or the user's settings. While the above description is provided in conjunction with a visual indication on the user interface device, within the scope of the present invention, other output indications may be similarly configured and used, such as audible notifications, vibratory or tactile notifications, and the like, each of which may be similarly configured by the patient or the user.
  • Within the scope of the present disclosure, the metrics may be provided on other devices that may be configured to receive periodic updates from the user interface device of the therapy management system. In one aspect, such other devices may include mobile telephones, personal digital assistants, pager devices, Blackberry devices, remote care giver devices, remote health monitoring system or device, which may be configured for communication with the therapy management system 100, and that may be configured to process the data from the therapy management system 100 to determine and output the metrics. This may be based on real time or substantially real time data communication with the therapy management system 1 00. In other aspects, the therapy management system 100 may be configured to process and determine the various metrics, and transmit the determined metrics to the other devices asynchronously, or based on a polling request received from the other devices by the therapy management system 100.
  • The user interface device in the therapy management system 100 may be configurable such that the patient or the user may customize which metric they would like to view on the home screen (in the case of visual indication device such as a display unit). Moreover, other parameters associated with the metrics determination, such as, for example, but not limited to the relevant time period for the particular metric, the number of metrics to be output or displayed on a screen, and the like may be configured by the user or the patient.
  • In a further aspect, the metric determination processing may include routines to account for device anomalies (for example, in the therapy management system 100), such as signal attenuation (ESA) or dropouts, analyte sensor calibration, or other physiological conditions associated with the patient as well as operational condition of the devices in the therapy management system such as the fluid delivery device 120 (FIG. 1) or the analyte monitoring system 110 (FIG. 1).
  • Some glucose measurement anomalies may not be detected in real time and thus require retrospective detection and/or compensation. When processing a batch current and past analyte sensor data to, for example, determine a particular metric, determine a desired bolus dosage amount, evaluate data to detect glucose control conditions, perform a data fit function to a model to execute therapy simulations, or perform any other process that may be contemplated which requires the processing of prior glucose related data, anomalies such as signal attenuation, dropouts, noise burse, calibration errors or other anomalies may be detected and/or compensated. For example, a signal dropout detector may be used to invalidate a portion of the prior glucose related data, to invalidate an entire data set, or to notify the patient or the user of the corresponding variation or uncertainly in accuracy in a predetermined one or more metrics or calculations.
  • For example, referring to FIG. 11 which illustrates metric analysis in accordance with another embodiment of the present disclosure, based on current and past stored sensor data and blood glucose data received (1110), retrospective validation of data used in metric calculation is performed (1120), which includes one or more metric calculation parameters (1130). Referring to FIG. 11, in one aspect, the metric calculation parameters (1130) may be used in the metric calculation (1140) which, as shown, may be performed after the data to be used in the metric calculation are retrospectively validated.
  • In one aspect, the metrics may be determined or recalculated after each received analyte sensor data and thereafter, displayed or provided to the user or the patient upon request, or alternatively, automatically, for example, by refreshing the display screen of the user interface device in the therapy management system 100 (FIG. 1), or otherwise providing an audible or vibratory indication to the patient or the user.
  • FIG. 12 is illustrates metric analysis in accordance with yet another embodiment of the present disclosure. Referring to FIG. 12, upon detection of display activation (1210), the user interface device may be configured to activate a home screen or main menu configuration or setup function based on detected display element selection (1220). That is, in one aspect, the user or the patient may call a configuration function to customize the displayed menu associated with the display or output indication of the metrics.
  • Referring to FIG. 12, from the configuration menu on the user interface device, the user or patient selection of one or more metrics to be displayed or output on the main menu or home screen on the user interface device is detected (1230). After storing the user defined or selected metrics related configuration, the user interface device is configured to display or output the selected one or more metrics on the home screen or the main menu each time the user interface device is activated (1240). In this manner, in one aspect, the user or the patient may be provided with an option to display or output a particular subset of available metrics on the main display screen of the user interface device. In another aspect, the user interface device in the therapy management system 100 may be configured to include a default set of metrics to displayed and/or updated, either in real time, or substantially in real time, or based in response to another related event such as an alarm condition, or a monitored glucose level. The system may be configured to not output any metrics.
  • FIG. 13 illustrates metric analysis in accordance with a further embodiment of the present disclosure. Referring to FIG. 13, upon detection of the display or user interface device activation (1310), metric calculation setup function is called based on detection of a display selection to activate the same (1320), and detection of a selection from a list of metrics that allow the calculations to be modified (or alarms associated) (1330). The configuration options including metric calculation parameters, for example, are displayed (1340) in one embodiment, and the selected metric may be calculated, with one or more parameters modified or otherwise programmed, and optionally with one or more alarm conditions or settings associated with the selected metric (1 350).
  • In this manner, the patient or the user may in one embodiment interact with the user interface device to customize or program the determination or calculation of the particular one or more metrics for display, and further, to modify the parameters associated with the calculation of the various metrics. Accordingly, in one aspect of the present disclosure, therapy related information may be configured for output to the user to, among others, provide the patient or the user of the associated physiological condition and the related therapy compliance state.
  • In accordance with still another aspect of the present disclosure, the therapy management system 100 (FIG. 1) may be configured to monitor potential adverse conditions related to the patient's physiological conditions. For example, a prevalence of glucose levels for a predetermined time period, pre-prandial, may be analyzed to determine if the prevalence exceeds a predefined threshold, with some consistency. Upon detection of the predefined adverse condition, the user interface device may be configured to provide a notification (visual or otherwise) to the patient or the user, and varying degrees of detailed information associated with the detected adverse condition may be provided to the patient or the user. Such notification may include text information such as, for example “Your pre-meal glucose tends to be high”, or graphically by use of an arrow icon or other suitable visual indication, or a combination of text and graphics.
  • Adverse conditions that are not related to the monitored analyte level, such as insulin delivery data that is consistent with insulin stacking may be detected. Other examples include mean bolus event that appear to occur too late relative to the meal related glucose increases may be detected, or excessive use of temporary basal or bolus dosage or other modes of enhanced insulin delivery beyond the basal delivery profiles. Also device problems such as excessive signal dropouts from the analyte sensor may be detected and reported to the user.
  • In one aspect, the user interface device may be configured to customize or program the visual output indication such as icon appearance, such as enabling or disabling the icon appearance or one or more alarms associated with the detection of the adverse conditions. The notification to the user may be real time, active or passive, such that portions of the user interface device is updated to provide real time detection of the adverse conditions. Moreover, the adverse condition detection thresholds may be configured to be more or less sensitive to the triggering event, and further, parameters associated with the adverse condition detection determination may be adjusted—for example, the time period for calculating a metric.
  • In a further aspect, the user interface device may provide indication of a single adverse detection condition, based on a priority list of possible adverse conditions, a list of detected adverse conditions, optionally sorted by priority, or prior detection of adverse conditions. Also, the user interface device may provide treatment recommendation related to the detected adverse condition, displayed concurrently, or options to resolve the detected adverse condition along with the detected adverse condition. In still another aspect, the notification of the detected adverse condition may be transmitted to another device, for example, that the user or the patient is carrying or using such as, for example, mobile telephone, a pager device, a personal digital assistant, or to a remote device over a data network such as a personal computer, server terminal or the like.
  • In still another embodiment, some or all aspects of the adverse condition detection and analysis may be performed by a data management system, for example, by the remote terminal 140 (FIG. 1) or a server terminal coupled to the therapy management system 100. In this case, the analysis, detection and display of the adverse condition may be initiated upon the initial upload of data from the one or more analyte monitoring system 110 or the fluid delivery device 120, or both. Additionally, the adverse condition process may also account for potential measurement anomalies such as analyte sensor attenuation conditions or dropouts, or sensor calibration failures.
  • FIG. 14 illustrates condition detection or notification analysis in accordance with one embodiment of the present disclosure. Referring to FIG. 14, upon user interface device activation detection (1410) such as activation of a display device in the therapy management system 100 (FIG. 1), preprogrammed or predefined adverse condition is detected (1420), and displayed (1430) on the home screen of the user interface device using, for example, a problem icon. When the selection of the icon display element associated with the adverse condition is detected (1440), for example, indicating that the patient or the user desires additional information associated with the detected adverse condition, additional detailed information associated with the adverse condition is determined, as appropriate (1450), and thereafter, the additional detailed information is displayed to the user (1460).
  • FIG. 15 illustrates condition detection or notification analysis in accordance with another embodiment of the present disclosure. Referring to FIG. 15, current and prior stored analyte sensor data and blood glucose data are retrieved (1510) and retrospective validation of the data for use in the adverse condition detection process is performed (1530), based also, at least in part, on the detection calculation parameters (1520) which may be user input or preprogrammed and stored. Thereafter, the adverse condition detection process is performed (1540), for example, the parameters associated with the programmed adverse conditions are monitored and upon detection, notified to the patient or the user.
  • In accordance with yet a further aspect of the present disclosure, therapy analysis system is provided. In one aspect, the therapy management system 100 (FIG. 1) may be used to collect and store patient related data for analysis to optimizing therapy profiles and associated parameters for providing treatment to the patients. More specifically, FIG. 16 illustrates therapy parameter analysis in accordance with one embodiment of the present disclosure. As shown, data from a continuous glucose monitoring system (CGM) such as an analyte monitoring system 110 (FIG. 1) and an insulin pump such as, for example, fluid delivery device 120 (FIG. 1) are collected or stored over a predetermined time period. In addition, during this time period, meal intake information may be stored, along with other relevant data such as, exercise information, and other health related information. All data are stored with a corresponding date and time stamp and are synchronized.
  • After the predetermined time period, the stored data including, for example, time synchronized analyte sensor data (CGM), blood glucose (BG) data, insulin delivery information, meal intake information and pump therapy settings, among others, are uploaded to a personal computer, for example, such as the remote terminal 140 (FIG. 1) for further analysis (1601). The received data are used as input data including, for example, actual glucose data (CGM), actual blood glucose data (BG), actual insulin amount delivered, actual pump settings including carbohydrate ratio, insulin sensitivity, and basal rate, among other (1607), as well as actual meal information (1608), to perform a system identification process (1602).
  • More specifically, the system identification process (1602) in one embodiment is configured to fit the received input data to a generic physiological model that dynamically describes the interrelationship between the glucose levels and the delivered insulin level as well as meal intake. In this manner, in one aspect, the system identification process (1602) is configured to predict or determine glucose levels that closely matches the actual glucose level (CGM) received as one of the input parameters.
  • Referring to FIG. 16, as shown the parameters of the generic physiological model are adjusted so that the model output (glucose level) closely matches the actual monitored glucose level when the measured inputs are applied (1610). That is, a newly identified model is generated based, at least in part, on meal dynamics, insulin absorption dynamics, and glucose response dynamics. Thereafter, based on the newly identified model (1610), actual meal information representing carbohydrate intake data (1608), and the glucose profile target(s) as well as any other constraints such as insulin delivery limits, low glucose limits, for example (1609), to determine the optimal pump setting to obtain the target glucose profile(s) (1603). That is, in one aspect, based on a predefined cost function such as minimizing the area about a preferred glucose level, or some other boundaries, predicted glucose levels are determined based on optimal pump therapy settings, and optimal insulin delivery information (1611).
  • Based on the analysis performed as described above, a report may be generated which show modal day results, with median and quartile traces, and illustrating the actual glucose levels and glucose levels predicted based on the identified model parameters, actual insulin delivery information and optimal insulin delivery information, actual mean intake information, and actual and optimal insulin therapy settings (1604). Other report types can be generated as desired. In one aspect, a physician or a treatment provider may modify one or more parameters to view a corresponding change in the predicted glucose values, for example, that may be more conservative to reduce the possibility of hypoglycemia.
  • Referring again to FIG. 16, a new predicted glucose and insulin delivery information based on the adjusted setting are determined (1605). The predicted glucose values and insulin delivery information are added to the plot displayed and in one aspect, configured to dynamically change, in real time, in response to the parameter adjustments. Upon determination of an acceptable therapy profile, the settings and/or parameters associated with the insulin delivery, including, for example, modified basal profiles, for the insulin pump, may be downloaded (1606) to the pump controller from the computer terminal (for example, the remote terminal 140) for execution by the insulin pump, for example, the fluid delivery device 120 (FIG. 1).
  • FIG. 17 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with one embodiment of the present disclosure. Referring to FIG. 17, in one aspect of the present disclosure, the physiological profile of a patient or user based on data collected or received from one or more of the analyte monitoring system 110 (FIG. 1) or the fluid delivery device (120) for example, are retrieved (1710). For example, based on a collection of data associated with monitored analyte levels of a patient and/or the therapy information such as the actual or programmed insulin delivery profiles, the profile of a patient which represents the physiological condition of the patient is retrieved (1720). Other relevant data could be collected, for example, but not limited to, the patient's physical activities, meal consumption information including the particular content of the consumed meal, medication intake including programmed and executed basal and/or bolus profiles, other medication ingested during the relevant time period of interest.
  • Thereafter, a simulation of a physiological model based on the retrieved physiological condition is generated. In one aspect, the generated physiological model includes one or more parameters associated with the patient's physiological condition including, for example, insulin sensitivity, carbohydrate ratio and basal insulin needs. In one aspect, the relevant time period of interest for physiological simulation may be selected by the patient, physician or the care provider as may be desired. In one aspect, there may be a threshold time period which is necessary to generate the physiological model, and thus a selection of a time period shorter than the threshold time period may not result in accurate physiological modeling. For example, in one aspect, the data processing system or device may be configured to establish a seven day period as the minimum number of days based on which, the physiological modeling may be achieved.
  • Referring to FIG. 17, with the generated physiological model based on the patient's profile, one or more patient condition parameters may be modified (1730). For example, the basal profile for the infusion device of the patient may be modified and entered into the simulation module. Alternatively or in addition, the patient's profile may be modified. For example, the type or amount of food to be ingested may be provided into the simulation module. Within the scope of the present disclosure, the patient, the physician or the care provider may modify one or more of the condition parameters to determine the simulated effect of the modified condition parameter or profile component to the physiological model generated. More specifically, referring back to FIG. 17, when one or more patient condition parameters or one or more profiles components is modified, the simulated physiological model is modified or altered in response to the modified condition parameter(s) (1740).
  • That is, in one aspect, the simulation of the initial physiological profile of a patient may be generated based on collected/monitored data. Thereafter, one or more parameters may be modified to show the resulting effect of such modified one or more patient condition parameters on the simulation of the patient's physiological model. In this manner, in one aspect, the patient, physician or the healthcare provider may be provided with a simulation tool to assist in the therapy management of the patient, where a model based on the patient's condition is first built, and thereafter, with adjustment or modification of one or more parameters, the simulation model provides the resulting effect of the adjustment or modification so as to allow the patient, physician or the healthcare provider to take appropriate actions to improve the therapy management of the patient's physiological condition.
  • FIG. 18 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with another embodiment of the present disclosure. Referring to FIG. 18, in another embodiment, a user selects, using one or more user input devices of a personal computer or other computing or data processing device, the desired physiological profile (1810), and thereafter, one or more condition parameters displayed to the user may be selected as desired. For example, the user may be prompted to select an insulin level adjustment setting, to view a simulation of the physiological profile model responding to such insulin level adjustment setting.
  • In another aspect, the user may select an activity adjustment setting to view the effect of the selected activity on the physiological profile model. For example, the user may select to exercise for 30 minutes before dinner every day. With this adjustment to the condition parameter, the physiological profile model simulation module may be configured to modify the generated physiological model to show the resulting effect of the exercise to the glucose level of the patient in view of the existing insulin delivery profile, for example. In this manner, one or more parameters associated with the patient's physiological condition may be modified as a condition parameter and provided to the model simulation module to determine the resulting effect of such modified condition parameter (1820). Indeed, referring back to FIG. 18, with the entered condition parameter(s) selected by the patient, physician or the healthcare provider, the simulation module in one aspect may be configured to generate a modified physiological profile model which is received or output to the user, patient, physician or the healthcare provider, visually, graphically, in text form, or one or more combinations thereof (1830).
  • FIG. 19 is a flowchart illustrating dynamic physiological profile simulation routine in accordance with still another embodiment of the present disclosure. Referring to FIG. 19, in one aspect, when the physiological profile model is selected (1910) and the desired modified parameter(s) is selected for the condition(s) associated with the physiological profile model (1920), a modified physiological model is received (1930) or output to the user on a display device of the data processing terminal or computer. Thereafter, the simulation module may prompt the patient, the user, physician or the healthcare provider to either enter additional or different condition parameters to view the resulting effect on the simulated physiological model, or alternatively, select the option to indicate the completion of the modification to the condition parameters (1940).
  • In this manner, an iteration may be provided such that the patient, user, physician or the healthcare provider may modify one or more conditions associated with the patient's physiological condition, and in response, view or receive in real time, the resulting effect of the modified one or more conditions to the modeled physiological condition simulation. Thereafter, optionally, the modified as well as the initial physiological profile model (and including any intermediate modification to the physiological profile model based on one or more parameter inputs) may be stored in the memory or storage unit of the data processing terminal or computer (1950).
  • In this manner, in one aspect, when the simulation module has sufficient data associated with the patient's physiological condition or state to define the simulation model parameters, the patient, healthcare provider, physician or the user may model different treatment scenarios to determine strategies for managing the patient's condition such as the diabetic condition in an interactive manner, for example. Thus, changes to the resulting physiological model may be displayed or provided to the patient, physician or the healthcare provider based on one or more potential changes to the treatment regimen.
  • FIG. 20 is a flowchart illustrating visual medication delivery profile programming in accordance with one embodiment of the present disclosure. Referring to FIG. 20, medication delivery profile such as a basal rate profile is retrieved (2010), for example, from memory of the remote terminal 140 (FIG. 1) or received from the fluid delivery device 120 (FIG. 1) such as an insulin pump. Thereafter, a graphical representation of the medication delivery profile is generated and displayed (2020) on the display unit of the remote terminal 140. For example, the graphical representation of the medication delivery profile may include a line graph of the insulin level over a predetermined time period for the corresponding medication delivery profile.
  • In one aspect, the graphically displayed medication delivery profile may be configured to be manipulated using an input device for the remote terminal 140 such as, for example, a computer mouse, a pen type pointing device, or any other types of user input device that is configured for manipulation of the displayed objects on the display unit of the remote terminal 140. In addition to the graphical display of the medication delivery profile, one or more of a corresponding therapy or physiological profile for a particular patient or user may be displayed. For example, in one embodiment, based on data received from the analyte monitoring system 110 and/or the fluid delivery device 120, the remote terminal 140 may be configured to display the basal profile programmed in the fluid delivery device 120 indicating the amount of insulin that has been programmed to administer to the patient, and the corresponding monitored analyte level of the patient, insulin sensitivity, insulin to carbohydrate ratio, and any other therapy or physiological related parameters.
  • Referring to FIG. 20, the patient or the user including a physician or the healthcare provider may manipulate the user input device such as the computer mouse coupled to the remote terminal 140 to select and modify one or more segments of the graphically displayed medication delivery profile (2030). In response to the display manipulation/modification, the corresponding displayed therapy/physiological profile may be dynamically updated (2040). For example, using one or more of the user input devices, the user or the patient may select a portion or segment of the basal profile line graph, and either move the selected portion or segment of the line graph in vertical or horizontal direction (or at an angle), to correspondingly modify the level of the medication segment for a given time period as graphically displayed by the line graph.
  • In one aspect, the medication delivery profile in one aspect may be displayed as a line graph with time of day represented along the X-axis and the value or level of the medication on the Y-axis. When the computer mouse is moved near a segment of the line graph, the cursor displayed on the remote terminal 140 display unit may be configured to change to indicate that the portion of the line graph may be selected and dragged on the displayed screen. For example, the horizontal portions of the line graph may be dragged in a vertical direction to increase or decrease the setting or the medication level for that selected time period, while the vertical portions of the line graph may be dragged in the horizontal direction to adjust the time associated with the particular medication level selected.
  • Referring again to FIG. 20, in one aspect, the modified medication delivery profile and the updated therapy/physiological profile are stored (2050) in a storage unit such as a memory of the remote terminal 140, and thereafter, may be transmitted to one or more of the fluid delivery device 120 or the analyte monitoring system 110 (2060). In this manner, in one aspect, the patient or the user may be provided with an intuitive and graphical therapy management tool which allows manipulation of one or more parameters associated with the patient's condition such as diabetes, and receive real time visual feedback of based on the manipulation of the one or more parameters to determine the appropriate therapy regimen.
  • For example, when the user or the patient wishes to maintain his or her blood glucose level within a predetermined range, the user may manipulate the line graph associated with the insulin delivery rate, for example, to receive feedback on the effect of the change to the insulin amount on the blood glucose level. The modeling of the physiological parameters associated with the patient in one aspect may be generated using computer algorithms that provide simulated model of the patient's physiological condition based on the monitored physiological condition, medication delivery rate, patient specific conditions such as exercise and meal events (and the types of exercise and meal for the particular times), which may be stored and later retrieved for constructing or modeling the patient's physiological conditions.
  • FIG. 21 is a flowchart illustrating visual medication delivery profile programming in accordance with another embodiment of the present disclosure. Referring to FIG. 21, medication delivery profile for a particular patient may be graphically displayed (2110), and thereafter, upon detection of an input command to modify the displayed medication delivery profile (2120), the corresponding displayed therapy physiological profile is modified (2130). As discussed above, the input command may be received from an input device such as a computer mouse executing select and drag functions, for example, on the display screen of the remote terminal 140. In one aspect, in response to the input command, the displayed medication delivery profile as well as the corresponding displayed therapy/physiological profile may be graphically updated to provide visual feedback to the patient or the user of the effect resulting from the input command modifying the medication delivery profile.
  • Referring to FIG. 21, when the confirmation of the modified medication delivery profile is received (2140), for example, via the user input device, the modified medication delivery profile may be transmitted (2150) and, the modified medication delivery profile and the updated therapy/physiological profile are stored (2160). That is, when the user or the patient confirms or accepts the modification or update to the medication delivery profile based, for example, on the visual feedback received corresponding to the change to the therapy/physiological profile, in one aspect, the modified medication delivery profile may be transmitted to the fluid delivery device 120 to program the device for execution, for example. The transmission may be wireless using RF communication, infrared communication or any other suitable wireless communication techniques, or alternatively, may include cabled connection using, for example, USB or serial connection.
  • In this manner, in one aspect, there is provided an intuitive and easy to use visual feedback mechanism to improve treatment of a medical condition such as diabetes, by providing visual modeling of the therapy regimen that can be dynamically adjusted to show the effect of such adjustment to the physiological condition.
  • FIG. 22 is an exemplary screen display of a medication delivery profile. As can be seen, in one aspect, the basal rate, insulin sensitivity and the insulin to carbohydrate ratio (CHO) are shown on the Y-axis, while the X-axis represents the corresponding time of day. For each of these therapy parameters, the existing profile is shown 2320 and the optimal profile proposed by the therapy calculator is shown 2330. FIG. 23 is an exemplary screen display illustrating vertical modification of the proposed medication delivery profile as shown by the directional arrow 2310, while FIG. 24 illustrates an exemplary screen display with horizontal modification of the proposed medication delivery profile shown by the directional arrow 2410. Referring still to the Figures, FIG. 25 illustrates addition of a transition 2510 in the medication delivery profile, while FIG. 26 illustrates deletion 2610 of a transition in the medication delivery profile.
  • In this manner, in one aspect, the visual modeling and dynamic feedback in therapy management provides immediate feedback on the anticipated results or effect of a proposed modification to the therapy profile such as increase or decrease of insulin administration to the patient. Accordingly, the patient, the physician or the healthcare provider may be provided with a graphical treatment tool to assist in the treatment of the patient's condition.
  • In another aspect, the visual modeling and dynamic feedback in the therapy management includes illustration of a current physiological profile such as the glucose level and one or more time corresponding parameter values associated with the current physiological profile such that, when the user, patient or healthcare provider modifies the displayed one or more parameter values (such as, but not limited to, the corresponding medication level including basal profile, insulin sensitivity, and/or insulin to carbohydrate ratio), the corresponding current physiological profile is responsively modified and displayed in real time, while leaving a trace (referring to herein as a phantom plot) of the current physiological profile and the time corresponding one or more parameter values associated with the current physiological profile.
  • That is, by manipulating the display of the therapy related parameter value to a modified level (for example, using a conventional click and drag operation of an input device such as a computer mouse), the displayed current physiological profile is modified on the screen accordingly, while maintaining the display of the current physiological profile as well as the initial or current therapy related parameter value. In other words, in one aspect, the display or screen is configured to represent both the initial profile and the modified profile so that the user, patient or healthcare provider can readily see the change to the plotted physiological profile in response to the modification to the one or more parameter values, for example, the initial profile or plot shown as a lighter trace (phantom plot) or of a different color or representation), while maintaining a darker color or thickness of the plot for the modified profile/plot.
  • For example, with a plot of a glucose level information and a corresponding basal profile on the screen, when the user, patient or the healthcare provider selects the basal profile and moves or modifies one or more sections of the basal profile, the initial position of the glucose level remains displayed as a trace (phantom plot), while displaying the new or modified glucose level. In addition, both the initial and the modified basal profile of the time corresponding basal profile are displayed on the same chart or plot. In this manner, in one aspect, the display of the remote terminal 140 (FIG. 1) and/or the display of the analyte monitoring system 110 or the display of the fluid delivery device 120 may be manipulated using, for example, user interface capabilities such as input device (computer mouse for use with the remote terminal 140, input/select buttons on the analyte monitoring system 110 or the fluid delivery device 120 to provide visual indications of the extent of adjustment to one or more parameters from the initial or recommended settings or profiles and the corresponding modification to the associated physiological or other monitored profile such as glucose levels in addition to the initial displayed profile.
  • FIG. 27 is an exemplary display illustrating an initial glucose level and a corresponding parameter value, and FIGS. 28-29 are exemplary displays illustrating response to the manipulation of the parameter plot or value segment of FIG. 27 and corresponding modification to the displayed glucose profile as a function of time in one embodiment. Referring to FIGS. 27-29, an initial display of one parameter value 2720 (FIG. 27) is plotted along with a time corresponding plot of the glucose level 2710 (FIG. 27). In one aspect, the user, patient or the healthcare provider may move the computer mouse to position the cursor over and select a segment of the plotted parameter value 2720 (for example, between two displayed dots at each transition point in the displayed plot). With the selected segment of the plotted parameter, the user, patient or the healthcare provider may move the selected segment in a vertical direction as shown in FIG. 28, in a horizontal direction, or in both a horizontal and vertical direction as shown in FIG. 29.
  • Referring back to FIG. 28, when the selected segment of the displayed parameter 2840 is moved in an upward vertical direction to a new position 2830 as shown, the corresponding initial glucose profile 2810 is updated to the modified glucose profile 2820. As shown in FIG. 28, it can be seen that both the initial position and the modified position of the parameter plot and those of the glucose levels are shown. In particular, in one embodiment, when a modification to the parameter value is effected, the segment of the initial position or plot of the parameter value (and the corresponding initial display of the glucose level) is displayed as a lighter trace or of a different color (for example, the initial parameter segment 2840 and the initial glucose profile 2810) to be distinguishable with the modified parameter segment 2830 and the corresponding modified glucose profile 2820. In one aspect, the particular type of display modes (different color, thickness, legend indicating the initial and modified chart or profile segment) may be user definable or configurable.
  • Referring to FIG. 29, when a segment 2940 of the parameter displayed is modified in both the vertical and the horizontal direction to the modified position 2930 as shown, the corresponding displayed initial glucose level display 2910 is updated to a modified profile 2920 in the direction shown by the arrow illustrating a movement from the initial display 2910 to the modified display 2920 in addition to the display of the initial glucose profile 2910 and the initial parameter value 2940.
  • In this manner, in one aspect, proposed or recommended modification to therapy profiles such as basal profiles may be displayed including the initial and modified profiles, and the corresponding initial and modified physiological profiles recalculated or determined in response to the proposed or recommended modification to the therapy profiles may be visually output to the user, patient or the healthcare provider to enhance visual representation of the proposed or recommended modification to the therapy profiles in the course of the treatment and therapy of physiological conditions such as diabetes. In this manner, the user, patient or the healthcare provider may easily and visually understand the degree of parameter change and effect of the change on the output values such as insulin delivery and glucose level.
  • While a single parameter plot is shown in conjunction with the discussion above and FIGS. 27-29, in accordance with the embodiments of the present disclosure, multiple parameter values or profiles may be displayed and modified by the user, patient, or the healthcare provider. In such cases, for each parameter displayed, when a modification to the parameter is performed, both the initial and the modified profile or plot may be displayed. Moreover, while glucose level is discussed above in the physiological profile displayed, embodiments of the present disclosure may be used to display other physiological profiles and associated parameters that affects the physiological profile, such as blood pressure level or other physiological conditions.
  • In accordance with the embodiments of the present disclosure, other variations of the embodiments discussed above are contemplated. For example, the phantom plots may be associated with the plots that are adjusted rather than the plots that stay in the same position. Also, as discussed above, the phantom plots may be represented other than as a thinner line (compared to the non-phantom or the modified profile), including, such as, for example, with different colors, line types, icon indication, legends, labels and the like. In addition, the modification to the initial profile or parameter may be represented in tabular form with numeric value entries, with some table elements associated with the original or initial values and other table elements representing the adjusted/modified values.
  • In a further embodiment, for multiple adjustments or modifications, the phantom (original) plot may be updated or modified after each adjustment, relative to the immediately prior modification position. In this case, optionally, multiple phantom plots may be displayed (using different indications such as gradually increasing thickness of the plotted line, or different color or legend, for example) such that the modifications may be visually represented in a graphically sweeping manner, illustrating each modification to the parameter(s) and the corresponding modification to the physiological profile in, for example, a single chart or display.
  • Moreover, other mechanisms may be contemplated to allow the user, patient or the healthcare provider to make the adjustments to the parameters. For example, a table may be provided and displayed with numeric values associated with parameter segments, and the user, patient or the healthcare provider may edit the numeric values in the table. After the adjustment or modification to the numeric value in the table, the corresponding plots may be modified as described above, in a similar manner as when the graphical segment is modified using, for example, the computer mouse by click and drag operation.
  • In addition, adjustment or modification to the parameters may be performed in other manner. For example, segments of the parameter plots may be predefined, for instance, at a segment of 15 minutes or other time periods. Alternatively, the segments may be defined by changes in time for the original parameter value. Additionally, new segments may be defined by the user using for example, the computer mouse by clicking the mouse button with a cursor near a point on the parameter plot, where the selected or clicked point representing the end of a segment with the beginning of a segment already defined on the plot (as indicated by a dot on the plot). Also, a segment may be defined by the user with a mouse click once near one point on a plot and again near a second point, where the points define a segment. In this aspect, the segment may be visually highlighted (for example, made thicker) to indicate to the user that it can be dragged or otherwise adjusted or modified. Furthermore, these defined segments may be limited to a predefined time resolution as defined by the insulin delivery device, for example. That is, fluid delivery device 120 (FIG. 1) may be limited to a 15 minute resolution of parameter changes, in which case, the plotting routine may locate the 15 minute point on the plot closest to where the user selected with the mouse.
  • In another aspect, the display discussed above may include one or more error indication. For example, the glucose display may show, along with the median glucose profile, the upper and lower glucose quartiles. This information may be useful to the user when making corresponding adjustments to the therapy profile. For example, if the user, patient or the healthcare provider desires to make parameter adjustments in order to lower the median glucose profile, they may understand from the lower quartile plot that there is a high degree of glucose variation and that it may not be safe or desirable to lower the median profile as much as they intended or desired. In one aspect, the phantom plots discussed above may be associated with these types of displayed error indications.
  • As described above, the profile modification and the corresponding displays may be based on data organized around time-of-day information. In another aspect, the modifications or determinations and the corresponding display plots may be based on meals markers or meal bolus events recorded in time. These events may be entered into the system manually (for instance a meal event may be entered into the system by the user) or automatically (the system may record a meal bolus when it is delivered, using, for example, the fluid delivery device 120). The parameter, insulin delivery and glucose data may be organized in data sets, with time relative to the meal bolus event. A resulting data set for each may be generated using a median calculation or average calculation, or other appropriate calculation, to generate a profile in time relative to the meal bolus event. For example, each data set may be defined one hour prior to and 5 hours after when meals bolus event occurs. Adjustments, as described above for plots over time-of-day, may be made similarly for plots over time-relative-to-meal-events. Also, determination and display of parameters, insulin delivery and glucose profiles may be made for data sets generated relative to correction bolus events.
  • In one aspect, the user may select from a list of possible parameters to adjust or modify based on one or more indications presenting the parameters available for modification. For example, if the basal parameter adjustment is selected, then the determination or modification and display may be associated with time-of-day. In this case, when the user adjusts the glucose values, the basal profile parameter may be adjusted to correlate with glucose level adjustments. As a further example, if the carbohydrate ratio parameter is selected, the modification and display may be associated with time relative to meal bolus or meal events. As yet a further example, when the insulin sensitivity parameter adjustment is selected, the modification and display may be associated with time relative to a correction bolus.
  • Additionally, when modifications and displays are associated with time relative to an event, they may be restricted to time of day periods. For example, the profile modification determination may be restricted to one or more meal bolus that occur in a morning period, for instance, between 6 am and 11 am. This restriction may be used to associate a single carbohydrate ratio parameter for this time period. Also, the resulting modified parameters may be constrained by resolution restrictions imposed by the insulin delivery device 120 discussed above.
  • In an alternative embodiment, the parameter and/or physiological profile display may include both actual and recommended glucose traces, insulin traces and therapy parameter traces, in addition to the modified traces, and further, user definable or configurable.
  • Within the scope of the present disclosure, data mining techniques may be used to generate and/or modify the physiological profile models based on the patient's data as well as data from other patient's that have similar physiological characteristics. Such data mining techniques may be used to filter and extract physiological profile models that meet a predetermined number of criteria and ranked in a hierarchy of relevance or applicability to the particular patient's physiological condition. The simulation module may be implemented by computer software with algorithm that defines the parameters associated with the patient's physiological conditions, and may be configured to model the various different conditions of the patient's physiology.
  • Within the scope of the present disclosure, the therapy analysis system described above may be implemented in a database management system and used for treatment of diabetic patients by general practitioner. Additionally, the therapy analysis system may be implemented based on multiple daily doses of insulin (using, for example, syringe type insulin injector, or inhalable insulin dispenser) rather than based on an insulin pump, where the insulin related information may be recorded by the patient and uploaded or transferred to the data management system (for example, the remote terminal 140 (FIG. 1)). Also, some or all of the data analysis and display described above may be performed by the analyte monitoring system 110 (FIG. 1) or the fluid delivery device (120), or by a separate controller configured for communication with the therapy management system 100.
  • In one embodiment, a method may comprise displaying a first representation of a medication treatment parameter profile, displaying a first representation of a physiological profile associated with the medication treatment parameter profile, detecting a modification to a segment of the medication treatment parameter profile, displaying a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modifying an attribute of the first representation of the medication treatment parameter profile, and modifying an attribute of the first representation of the physiological profile.
  • In one aspect modifying the attribute of the first representation of the medication treatment parameter profile may include modifying a visual attribute without modifying the underlying value associated with the profile.
  • Moreover, the visual attribute may include one or more of a color representation, a line representation, visual contrast representation.
  • In another aspect, the modified representation and the first representation of the medication treatment parameter profile may include at least an overlapping displayed segment.
  • In yet another aspect the modified representation and the first representation of the physiological profile may be substantially non-overlapping.
  • In one aspect, the medication treatment parameter profile may include one or more of a basal rate profile, an insulin sensitivity profile, an insulin to carbohydrate ratio, an meal event, a bolus event, or an insulin type profile.
  • In another aspect, the physiological profile may include a glucose level profile, an oxygen level profile, or a blood pressure level profile.
  • In yet another aspect, modifying the attribute of the first representation of the physiological profile may include modifying a visual attribute without modifying the underlying value associated with the profile.
  • Moreover, when the attribute of the first representation of the medication treatment parameter profile is modified, the displayed position of the first representation of the medication treatment parameter profile is not changed.
  • Moreover, when the attribute of the first representation of the physiological profile is modified, the displayed position of the first representation of the physiological profile is not changed.
  • Furthermore, the displayed first representation of the medication treatment parameter profile and the physiological profile respectively may include one or more of a line graph, a bar graph, a 2-dimensional graph, or a 3-dimensional graph.
  • In another embodiment, an apparatus may comprise, a display unit, one or more processing units coupled to the display unit, and a memory for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to display a first representation of a medication treatment parameter profile, display a first representation of a physiological profile associated with the medication treatment parameter profile, detect a modification to a segment of the medication treatment parameter profile, display a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modify an attribute of the first representation of the medication treatment parameter profile, and modify an attribute of the first representation of the physiological profile.
  • In one aspect, the memory for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to modify a visual attribute associated with the physiological profile without modifying the underlying value associated with the first representation of the physiological profile, and to modify a visual attribute associated with the first representation of the medication treatment parameter profile without modifying the underlying value associated with the medication treatment parameter profile.
  • Moreover, the visual attribute may include one or more of a color representation, a line representation, visual contrast representation.
  • In another aspect, the modified representation and the first representation of the medication treatment parameter profile may include at least an overlapping displayed segment.
  • Furthermore, the modified representation and the first representation of the physiological profile may be substantially non-overlapping.
  • In yet another aspect, the medication treatment parameter profile may include one or more of a basal rate profile, an insulin sensitivity profile, an insulin to carbohydrate ratio, an meal event, a bolus event, or an insulin type profile.
  • Moreover, the physiological profile may include a glucose level profile, an oxygen level profile, or a blood pressure level profile.
  • In yet another aspect, when the attribute of the first representation of the medication treatment parameter profile is modified, the displayed position of the first representation of the medication treatment parameter profile may not be changed, and further, when the attribute of the first representation of the physiological profile is modified, the displayed position of the first representation of the physiological profile may not be changed.
  • The various processes described above including the processes performed by the processor 210 (FIG. 2) in the software application execution environment in the fluid delivery device 120 (FIG. 1) as well as any other suitable or similar processing units embodied in the analyte monitoring system 110, the fluid delivery device 120, and/or the remote terminal 140, including the processes and routines described in conjunction with FIGS. 3-16, may be embodied as computer programs developed using an object oriented language that allows the modeling of complex systems with modular objects to create abstractions that are representative of real world, physical objects and their interrelationships. The software required to carry out the inventive process, which may be stored in the memory unit 240 (or similar storage devices in the analyte monitoring system 110 and the remote terminal 140) and executed by the processor 210, may be developed by a person of ordinary skill in the art and may include one or more computer program products.
  • Various other modifications and alterations in the structure and method of operation of this disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the disclosure. Although the present disclosure has been described in connection with specific preferred embodiments, it should be understood that the present disclosure as claimed should not be unduly limited to such specific embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims (19)

1. A method, comprising:
displaying a first representation of a medication treatment parameter profile;
displaying a first representation of a physiological profile associated with the medication treatment parameter profile;
detecting a modification to a segment of the medication treatment parameter profile;
displaying a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile;
modifying an attribute of the first representation of the medication treatment parameter profile; and
modifying an attribute of the first representation of the physiological profile.
2. The method of claim 1 wherein modifying the attribute of the first representation of the medication treatment parameter profile includes modifying a visual attribute without modifying the underlying value associated with the profile.
3. The method of claim 2 wherein the visual attribute includes one or more of a color representation, a line representation, visual contrast representation.
4. The method of claim 1 wherein the modified representation and the first representation of the medication treatment parameter profile includes at least an overlapping displayed segment.
5. The method of claim 1 wherein the modified representation and the first representation of the physiological profile are substantially non-overlapping.
6. The method of claim 1 wherein the medication treatment parameter profile includes one or more of a basal rate profile, an insulin sensitivity profile, an insulin to carbohydrate ratio, an meal event, a bolus event, or an insulin type profile.
7. The method of claim 1 wherein the physiological profile includes a glucose level profile, an oxygen level profile, or a blood pressure level profile.
8. The method of claim 1 wherein modifying the attribute of the first representation of the physiological profile includes modifying a visual attribute without modifying the underlying value associated with the profile.
9. The method of claim 1 wherein when the attribute of the first representation of the medication treatment parameter profile is modified, the displayed position of the first representation of the medication treatment parameter profile is not changed.
10. The method of claim 1 wherein when the attribute of the first representation of the physiological profile is modified, the displayed position of the first representation of the physiological profile is not changed.
11. The method of claim 1 wherein the displayed first representation of the medication treatment parameter profile and the physiological profile respectively includes one or more of a line graph, a bar graph, a 2-dimensional graph, or a 3-dimensional graph.
13. An apparatus, comprising:
a display unit;
one or more processing units coupled to the display unit; and
a memory for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to display a first representation of a medication treatment parameter profile, display a first representation of a physiological profile associated with the medication treatment parameter profile, detect a modification to a segment of the medication treatment parameter profile, display a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modify an attribute of the first representation of the medication treatment parameter profile, and modify an attribute of the first representation of the physiological profile.
14. The apparatus of claim 13 wherein the memory for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to modify a visual attribute associated with the physiological profile without modifying the underlying value associated with the first representation of the physiological profile, and to modify a visual attribute associated with the first representation of the medication treatment parameter profile without modifying the underlying value associated with the medication treatment parameter profile.
15. The apparatus of claim 14 wherein the visual attribute includes one or more of a color representation, a line representation, visual contrast representation.
16. The apparatus of claim 13 wherein the modified representation and the first representation of the medication treatment parameter profile includes at least an overlapping displayed segment.
17. The apparatus of claim 13 wherein the modified representation and the first representation of the physiological profile are substantially non-overlapping.
18. The apparatus of claim 13 wherein the medication treatment parameter profile includes one or more of a basal rate profile, an insulin sensitivity profile, an insulin to carbohydrate ratio, an meal event, a bolus event, or an insulin type profile.
19. The apparatus of claim 13 wherein the physiological profile includes a glucose level profile, an oxygen level profile, or a blood pressure level profile.
20. The apparatus of claim 13 wherein when the attribute of the first representation of the medication treatment parameter profile is modified, the displayed position of the first representation of the medication treatment parameter profile is not changed, and further, wherein when the attribute of the first representation of the physiological profile is modified, the displayed position of the first representation of the physiological profile is not changed.
US12/242,799 2007-12-19 2008-09-30 Dynamic Display Of Glucose Information Abandoned US20090164239A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/242,799 US20090164239A1 (en) 2007-12-19 2008-09-30 Dynamic Display Of Glucose Information
PCT/US2009/058894 WO2010039743A1 (en) 2008-09-30 2009-09-29 Dynamic display of glucose information
US14/981,863 US10685749B2 (en) 2007-12-19 2015-12-28 Insulin delivery apparatuses capable of bluetooth data transmission
US15/468,156 US11749410B2 (en) 2007-12-19 2017-03-24 Dynamic display of glucose information
US18/156,212 US20230154625A1 (en) 2007-12-19 2023-01-18 Dynamic display of glucose information

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1518507P 2007-12-19 2007-12-19
US12/024,082 US20090164251A1 (en) 2007-12-19 2008-01-31 Method and apparatus for providing treatment profile management
US12/242,799 US20090164239A1 (en) 2007-12-19 2008-09-30 Dynamic Display Of Glucose Information

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/024,082 Continuation-In-Part US20090164251A1 (en) 2007-12-19 2008-01-31 Method and apparatus for providing treatment profile management

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/981,863 Continuation US10685749B2 (en) 2007-12-19 2015-12-28 Insulin delivery apparatuses capable of bluetooth data transmission

Publications (1)

Publication Number Publication Date
US20090164239A1 true US20090164239A1 (en) 2009-06-25

Family

ID=42073838

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/242,799 Abandoned US20090164239A1 (en) 2007-12-19 2008-09-30 Dynamic Display Of Glucose Information
US14/981,863 Active 2031-02-17 US10685749B2 (en) 2007-12-19 2015-12-28 Insulin delivery apparatuses capable of bluetooth data transmission
US15/468,156 Active 2030-06-27 US11749410B2 (en) 2007-12-19 2017-03-24 Dynamic display of glucose information

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/981,863 Active 2031-02-17 US10685749B2 (en) 2007-12-19 2015-12-28 Insulin delivery apparatuses capable of bluetooth data transmission
US15/468,156 Active 2030-06-27 US11749410B2 (en) 2007-12-19 2017-03-24 Dynamic display of glucose information

Country Status (2)

Country Link
US (3) US20090164239A1 (en)
WO (1) WO2010039743A1 (en)

Cited By (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100064257A1 (en) * 2008-09-05 2010-03-11 Roche Diagnostics Operations, Inc. Insulin pump configuration programming invalid settings notification and correction
US20100125183A1 (en) * 2008-11-17 2010-05-20 Honeywell International Inc. System and method for dynamically configuring functionality of remote health monitoring device
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7768387B2 (en) 2007-04-14 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US20100198142A1 (en) * 2009-02-04 2010-08-05 Abbott Diabetes Care Inc. Multi-Function Analyte Test Device and Methods Therefor
US7826382B2 (en) 2008-05-30 2010-11-02 Abbott Diabetes Care Inc. Close proximity communication device and methods
US20110004649A1 (en) * 2009-05-02 2011-01-06 Nord Joseph Methods and systems for providing a consistent profile to overlapping user sessions
US20110022981A1 (en) * 2009-07-23 2011-01-27 Deepa Mahajan Presentation of device utilization and outcome from a patient management system
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US20110046498A1 (en) * 2007-05-02 2011-02-24 Earlysense Ltd Monitoring, predicting and treating clinical episodes
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
WO2011112974A1 (en) * 2010-03-11 2011-09-15 University Of Virginia Patent Foundation Method and system for the safety, analysis and supervision of insulin pump action and other modes of insulin delivery in diabetes
US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
WO2011133768A1 (en) * 2010-04-22 2011-10-27 Abbott Diabetes Care Inc. Devices, systems, and methods related to analyte monitoring and management
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8103456B2 (en) * 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US8116840B2 (en) 2003-10-31 2012-02-14 Abbott Diabetes Care Inc. Method of calibrating of an analyte-measurement device, and associated methods, devices and systems
US8121857B2 (en) 2007-02-15 2012-02-21 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US20120046962A1 (en) * 2010-08-20 2012-02-23 James Andrew Fant System and method for glucose monitoring and analysis
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8135548B2 (en) 2006-10-26 2012-03-13 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US8140142B2 (en) 2007-04-14 2012-03-20 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8149117B2 (en) 2007-05-08 2012-04-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8185181B2 (en) 2009-10-30 2012-05-22 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US8211016B2 (en) 2006-10-25 2012-07-03 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8368556B2 (en) 2009-04-29 2013-02-05 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8376945B2 (en) 2006-08-09 2013-02-19 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US8483967B2 (en) 2009-04-29 2013-07-09 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8514086B2 (en) 2009-08-31 2013-08-20 Abbott Diabetes Care Inc. Displays for a medical device
US8515517B2 (en) 2006-10-02 2013-08-20 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
WO2013150523A1 (en) * 2012-04-01 2013-10-10 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8593109B2 (en) 2006-03-31 2013-11-26 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8597188B2 (en) 2007-06-21 2013-12-03 Abbott Diabetes Care Inc. Health management devices and methods
US8603010B2 (en) 2004-02-05 2013-12-10 Earlysense Ltd. Techniques for prediction and monitoring of clinical episodes
US8617069B2 (en) 2007-06-21 2013-12-31 Abbott Diabetes Care Inc. Health monitor
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
WO2014018788A1 (en) * 2012-07-26 2014-01-30 Rimidi Diabetes Improved glucose management through modeling of circadian profiles
WO2014018797A1 (en) * 2012-07-26 2014-01-30 Rimidi Diabetes Improved glucose management through cloud-based modeling of circadian profiles
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US20140068487A1 (en) * 2012-09-05 2014-03-06 Roche Diagnostics Operations, Inc. Computer Implemented Methods For Visualizing Correlations Between Blood Glucose Data And Events And Apparatuses Thereof
US8679030B2 (en) 2004-02-05 2014-03-25 Earlysense Ltd. Monitoring a condition of a subject
US20140100435A1 (en) * 2012-10-04 2014-04-10 Roche Diagnostics Operations, Inc. System and method for assessing risk associated with a glucose state
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8756043B2 (en) 2012-07-26 2014-06-17 Rimidi Diabetes, Inc. Blood glucose meter and computer-implemented method for improving glucose management through modeling of circadian profiles
US8755938B2 (en) 2011-05-13 2014-06-17 Roche Diagnostics Operations, Inc. Systems and methods for handling unacceptable values in structured collection protocols
US8761940B2 (en) 2010-10-15 2014-06-24 Roche Diagnostics Operations, Inc. Time block manipulation for insulin infusion delivery
CN103889317A (en) * 2011-06-23 2014-06-25 弗吉尼亚大学专利基金会 Unified platform for monitoring and control of blood glucose levels in diabetic patients
US8766803B2 (en) 2011-05-13 2014-07-01 Roche Diagnostics Operations, Inc. Dynamic data collection
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US8795252B2 (en) 2008-08-31 2014-08-05 Abbott Diabetes Care Inc. Robust closed loop control and methods
US8821418B2 (en) 2007-05-02 2014-09-02 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US8849458B2 (en) 2008-12-23 2014-09-30 Roche Diagnostics Operations, Inc. Collection device with selective display of test results, method and computer program product thereof
US20140323961A1 (en) * 2008-01-09 2014-10-30 Tandem Diabetes Care, Inc. Infusion pump incorporating information from personal information manager devices
US8882684B2 (en) 2008-05-12 2014-11-11 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8942779B2 (en) 2004-02-05 2015-01-27 Early Sense Ltd. Monitoring a condition of a subject
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US8993331B2 (en) 2009-08-31 2015-03-31 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9069536B2 (en) 2011-10-31 2015-06-30 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
US9117015B2 (en) 2008-12-23 2015-08-25 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9204827B2 (en) 2007-04-14 2015-12-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US20160030670A1 (en) * 2014-08-01 2016-02-04 The General Hospital Corporation Blood Glucose and Insulin Control Systems and Methods
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9326709B2 (en) 2010-03-10 2016-05-03 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US20160206817A1 (en) * 2009-09-10 2016-07-21 Medipacs, Inc Low profile actuator and improved method of caregiver controlled administration of therapeutics
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US9532737B2 (en) 2011-02-28 2017-01-03 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
WO2017027459A1 (en) 2015-08-07 2017-02-16 Trustees Of Boston University Glucose control system with automatic adaptation of glucose target
US9615780B2 (en) 2007-04-14 2017-04-11 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9659037B2 (en) 2008-12-23 2017-05-23 Roche Diabetes Care, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9750444B2 (en) 2009-09-30 2017-09-05 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US9883809B2 (en) 2008-05-01 2018-02-06 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9918635B2 (en) 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
US20180085532A1 (en) * 2016-09-27 2018-03-29 Bigfoot Biomedical, Inc. Medicine injection and disease management systems, devices, and methods
US20180099092A1 (en) * 2016-10-06 2018-04-12 Medtronic Minimed, Inc. Infusion systems and methods for automated exercise mitigation
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
CN108261591A (en) * 2016-12-30 2018-07-10 上海移宇科技股份有限公司 A kind of closed loop control algorithm of artificial pancreas
US10022499B2 (en) 2007-02-15 2018-07-17 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US10111608B2 (en) 2007-04-14 2018-10-30 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10136816B2 (en) 2009-08-31 2018-11-27 Abbott Diabetes Care Inc. Medical devices and methods
US10194850B2 (en) 2005-08-31 2019-02-05 Abbott Diabetes Care Inc. Accuracy of continuous glucose sensors
US10208158B2 (en) 2006-07-10 2019-02-19 Medipacs, Inc. Super elastic epoxy hydrogel
US10216767B2 (en) 2008-12-23 2019-02-26 Roche Diabetes Care, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US10292625B2 (en) 2010-12-07 2019-05-21 Earlysense Ltd. Monitoring a sleeping subject
US10307538B2 (en) * 2016-01-14 2019-06-04 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
US20190175119A1 (en) * 2006-08-07 2019-06-13 Abbott Diabetes Care Inc. Method and system for providing integrated analyte monitoring and infusion system therapy management
US10437962B2 (en) 2008-12-23 2019-10-08 Roche Diabetes Care Inc Status reporting of a structured collection procedure
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US10456036B2 (en) 2008-12-23 2019-10-29 Roche Diabetes Care, Inc. Structured tailoring
US10500334B2 (en) 2017-01-13 2019-12-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10522247B2 (en) 2010-12-29 2019-12-31 Roche Diabetes Care, Inc. Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels
US10555695B2 (en) 2011-04-15 2020-02-11 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10583250B2 (en) 2017-01-13 2020-03-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10610644B2 (en) 2017-01-13 2020-04-07 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US10685749B2 (en) 2007-12-19 2020-06-16 Abbott Diabetes Care Inc. Insulin delivery apparatuses capable of bluetooth data transmission
US10758675B2 (en) 2017-01-13 2020-09-01 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10881792B2 (en) 2017-01-13 2021-01-05 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10943687B2 (en) 2007-05-24 2021-03-09 Tandem Diabetes Care, Inc. Expert system for insulin pump therapy
US10940267B2 (en) 2019-07-16 2021-03-09 Beta Bionics, Inc. Blood glucose control system with real-time glycemic control optimization
US10963417B2 (en) 2004-06-04 2021-03-30 Abbott Diabetes Care Inc. Systems and methods for managing diabetes care data
USD918227S1 (en) 2018-08-20 2021-05-04 Tandem Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11006872B2 (en) 2009-02-03 2021-05-18 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11027063B2 (en) 2017-01-13 2021-06-08 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US11096624B2 (en) 2016-12-12 2021-08-24 Bigfoot Biomedical, Inc. Alarms and alerts for medication delivery devices and systems
US11103638B2 (en) * 2019-07-16 2021-08-31 Beta Bionics, Inc. Ambulatory medicament device with gesture-based control of medicament delivery
USD931306S1 (en) 2020-01-20 2021-09-21 Tandem Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
US11158413B2 (en) * 2018-04-23 2021-10-26 Medtronic Minimed, Inc. Personalized closed loop medication delivery system that utilizes a digital twin of the patient
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
US11224693B2 (en) 2018-10-10 2022-01-18 Tandem Diabetes Care, Inc. System and method for switching between medicament delivery control algorithms
US11229382B2 (en) 2013-12-31 2022-01-25 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US20220044785A1 (en) * 2018-04-23 2022-02-10 Medtronic Minimed, Inc. Determination of adjustments to fluid delivery settings
US20220101995A1 (en) * 2010-02-12 2022-03-31 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US11302433B2 (en) 2008-01-07 2022-04-12 Tandem Diabetes Care, Inc. Diabetes therapy coaching
US11324898B2 (en) 2013-06-21 2022-05-10 Tandem Diabetes Care, Inc. System and method for infusion set dislodgement detection
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11488549B2 (en) * 2008-05-02 2022-11-01 Tandem Diabetes Care, Inc. Display for pump
US11534089B2 (en) 2011-02-28 2022-12-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US11576594B2 (en) 2007-05-30 2023-02-14 Tandem Diabetes Care, Inc. Insulin pump based expert system
US11581080B2 (en) 2020-12-07 2023-02-14 Beta Bionics, Inc. Ambulatory medicament pump voice operation
USD980232S1 (en) 2018-08-20 2023-03-07 Tandem Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
USD980858S1 (en) 2020-03-10 2023-03-14 Beta Bionics, Inc. Display screen with transitional graphical user interface
WO2023036878A1 (en) 2021-09-08 2023-03-16 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Use of diazirine linker for drug conjugates
US11610661B2 (en) 2020-12-07 2023-03-21 Beta Bionics, Inc. Ambulatory medicament pump with safe access control
US11676694B2 (en) 2012-06-07 2023-06-13 Tandem Diabetes Care, Inc. Device and method for training users of ambulatory medical devices
US11717225B2 (en) 2014-03-30 2023-08-08 Abbott Diabetes Care Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems
US20230310744A1 (en) * 2008-10-15 2023-10-05 Insulet Corporation Infusion pump system and methods
US11793936B2 (en) 2009-05-29 2023-10-24 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
US11812936B2 (en) 2014-09-03 2023-11-14 Hill-Rom Services, Inc. Apparatus and methods for monitoring a sleeping subject
USD1014513S1 (en) 2018-08-20 2024-02-13 Tandem Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
US11918783B2 (en) * 2023-04-20 2024-03-05 Insulet Corporation Infusion pump system and methods

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1762259T3 (en) 2005-09-12 2011-01-03 Unomedical As Infusion set insertion device with a first and a second spring assembly
EP2552513B1 (en) 2010-03-30 2014-03-19 Unomedical A/S Medical device
WO2012123274A1 (en) 2011-03-14 2012-09-20 Unomedical A/S Inserter system with transport protection
CN103957962B (en) 2011-10-05 2017-07-07 犹诺医药有限公司 Insert for inserting multiple percutaneous parts simultaneously
EP2583715A1 (en) 2011-10-19 2013-04-24 Unomedical A/S Infusion tube system and method for manufacture
CN106061528B (en) 2013-10-24 2020-10-16 波士顿大学信托人 Infusion system for preventing misdirection of multiple medicaments
JP7125204B2 (en) 2015-07-08 2022-08-24 トラスティーズ オブ ボストン ユニバーシティ Infusion system and its components
WO2017125817A1 (en) 2016-01-19 2017-07-27 Unomedical A/S Cannula and infusion devices
US11260162B2 (en) 2016-05-04 2022-03-01 Board Of Regents, The University Of Texas System Airway suction device
US10854323B2 (en) 2016-12-21 2020-12-01 Medtronic Minimed, Inc. Infusion systems and related personalized bolusing methods
WO2018129354A1 (en) 2017-01-06 2018-07-12 Trustees Of Boston University Infusion system and components thereof
USD853583S1 (en) 2017-03-29 2019-07-09 Becton, Dickinson And Company Hand-held device housing
WO2018184012A1 (en) 2017-03-31 2018-10-04 Capillary Biomedical, Inc. Helical insertion infusion device
EP3634528B1 (en) 2017-06-07 2023-06-07 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
USD839294S1 (en) 2017-06-16 2019-01-29 Bigfoot Biomedical, Inc. Display screen with graphical user interface for closed-loop medication delivery
WO2019094963A1 (en) 2017-11-13 2019-05-16 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
US10722631B2 (en) 2018-02-01 2020-07-28 Shifamed Holdings, Llc Intravascular blood pumps and methods of use and manufacture
AU2020279722A1 (en) 2019-05-20 2021-11-18 Jesper Ortld Erichsen Rotatable infusion device and methods thereof
DE112020003400T5 (en) 2019-07-16 2022-03-31 Beta Bionics, Inc. OUTPATIENT INSTITUTION AND ITS COMPONENTS
WO2021016372A1 (en) 2019-07-22 2021-01-28 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
WO2023064292A1 (en) 2021-10-11 2023-04-20 Abbott Diabetes Care Inc. Systems, devices, and methods for communication between an analyte sensor and external devices
CN116386831B (en) * 2023-05-26 2023-08-15 四川云合数创信息技术有限公司 Data visual display method and system based on intelligent hospital management platform

Citations (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4245634A (en) * 1975-01-22 1981-01-20 Hospital For Sick Children Artificial beta cell
US4373527A (en) * 1979-04-27 1983-02-15 The Johns Hopkins University Implantable, programmable medication infusion system
US4425920A (en) * 1980-10-24 1984-01-17 Purdue Research Foundation Apparatus and method for measurement and control of blood pressure
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4494950A (en) * 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
US4847785A (en) * 1985-01-22 1989-07-11 International Business Machines Corp. Interactive display for trend or bar graph
US4890620A (en) * 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
US4986271A (en) * 1989-07-19 1991-01-22 The University Of New Mexico Vivo refillable glucose sensor
US4995402A (en) * 1988-10-12 1991-02-26 Thorne, Smith, Astill Technologies, Inc. Medical droplet whole blood and like monitoring
US5082550A (en) * 1989-12-11 1992-01-21 The United States Of America As Represented By The Department Of Energy Enzyme electrochemical sensor electrode and method of making it
US5279294A (en) * 1985-04-08 1994-01-18 Cascade Medical, Inc. Medical diagnostic system
US5284425A (en) * 1992-11-18 1994-02-08 The Lee Company Fluid metering pump
US5285792A (en) * 1992-01-10 1994-02-15 Physio-Control Corporation System for producing prioritized alarm messages in a medical instrument
US5379238A (en) * 1989-03-03 1995-01-03 Stark; Edward W. Signal processing method and apparatus
US5384547A (en) * 1993-08-02 1995-01-24 Motorola, Inc. Apparatus and method for attenuating a multicarrier input signal of a linear device
US5391250A (en) * 1994-03-15 1995-02-21 Minimed Inc. Method of fabricating thin film sensors
US5390671A (en) * 1994-03-15 1995-02-21 Minimed Inc. Transcutaneous sensor insertion set
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US5711001A (en) * 1992-05-08 1998-01-20 Motorola, Inc. Method and circuit for acquisition by a radio receiver
US5711861A (en) * 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
US6024699A (en) * 1998-03-13 2000-02-15 Healthware Corporation Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6028413A (en) * 1997-09-19 2000-02-22 Perdix Oy Charging device for batteries in a mobile electrical device
US6175752B1 (en) * 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US20020019022A1 (en) * 1998-09-30 2002-02-14 Cygnus, Inc. Method and device for predicting physiological values
US20020019612A1 (en) * 2000-08-14 2002-02-14 Takashi Watanabe Infusion pump
US20030004403A1 (en) * 2001-06-29 2003-01-02 Darrel Drinan Gateway platform for biological monitoring and delivery of therapeutic compounds
US20030023317A1 (en) * 2001-07-27 2003-01-30 Dexcom, Inc. Membrane for use with implantable devices
US20030028089A1 (en) * 2001-07-31 2003-02-06 Galley Paul J. Diabetes management system
US20030032874A1 (en) * 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US6675030B2 (en) * 2000-08-21 2004-01-06 Euro-Celtique, S.A. Near infrared blood glucose monitoring system
US6676816B2 (en) * 2001-05-11 2004-01-13 Therasense, Inc. Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes
US20040010186A1 (en) * 2002-07-11 2004-01-15 Optical Sensors, Inc. Calibration technique for non-invasive medical devices
US20040010207A1 (en) * 2002-07-15 2004-01-15 Flaherty J. Christopher Self-contained, automatic transcutaneous physiologic sensing system
US20040015131A1 (en) * 2002-07-16 2004-01-22 Flaherty J. Christopher Flow restriction system and method for patient infusion device
US20040011671A1 (en) * 1997-03-04 2004-01-22 Dexcom, Inc. Device and method for determining analyte levels
US6687546B2 (en) * 2000-01-21 2004-02-03 Medtronic Minimed, Inc. Ambulatory medical apparatus and method using a robust communication protocol
US20040024553A1 (en) * 2002-03-08 2004-02-05 Monfre Stephen L. Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers
US6689056B1 (en) * 1999-04-07 2004-02-10 Medtronic Endonetics, Inc. Implantable monitoring probe
US20040034289A1 (en) * 2000-06-16 2004-02-19 Eric Teller System for monitoring health, wellness and fitness
US6695860B1 (en) * 2000-11-13 2004-02-24 Isense Corp. Transcutaneous sensor insertion device
US20040039298A1 (en) * 1996-09-04 2004-02-26 Abreu Marcio Marc Noninvasive measurement of chemical substances
US20050004494A1 (en) * 2001-01-22 2005-01-06 Perez Edward P. Lancet device having capillary action
US20050004439A1 (en) * 2000-02-23 2005-01-06 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US20050001024A1 (en) * 2001-12-03 2005-01-06 Yosuke Kusaka Electronic apparatus, electronic camera, electronic device, image display apparatus, and image transmission system
US20050027462A1 (en) * 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20050027177A1 (en) * 2000-02-23 2005-02-03 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US20050031689A1 (en) * 2003-05-21 2005-02-10 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US6983176B2 (en) * 2001-04-11 2006-01-03 Rio Grande Medical Technologies, Inc. Optically similar reference samples and related methods for multivariate calibration models used in optical spectroscopy
US20060004270A1 (en) * 2004-06-23 2006-01-05 Michel Bedard Method and apparatus for the monitoring of clinical states
US20060001538A1 (en) * 2004-06-30 2006-01-05 Ulrich Kraft Methods of monitoring the concentration of an analyte
US20060001551A1 (en) * 2004-06-30 2006-01-05 Ulrich Kraft Analyte monitoring system with wireless alarm
US20060015020A1 (en) * 2004-07-06 2006-01-19 Dexcom, Inc. Systems and methods for manufacture of an analyte-measuring device including a membrane system
US20060015024A1 (en) * 2004-07-13 2006-01-19 Mark Brister Transcutaneous medical device with variable stiffness
US20060020188A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060020300A1 (en) * 2004-06-09 2006-01-26 David Nghiem Implantable medical device package antenna
US20060016700A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060017923A1 (en) * 1999-01-22 2006-01-26 Ruchti Timothy L Analyte filter method and apparatus
US20060272652A1 (en) * 2005-06-03 2006-12-07 Medtronic Minimed, Inc. Virtual patient software system for educating and treating individuals with diabetes
US20070010950A1 (en) * 2004-12-03 2007-01-11 Abensour Daniel S Method to determine the degree and stability of blood glucose control in patients with diabetes mellitus via the creation and continuous update of new statistical indicators in blood glucose monitors or free standing computers
US20070007133A1 (en) * 2003-09-30 2007-01-11 Andre Mang Sensor with increased biocompatibility
US20070016381A1 (en) * 2003-08-22 2007-01-18 Apurv Kamath Systems and methods for processing analyte sensor data
US20070017983A1 (en) * 2005-07-19 2007-01-25 3M Innovative Properties Company RFID reader supporting one-touch search functionality
US20070032706A1 (en) * 2003-08-22 2007-02-08 Apurv Kamath Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7317938B2 (en) * 1999-10-08 2008-01-08 Sensys Medical, Inc. Method of adapting in-vitro models to aid in noninvasive glucose determination
US20080009692A1 (en) * 2005-09-30 2008-01-10 Abbott Diabetes Care, Inc. Method and Apparatus for Providing Analyte Sensor and Data Processing Device
US20080021436A1 (en) * 1998-04-30 2008-01-24 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US20080017522A1 (en) * 1997-02-06 2008-01-24 Therasense, Inc. Integrated Lancing and Measurement Device
US20080234943A1 (en) * 2007-03-20 2008-09-25 Pinaki Ray Computer program for diabetes management
US20090006034A1 (en) * 2007-05-14 2009-01-01 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US20090006133A1 (en) * 2007-06-27 2009-01-01 Roche Diagnostics Operations, Inc. Patient information input interface for a therapy system
US20090005665A1 (en) * 2007-05-14 2009-01-01 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US7474992B2 (en) * 2004-01-28 2009-01-06 Honeywell International Inc. Trending system
US20090018425A1 (en) * 2005-12-28 2009-01-15 Tianmei Ouyang Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent
US20090018424A1 (en) * 2006-10-04 2009-01-15 Dexcom, Inc. Analyte sensor
US20090030294A1 (en) * 2004-05-03 2009-01-29 Dexcom, Inc. Implantable analyte sensor
US20100010324A1 (en) * 2003-12-09 2010-01-14 Dexcom, Inc. Signal processing for continuous analyte sensor
US20100010329A1 (en) * 2008-07-14 2010-01-14 Abbott Diabetes Care Inc. Closed Loop Control System Interface and Methods
US20100016698A1 (en) * 2003-11-19 2010-01-21 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US7653425B2 (en) * 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US7651596B2 (en) * 2005-04-08 2010-01-26 Dexcom, Inc. Cellulosic-based interference domain for an analyte sensor
US7651845B2 (en) * 2004-05-13 2010-01-26 The Regents Of The University Of California Method and apparatus for glucose control and insulin dosing for diabetics

Family Cites Families (756)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1191363A (en) 1968-02-19 1970-05-13 Pavelle Ltd Improvements in or relating to Electronic Thermostats.
US3949388A (en) 1972-11-13 1976-04-06 Monitron Industries, Inc. Physiological sensor and transmitter
US3926760A (en) 1973-09-28 1975-12-16 Du Pont Process for electrophoretic deposition of polymer
US3978856A (en) 1975-03-20 1976-09-07 Michel Walter A Heart beat waveform monitoring apparatus
US4036749A (en) 1975-04-30 1977-07-19 Anderson Donald R Purification of saline water
US3960497A (en) 1975-08-19 1976-06-01 Beckman Instruments, Inc. Chemical analyzer with automatic calibration
US4055175A (en) 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
US4129128A (en) 1977-02-23 1978-12-12 Mcfarlane Richard H Securing device for catheter placement assembly
US4344438A (en) 1978-08-02 1982-08-17 The United States Of America As Represented By The Department Of Health, Education And Welfare Optical sensor of plasma constituents
AU530979B2 (en) 1978-12-07 1983-08-04 Aus. Training Aids Pty. Ltd., Detecting position of bullet fired at target
US4731051A (en) 1979-04-27 1988-03-15 The Johns Hopkins University Programmable control means for providing safe and controlled medication infusion
CS210174B1 (en) 1979-07-12 1982-01-29 Ivan Emmer Method of making the electric hygrometric sensor
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4392849A (en) 1981-07-27 1983-07-12 The Cleveland Clinic Foundation Infusion pump controller
DE3138194A1 (en) 1981-09-25 1983-04-14 Basf Ag, 6700 Ludwigshafen WATER-INSOLUBLE POROESES PROTEIN MATERIAL, THEIR PRODUCTION AND USE
DE3278334D1 (en) 1981-10-23 1988-05-19 Genetics Int Inc Sensor for components of a liquid mixture
US4462048A (en) 1982-02-11 1984-07-24 Rca Corporation Noise reduction circuitry for audio signals
FI831399L (en) 1982-04-29 1983-10-30 Agripat Sa KONTAKTLINS AV HAERDAD POLYVINYL ALCOHOL
EP0098592A3 (en) 1982-07-06 1985-08-21 Fujisawa Pharmaceutical Co., Ltd. Portable artificial pancreas
US4509531A (en) 1982-07-28 1985-04-09 Teledyne Industries, Inc. Personal physiological monitor
US4464170A (en) 1982-09-29 1984-08-07 Miles Laboratories, Inc. Blood glucose control apparatus and method
US4527240A (en) 1982-12-29 1985-07-02 Kvitash Vadim I Balascopy method for detecting and rapidly evaluating multiple imbalances within multi-parametric systems
US5682884A (en) 1983-05-05 1997-11-04 Medisense, Inc. Strip electrode with screen printing
US5509410A (en) 1983-06-06 1996-04-23 Medisense, Inc. Strip electrode including screen printing of a single layer
CA1219040A (en) 1983-05-05 1987-03-10 Elliot V. Plotkin Measurement of enzyme-catalysed reactions
CA1226036A (en) 1983-05-05 1987-08-25 Irving J. Higgins Analytical equipment and sensor electrodes therefor
US4538616A (en) 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
DE3429596A1 (en) 1984-08-10 1986-02-20 Siemens AG, 1000 Berlin und 8000 München DEVICE FOR THE PHYSIOLOGICAL FREQUENCY CONTROL OF A PACEMAKER PROVIDED WITH A PICTURE ELECTRODE
CA1254091A (en) 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US4671288A (en) 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4759366A (en) 1986-03-19 1988-07-26 Telectronics N.V. Rate responsive pacing using the ventricular gradient
US4757022A (en) 1986-04-15 1988-07-12 Markwell Medical Institute, Inc. Biological fluid measuring device
US4703756A (en) 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4731726A (en) 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
US5055171A (en) 1986-10-06 1991-10-08 T And G Corporation Ionic semiconductor materials and applications thereof
US5002054A (en) 1987-02-25 1991-03-26 Ash Medical Systems, Inc. Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body
US4777953A (en) 1987-02-25 1988-10-18 Ash Medical Systems, Inc. Capillary filtration and collection method for long-term monitoring of blood constituents
US4854322A (en) 1987-02-25 1989-08-08 Ash Medical Systems, Inc. Capillary filtration and collection device for long-term monitoring of blood constituents
US5365426A (en) 1987-03-13 1994-11-15 The University Of Maryland Advanced signal processing methodology for the detection, localization and quantification of acute myocardial ischemia
US4759828A (en) 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US4749985A (en) 1987-04-13 1988-06-07 United States Of America As Represented By The United States Department Of Energy Functional relationship-based alarm processing
EP0290683A3 (en) 1987-05-01 1988-12-14 Diva Medical Systems B.V. Diabetes management system and apparatus
GB8725936D0 (en) 1987-11-05 1987-12-09 Genetics Int Inc Sensing system
US4925268A (en) 1988-07-25 1990-05-15 Abbott Laboratories Fiber-optic physiological probes
EP0353328A1 (en) 1988-08-03 1990-02-07 Dräger Nederland B.V. A polarographic-amperometric three-electrode sensor
US5340722A (en) 1988-08-24 1994-08-23 Avl Medical Instruments Ag Method for the determination of the concentration of an enzyme substrate and a sensor for carrying out the method
US5360404A (en) 1988-12-14 1994-11-01 Inviro Medical Devices Ltd. Needle guard and needle assembly for syringe
US4947845A (en) 1989-01-13 1990-08-14 Pacesetter Infusion, Ltd. Method of maximizing catheter longevity in an implantable medication infusion system
US5068536A (en) 1989-01-19 1991-11-26 Futrex, Inc. Method for providing custom calibration for near infrared instruments for measurement of blood glucose
US5077476A (en) 1990-06-27 1991-12-31 Futrex, Inc. Instrument for non-invasive measurement of blood glucose
US5312762A (en) 1989-03-13 1994-05-17 Guiseppi Elie Anthony Method of measuring an analyte by measuring electrical resistance of a polymer film reacting with the analyte
JPH02298855A (en) 1989-03-20 1990-12-11 Assoc Univ Inc Electrochemical biosensor using immobilized enzyme and redox polymer
US4953552A (en) 1989-04-21 1990-09-04 Demarzo Arthur P Blood glucose monitoring system
EP0396788A1 (en) 1989-05-08 1990-11-14 Dräger Nederland B.V. Process and sensor for measuring the glucose content of glucosecontaining fluids
FR2648353B1 (en) 1989-06-16 1992-03-27 Europhor Sa MICRODIALYSIS PROBE
US5431160A (en) 1989-07-19 1995-07-11 University Of New Mexico Miniature implantable refillable glucose sensor and material therefor
US5320725A (en) 1989-08-02 1994-06-14 E. Heller & Company Electrode and method for the detection of hydrogen peroxide
US5264105A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5264104A (en) 1989-08-02 1993-11-23 Gregg Brian A Enzyme electrodes
US5262035A (en) 1989-08-02 1993-11-16 E. Heller And Company Enzyme electrodes
US5568400A (en) 1989-09-01 1996-10-22 Stark; Edward W. Multiplicative signal correction method and apparatus
US5050612A (en) 1989-09-12 1991-09-24 Matsumura Kenneth N Device for computer-assisted monitoring of the body
US5342789A (en) 1989-12-14 1994-08-30 Sensor Technologies, Inc. Method and device for detecting and quantifying glucose in body fluids
US5051688A (en) 1989-12-20 1991-09-24 Rohm Co., Ltd. Crossed coil meter driving device having a plurality of input parameters
US5165407A (en) 1990-04-19 1992-11-24 The University Of Kansas Implantable glucose sensor
GB2243211A (en) 1990-04-20 1991-10-23 Philips Electronic Associated Analytical instrument and method of calibrating an analytical instrument
US5202261A (en) 1990-07-19 1993-04-13 Miles Inc. Conductive sensors and their use in diagnostic assays
US5113869A (en) 1990-08-21 1992-05-19 Telectronics Pacing Systems, Inc. Implantable ambulatory electrocardiogram monitor
ATE106015T1 (en) 1990-09-28 1994-06-15 Pfizer METER DELIVERY DEVICE CONTAINING A HYDROPHOBIC AGENT.
US5251126A (en) 1990-10-29 1993-10-05 Miles Inc. Diabetes data analysis and interpretation method
JP2704672B2 (en) 1990-12-12 1998-01-26 シャーウッド・アイエムエス・インコーポレイテッド Infrared thermometer using calibration mapping
US5228449A (en) 1991-01-22 1993-07-20 Athanasios G. Christ System and method for detecting out-of-hospital cardiac emergencies and summoning emergency assistance
US5148812A (en) 1991-02-20 1992-09-22 Georgetown University Non-invasive dynamic tracking of cardiac vulnerability by analysis of t-wave alternans
JPH04278450A (en) 1991-03-04 1992-10-05 Adam Heller Biosensor and method for analyzing subject
US5262305A (en) 1991-03-04 1993-11-16 E. Heller & Company Interferant eliminating biosensors
US5469855A (en) 1991-03-08 1995-11-28 Exergen Corporation Continuous temperature monitor
US5135004A (en) 1991-03-12 1992-08-04 Incontrol, Inc. Implantable myocardial ischemia monitor and related method
US5204264A (en) 1991-03-14 1993-04-20 E. I. Du Pont De Nemours And Company Method for validation of calibration standards in an automatic chemical analyzer
US5199428A (en) 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5122925A (en) 1991-04-22 1992-06-16 Control Products, Inc. Package for electronic components
US5868711A (en) 1991-04-29 1999-02-09 Board Of Regents, The University Of Texas System Implantable intraosseous device for rapid vascular access
US5328460A (en) 1991-06-21 1994-07-12 Pacesetter Infusion, Ltd. Implantable medication infusion pump including self-contained acoustic fault detection apparatus
CA2074702C (en) 1991-07-29 1996-11-19 Donald J. Urbas Programmable transponder
US5231988A (en) 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
GB9120144D0 (en) 1991-09-20 1991-11-06 Imperial College A dialysis electrode device
US5322063A (en) 1991-10-04 1994-06-21 Eli Lilly And Company Hydrophilic polyurethane membranes for electrochemical glucose sensors
US5203326A (en) 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5372427A (en) 1991-12-19 1994-12-13 Texas Instruments Incorporated Temperature sensor
US5313953A (en) 1992-01-14 1994-05-24 Incontrol, Inc. Implantable cardiac patient monitor
US5246867A (en) 1992-01-17 1993-09-21 University Of Maryland At Baltimore Determination and quantification of saccharides by luminescence lifetimes and energy transfer
IL104365A0 (en) 1992-01-31 1993-05-13 Gensia Pharma Method and apparatus for closed loop drug delivery
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
DE69319771T2 (en) 1992-03-31 1999-04-22 Dainippon Printing Co Ltd Immobilized enzyme electrode, composition for its production and electrically conductive enzymes
EP0636009B1 (en) 1992-04-03 2000-11-29 Micromedical Industries Limited system for physiological monitoring
FR2690622B1 (en) 1992-04-29 1995-01-20 Chronotec Programmable ambulatory infusion pump system.
GB9211402D0 (en) 1992-05-29 1992-07-15 Univ Manchester Sensor devices
DK95792A (en) 1992-07-24 1994-01-25 Radiometer As Sensor for non-invasive, in vivo determination of an analyte and blood flow
US5330634A (en) 1992-08-28 1994-07-19 Via Medical Corporation Calibration solutions useful for analyses of biological fluids and methods employing same
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5376070A (en) 1992-09-29 1994-12-27 Minimed Inc. Data transfer system for an infusion pump
WO1994010553A1 (en) 1992-10-23 1994-05-11 Optex Biomedical, Inc. Fibre-optic probe for the measurement of fluid parameters
US5601435A (en) 1994-11-04 1997-02-11 Intercare Method and apparatus for interactively monitoring a physiological condition and for interactively providing health related information
US5899855A (en) 1992-11-17 1999-05-04 Health Hero Network, Inc. Modular microprocessor-based health monitoring system
US5918603A (en) 1994-05-23 1999-07-06 Health Hero Network, Inc. Method for treating medical conditions using a microprocessor-based video game
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
ZA938555B (en) 1992-11-23 1994-08-02 Lilly Co Eli Technique to improve the performance of electrochemical sensors
JPH08505967A (en) 1992-11-24 1996-06-25 パヴィリオン・テクノロジーズ・インコーポレイテッド Method and apparatus for operating a neural network with missing and / or incomplete data
US5410326A (en) 1992-12-04 1995-04-25 Goldstein; Steven W. Programmable remote control device for interacting with a plurality of remotely controlled devices
US5299571A (en) 1993-01-22 1994-04-05 Eli Lilly And Company Apparatus and method for implantation of sensors
EP0622626B1 (en) 1993-04-23 2002-03-06 Roche Diagnostics GmbH System for analysing the components of fluid samples
DE4329898A1 (en) 1993-09-04 1995-04-06 Marcus Dr Besson Wireless medical diagnostic and monitoring device
US5438983A (en) 1993-09-13 1995-08-08 Hewlett-Packard Company Patient alarm detection using trend vector analysis
US5425749A (en) 1993-09-16 1995-06-20 Angeion Corporation Preemptive cardioversion therapy in an implantable cardioverter defibrillator
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5400795A (en) 1993-10-22 1995-03-28 Telectronics Pacing Systems, Inc. Method of classifying heart rhythms by analyzing several morphology defining metrics derived for a patient's QRS complex
US5791344A (en) 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5497772A (en) 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US5320715A (en) 1994-01-14 1994-06-14 Lloyd Berg Separation of 1-pentanol from cyclopentanol by extractive distillation
DE4401400A1 (en) 1994-01-19 1995-07-20 Ernst Prof Dr Pfeiffer Method and arrangement for continuously monitoring the concentration of a metabolite
US5543326A (en) 1994-03-04 1996-08-06 Heller; Adam Biosensor including chemically modified enzymes
US5536249A (en) 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
AU2200895A (en) 1994-04-04 1995-10-23 Motorola, Inc. Method and apparatus for activating and accessing remote meter interface devices
US5609575A (en) 1994-04-11 1997-03-11 Graseby Medical Limited Infusion pump and method with dose-rate calculation
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
DE4415896A1 (en) 1994-05-05 1995-11-09 Boehringer Mannheim Gmbh Analysis system for monitoring the concentration of an analyte in the blood of a patient
US5472317A (en) 1994-06-03 1995-12-05 Minimed Inc. Mounting clip for a medication infusion pump
US5549115A (en) 1994-09-28 1996-08-27 Heartstream, Inc. Method and apparatus for gathering event data using a removable data storage medium and clock
US5520191A (en) 1994-10-07 1996-05-28 Ortivus Medical Ab Myocardial ischemia and infarction analysis and monitoring method and apparatus
US6038469A (en) 1994-10-07 2000-03-14 Ortivus Ab Myocardial ischemia and infarction analysis and monitoring method and apparatus
US5724030A (en) 1994-10-13 1998-03-03 Bio Medic Data Systems, Inc. System monitoring reprogrammable implantable transponder
ATE160079T1 (en) 1995-02-04 1997-11-15 Baumann & Haldi Sa SINGLE ARRANGEMENT FOR THE MEASURING, PROCESSING AND TRANSMISSION OF ESSENTIALLY PHYSIOLOGICAL PARAMETERS
US5586553A (en) 1995-02-16 1996-12-24 Minimed Inc. Transcutaneous sensor insertion set
US5568806A (en) 1995-02-16 1996-10-29 Minimed Inc. Transcutaneous sensor insertion set
US5752512A (en) 1995-05-10 1998-05-19 Massachusetts Institute Of Technology Apparatus and method for non-invasive blood analyte measurement
US5628310A (en) 1995-05-19 1997-05-13 Joseph R. Lakowicz Method and apparatus to perform trans-cutaneous analyte monitoring
US5665065A (en) 1995-05-26 1997-09-09 Minimed Inc. Medication infusion device with blood glucose data input
US5619631A (en) 1995-06-07 1997-04-08 Binaryblitz Method and apparatus for data alteration by manipulation of representational graphs
US5995860A (en) 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US7016713B2 (en) 1995-08-09 2006-03-21 Inlight Solutions, Inc. Non-invasive determination of direction and rate of change of an analyte
US5628890A (en) 1995-09-27 1997-05-13 Medisense, Inc. Electrochemical sensor
US5972199A (en) 1995-10-11 1999-10-26 E. Heller & Company Electrochemical analyte sensors using thermostable peroxidase
US5665222A (en) 1995-10-11 1997-09-09 E. Heller & Company Soybean peroxidase electrochemical sensor
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
US5748103A (en) 1995-11-13 1998-05-05 Vitalcom, Inc. Two-way TDMA telemetry system with power conservation features
FI960636A (en) 1996-02-12 1997-08-13 Nokia Mobile Phones Ltd A procedure for monitoring the health of a patient
US5833603A (en) 1996-03-13 1998-11-10 Lipomatrix, Inc. Implantable biosensing transponder
US5785660A (en) 1996-03-28 1998-07-28 Pacesetter, Inc. Methods and apparatus for storing intracardiac electrograms
DE19618597B4 (en) 1996-05-09 2005-07-21 Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm Method for determining the concentration of tissue glucose
US6130602A (en) 1996-05-13 2000-10-10 Micron Technology, Inc. Radio frequency data communications device
US20040249420A1 (en) 1996-05-14 2004-12-09 Medtronic, Inc. Prioritized rule based method and apparatus for diagnosis and treatment of arrhythmias
US5735285A (en) 1996-06-04 1998-04-07 Data Critical Corp. Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals
ES2195151T3 (en) 1996-06-18 2003-12-01 Alza Corp IMPROVEMENT OR SAMPLING DEVICE FOR TRANSDERMAL AGENTS.
JP3581218B2 (en) 1996-07-03 2004-10-27 株式会社東芝 Mobile communication terminal device and its mobile phone and data terminal device
EP0923335B1 (en) 1996-07-08 2006-08-23 Animas Corporation Implantable sensor and system for in vivo measurement and control of fluid constituent levels
US5707502A (en) 1996-07-12 1998-01-13 Chiron Diagnostics Corporation Sensors for measuring analyte concentrations and methods of making same
US5738220A (en) 1996-09-30 1998-04-14 Pacesetter, Inc. Distal tip protector cap
US5720295A (en) 1996-10-15 1998-02-24 Pacesetter, Inc. Pacemaker with improved detection of atrial fibrillation
US6071249A (en) 1996-12-06 2000-06-06 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US5964993A (en) 1996-12-19 1999-10-12 Implanted Biosystems Inc. Glucose sensor
US6130623A (en) 1996-12-31 2000-10-10 Lucent Technologies Inc. Encryption for modulated backscatter systems
US5914026A (en) 1997-01-06 1999-06-22 Implanted Biosystems Inc. Implantable sensor employing an auxiliary electrode
US6122351A (en) 1997-01-21 2000-09-19 Med Graph, Inc. Method and system aiding medical diagnosis and treatment
SE9700182D0 (en) 1997-01-22 1997-01-22 Pacesetter Ab Implantable heart stimulator
SE9700181D0 (en) 1997-01-22 1997-01-22 Pacesetter Ab Ischemia detector and heart stimulator provided with such an ischemia detector
US6093172A (en) 1997-02-05 2000-07-25 Minimed Inc. Injector for a subcutaneous insertion set
US6607509B2 (en) 1997-12-31 2003-08-19 Medtronic Minimed, Inc. Insertion device for an insertion set and method of using the same
US6293925B1 (en) 1997-12-31 2001-09-25 Minimed Inc. Insertion device for an insertion set and method of using the same
SE9700427D0 (en) 1997-02-07 1997-02-07 Pacesetter Ab Ischemia detector
US5980708A (en) 1997-02-12 1999-11-09 Champagne; Gilles Y. High sensitivity multiple waveform voltammetric instrument
US5749907A (en) 1997-02-18 1998-05-12 Pacesetter, Inc. System and method for identifying and displaying medical data which violate programmable alarm conditions
EP1011426A1 (en) 1997-02-26 2000-06-28 Diasense, Inc. Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose
US6159147A (en) 1997-02-28 2000-12-12 Qrs Diagnostics, Llc Personal computer card for collection of real-time biological data
US6558321B1 (en) 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US6741877B1 (en) 1997-03-04 2004-05-25 Dexcom, Inc. Device and method for determining analyte levels
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US7657297B2 (en) 2004-05-03 2010-02-02 Dexcom, Inc. Implantable analyte sensor
US7899511B2 (en) 2004-07-13 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US5959529A (en) 1997-03-07 1999-09-28 Kail, Iv; Karl A. Reprogrammable remote sensor monitoring system
US5891047A (en) 1997-03-14 1999-04-06 Cambridge Heart, Inc. Detecting abnormal activation of heart
US5792065A (en) 1997-03-18 1998-08-11 Marquette Medical Systems, Inc. Method and apparatus for determining T-wave marker points during QT dispersion analysis
SE9701121D0 (en) 1997-03-26 1997-03-26 Pacesetter Ab Implantable heart stimulator
SE9701122D0 (en) 1997-03-26 1997-03-26 Pacesetter Ab Medical implant
US6699187B2 (en) 1997-03-27 2004-03-02 Medtronic, Inc. System and method for providing remote expert communications and video capabilities for use during a medical procedure
US6270455B1 (en) 1997-03-28 2001-08-07 Health Hero Network, Inc. Networked system for interactive communications and remote monitoring of drug delivery
US5942979A (en) 1997-04-07 1999-08-24 Luppino; Richard On guard vehicle safety warning system
US5961451A (en) 1997-04-07 1999-10-05 Motorola, Inc. Noninvasive apparatus having a retaining member to retain a removable biosensor
US5935224A (en) 1997-04-24 1999-08-10 Microsoft Corporation Method and apparatus for adaptively coupling an external peripheral device to either a universal serial bus port on a computer or hub or a game port on a computer
US5954643A (en) 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor
US7267665B2 (en) 1999-06-03 2007-09-11 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6558351B1 (en) 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
JP2002505008A (en) 1997-06-16 2002-02-12 エラン コーポレーション ピーエルシー Methods for calibrating and testing sensors for in vivo measurement of analytes and devices for use in such methods
US6056435A (en) 1997-06-24 2000-05-02 Exergen Corporation Ambient and perfusion normalized temperature detector
US6066243A (en) 1997-07-22 2000-05-23 Diametrics Medical, Inc. Portable immediate response medical analyzer having multiple testing modules
US6731976B2 (en) 1997-09-03 2004-05-04 Medtronic, Inc. Device and method to measure and communicate body parameters
US6764581B1 (en) 1997-09-05 2004-07-20 Abbott Laboratories Electrode with thin working layer
US6259937B1 (en) 1997-09-12 2001-07-10 Alfred E. Mann Foundation Implantable substrate sensor
US6071391A (en) 1997-09-12 2000-06-06 Nok Corporation Enzyme electrode structure
US6117290A (en) 1997-09-26 2000-09-12 Pepex Biomedical, Llc System and method for measuring a bioanalyte such as lactate
US5904671A (en) 1997-10-03 1999-05-18 Navot; Nir Tampon wetness detection system
US6736957B1 (en) 1997-10-16 2004-05-18 Abbott Laboratories Biosensor electrode mediators for regeneration of cofactors and process for using
US6088608A (en) 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
US6119028A (en) 1997-10-20 2000-09-12 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces
FI107080B (en) 1997-10-27 2001-05-31 Nokia Mobile Phones Ltd measuring device
ES2281143T3 (en) 1997-11-12 2007-09-16 Lightouch Medical, Inc. METHOD FOR THE NON-INVASIVE MEASUREMENT OF AN ANALYTE.
CA2547299C (en) 1997-12-04 2009-03-03 Roche Diagnostics Corporation Instrument and method
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
US7494816B2 (en) 1997-12-22 2009-02-24 Roche Diagnostic Operations, Inc. System and method for determining a temperature during analyte measurement
US6073031A (en) 1997-12-24 2000-06-06 Nortel Networks Corporation Desktop docking station for use with a wireless telephone handset
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6103033A (en) 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US6197181B1 (en) 1998-03-20 2001-03-06 Semitool, Inc. Apparatus and method for electrolytically depositing a metal on a microelectronic workpiece
US6579231B1 (en) 1998-03-27 2003-06-17 Mci Communications Corporation Personal medical monitoring unit and system
JP3104672B2 (en) 1998-03-31 2000-10-30 日本電気株式会社 Current detection type sensor element and method of manufacturing the same
JPH11296598A (en) 1998-04-07 1999-10-29 Seizaburo Arita System and method for predicting blood-sugar level and record medium where same method is recorded
US6091987A (en) 1998-04-29 2000-07-18 Medtronic, Inc. Power consumption reduction in medical devices by employing different supply voltages
US7647237B2 (en) 1998-04-29 2010-01-12 Minimed, Inc. Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
GB2337122B (en) 1998-05-08 2002-11-13 Medisense Inc Test strip
ATE245937T1 (en) 1998-05-13 2003-08-15 Cygnus Therapeutic Systems MONITORING PHYSIOLOGICAL ANALYTES
PT1077636E (en) 1998-05-13 2004-06-30 Cygnus Therapeutic Systems SIGNAL PROCESSING FOR PHYSIOLOGICAL ANALYZES MEDICATION
US7043287B1 (en) 1998-05-18 2006-05-09 Abbott Laboratories Method for modulating light penetration depth in tissue and diagnostic applications using same
US6121611A (en) 1998-05-20 2000-09-19 Molecular Imaging Corporation Force sensing probe for scanning probe microscopy
US6493069B1 (en) 1998-07-24 2002-12-10 Terumo Kabushiki Kaisha Method and instrument for measuring blood sugar level
AU5394099A (en) 1998-08-07 2000-02-28 Infinite Biomedical Technologies, Incorporated Implantable myocardial ischemia detection, indication and action technology
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6248067B1 (en) 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
US6359270B1 (en) 1998-09-04 2002-03-19 Ncr Corporation Communications module mounting for domestic appliance
KR20000019716A (en) 1998-09-15 2000-04-15 박호군 Composition comprising bioflavonoid compounds for descending blood sugar
US6740518B1 (en) 1998-09-17 2004-05-25 Clinical Micro Sensors, Inc. Signal detection techniques for the detection of analytes
US6254586B1 (en) 1998-09-25 2001-07-03 Minimed Inc. Method and kit for supplying a fluid to a subcutaneous placement site
US6402689B1 (en) 1998-09-30 2002-06-11 Sicel Technologies, Inc. Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
ATE514372T1 (en) 1998-10-08 2011-07-15 Medtronic Minimed Inc LICENSE PLATE MONITORING SYSTEM WITH REMOTE MEASUREMENT
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6496729B2 (en) 1998-10-28 2002-12-17 Medtronic, Inc. Power consumption reduction in medical devices employing multiple supply voltages and clock frequency control
US6602469B1 (en) 1998-11-09 2003-08-05 Lifestream Technologies, Inc. Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system
DE69924749T2 (en) 1998-11-20 2006-04-27 The University Of Connecticut, Farmington Generically integrated implantable potentiostat remote sensing device for electrochemical probes
US6773671B1 (en) 1998-11-30 2004-08-10 Abbott Laboratories Multichemistry measuring device and test strips
JP4749549B2 (en) 1998-11-30 2011-08-17 アボット・ラボラトリーズ Analytical testing instrument with improved calibration and communication process
JP2002531884A (en) 1998-11-30 2002-09-24 ノボ ノルディスク アクティーゼルスカブ Method and system for assisting a user in self-treatment involving multiple actions
US6161095A (en) 1998-12-16 2000-12-12 Health Hero Network, Inc. Treatment regimen compliance and efficacy with feedback
AU3363000A (en) 1999-02-12 2000-08-29 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
EP1161277B1 (en) 1999-02-18 2006-10-11 Biovalve Technologies, Inc. Electroactive pore
US6112116A (en) 1999-02-22 2000-08-29 Cathco, Inc. Implantable responsive system for sensing and treating acute myocardial infarction
US6360888B1 (en) 1999-02-25 2002-03-26 Minimed Inc. Glucose sensor package system
US6424847B1 (en) 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods
US6296571B1 (en) 1999-03-02 2001-10-02 Logitech Europe S.A. Steering wheel spring assembly
US6272379B1 (en) 1999-03-17 2001-08-07 Cathco, Inc. Implantable electronic system with acute myocardial infarction detection and patient warning capabilities
US6128526A (en) 1999-03-29 2000-10-03 Medtronic, Inc. Method for ischemia detection and apparatus for using same
US6115628A (en) 1999-03-29 2000-09-05 Medtronic, Inc. Method and apparatus for filtering electrocardiogram (ECG) signals to remove bad cycle information and for use of physiologic signals determined from said filtered ECG signals
GB9907815D0 (en) 1999-04-06 1999-06-02 Univ Cambridge Tech Implantable sensor
US6416471B1 (en) 1999-04-15 2002-07-09 Nexan Limited Portable remote patient telemonitoring system
US6200265B1 (en) 1999-04-16 2001-03-13 Medtronic, Inc. Peripheral memory patch and access method for use with an implantable medical device
US6108577A (en) 1999-04-26 2000-08-22 Cardiac Pacemakers, Inc. Method and apparatus for detecting changes in electrocardiogram signals
US6669663B1 (en) 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6359444B1 (en) 1999-05-28 2002-03-19 University Of Kentucky Research Foundation Remote resonant-circuit analyte sensing apparatus with sensing structure and associated method of sensing
US6546268B1 (en) 1999-06-02 2003-04-08 Ball Semiconductor, Inc. Glucose sensor
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
DE19925910B4 (en) 1999-06-07 2005-04-28 Siemens Ag Method for processing or processing data
GB2351153B (en) 1999-06-18 2003-03-26 Abbott Lab Electrochemical sensor for analysis of liquid samples
AU5747100A (en) 1999-06-18 2001-01-09 Therasense, Inc. Mass transport limited in vivo analyte sensor
US6423035B1 (en) 1999-06-18 2002-07-23 Animas Corporation Infusion pump with a sealed drive mechanism and improved method of occlusion detection
US6413393B1 (en) 1999-07-07 2002-07-02 Minimed, Inc. Sensor including UV-absorbing polymer and method of manufacture
US6804558B2 (en) 1999-07-07 2004-10-12 Medtronic, Inc. System and method of communicating between an implantable medical device and a remote computer system or health care provider
US6514460B1 (en) 1999-07-28 2003-02-04 Abbott Laboratories Luminous glucose monitoring device
US6471689B1 (en) 1999-08-16 2002-10-29 Thomas Jefferson University Implantable drug delivery catheter system with capillary interface
US6923763B1 (en) 1999-08-23 2005-08-02 University Of Virginia Patent Foundation Method and apparatus for predicting the risk of hypoglycemia
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
US6343225B1 (en) 1999-09-14 2002-01-29 Implanted Biosystems, Inc. Implantable glucose sensor
AT408182B (en) 1999-09-17 2001-09-25 Schaupp Lukas Dipl Ing Dr Tech DEVICE FOR VIVO MEASURING SIZES IN LIVING ORGANISMS
EP1217942A1 (en) 1999-09-24 2002-07-03 Healthetech, Inc. Physiological monitor and associated computation, display and communication unit
US6294997B1 (en) 1999-10-04 2001-09-25 Intermec Ip Corp. RFID tag having timing and environment modules
US6478736B1 (en) 1999-10-08 2002-11-12 Healthetech, Inc. Integrated calorie management system
US6249705B1 (en) 1999-10-21 2001-06-19 Pacesetter, Inc. Distributed network system for use with implantable medical devices
US20060091006A1 (en) 1999-11-04 2006-05-04 Yi Wang Analyte sensor with insertion monitor, and methods
US6616819B1 (en) 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
DK1230249T3 (en) 1999-11-15 2004-08-30 Therasense Inc Transition metal complexes with bidentate ligand having an imidazole ring
US6291200B1 (en) 1999-11-17 2001-09-18 Agentase, Llc Enzyme-containing polymeric sensors
US6658396B1 (en) 1999-11-29 2003-12-02 Tang Sharon S Neural network drug dosage estimation
US6418346B1 (en) 1999-12-14 2002-07-09 Medtronic, Inc. Apparatus and method for remote therapy and diagnosis in medical devices via interface systems
US7060031B2 (en) 1999-12-17 2006-06-13 Medtronic, Inc. Method and apparatus for remotely programming implantable medical devices
US6497655B1 (en) 1999-12-17 2002-12-24 Medtronic, Inc. Virtual remote monitor, alert, diagnostics and programming for implantable medical device systems
US7286894B1 (en) 2000-01-07 2007-10-23 Pasco Scientific Hand-held computer device and method for interactive data acquisition, analysis, annotation, and calibration
JP3449958B2 (en) 2000-01-18 2003-09-22 理想科学工業株式会社 Printing system, printing method, and computer-readable recording medium storing printing program
US6377852B1 (en) 2000-01-20 2002-04-23 Pacesetter, Inc. Implanatable cardiac stimulation device and method for prolonging atrial refractoriness
US7369635B2 (en) 2000-01-21 2008-05-06 Medtronic Minimed, Inc. Rapid discrimination preambles and methods for using the same
DK1248660T3 (en) 2000-01-21 2012-07-23 Medtronic Minimed Inc Microprocessor controlled outpatient medical device with handheld communication device
WO2001052935A1 (en) 2000-01-21 2001-07-26 Medical Research Group, Inc. Ambulatory medical apparatus and method having telemetry modifiable control software
US7003336B2 (en) 2000-02-10 2006-02-21 Medtronic Minimed, Inc. Analyte sensor method of making the same
US20030060765A1 (en) 2000-02-16 2003-03-27 Arthur Campbell Infusion device menu structure and method of using the same
US7027931B1 (en) 2000-02-24 2006-04-11 Bionostics, Inc. System for statistical analysis of quality control data
US6572542B1 (en) 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
US6405066B1 (en) 2000-03-17 2002-06-11 The Regents Of The University Of California Implantable analyte sensor
EP1267708A4 (en) 2000-03-29 2006-04-12 Univ Virginia Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US6610012B2 (en) 2000-04-10 2003-08-26 Healthetech, Inc. System and method for remote pregnancy monitoring
US6561975B1 (en) 2000-04-19 2003-05-13 Medtronic, Inc. Method and apparatus for communicating with medical device systems
US6440068B1 (en) 2000-04-28 2002-08-27 International Business Machines Corporation Measuring user health as measured by multiple diverse health measurement devices utilizing a personal storage device
AU2001263022A1 (en) 2000-05-12 2001-11-26 Therasense, Inc. Electrodes with multilayer membranes and methods of using and making the electrodes
US7181261B2 (en) 2000-05-15 2007-02-20 Silver James H Implantable, retrievable, thrombus minimizing sensors
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
US7769420B2 (en) 2000-05-15 2010-08-03 Silver James H Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction
CN100464557C (en) 2000-05-31 2009-02-25 爱科来株式会社 Remote data control system and measuring data gathering method
JP2004512206A (en) 2000-05-31 2004-04-22 ダグラス オートテック コーポレィション Alarm mechanism
US6361503B1 (en) 2000-06-26 2002-03-26 Mediwave Star Technology, Inc. Method and system for evaluating cardiac ischemia
US6540675B2 (en) 2000-06-27 2003-04-01 Rosedale Medical, Inc. Analyte monitor
US6400974B1 (en) 2000-06-29 2002-06-04 Sensors For Medicine And Science, Inc. Implanted sensor processing system and method for processing implanted sensor output
CA2408338C (en) 2000-08-18 2009-09-08 Cygnus, Inc. Methods and devices for prediction of hypoglycemic events
WO2002017210A2 (en) 2000-08-18 2002-02-28 Cygnus, Inc. Formulation and manipulation of databases of analyte and associated values
US6575905B2 (en) 2000-09-22 2003-06-10 Knobbe, Lim & Buckingham Method and apparatus for real-time estimation of physiological parameters
US7226442B2 (en) 2000-10-10 2007-06-05 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
DE60139411D1 (en) 2000-10-26 2009-09-10 Medtronic Inc DEVICE FOR MINIMIZING THE EFFECTS OF A HEART INJURY
US6574510B2 (en) 2000-11-30 2003-06-03 Cardiac Pacemakers, Inc. Telemetry apparatus and method for an implantable medical device
US7052483B2 (en) 2000-12-19 2006-05-30 Animas Corporation Transcutaneous inserter for low-profile infusion sets
US20020147135A1 (en) 2000-12-21 2002-10-10 Oliver Schnell Method and device for producing an adapted travel treatment plan for administering a medicine in the event of a long-haul journey
US6490479B2 (en) 2000-12-28 2002-12-03 Ge Medical Systems Information Technologies, Inc. Atrial fibrillation detection method and apparatus
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US6970529B2 (en) 2001-01-16 2005-11-29 International Business Machines Corporation Unified digital architecture
US6529752B2 (en) 2001-01-17 2003-03-04 David T. Krausman Sleep disorder breathing event counter
US20040197846A1 (en) 2001-01-18 2004-10-07 Linda Hockersmith Determination of glucose sensitivity and a method to manipulate blood glucose concentration
US6749587B2 (en) 2001-02-22 2004-06-15 Insulet Corporation Modular infusion device and method
US20020130779A1 (en) 2001-03-13 2002-09-19 Herbert Ford Intensive care calculator
EP1384193A2 (en) 2001-03-14 2004-01-28 Baxter International Inc. Internet based therapy management system
CA2441054A1 (en) 2001-03-14 2002-09-19 Milton E. Hamilton Tracking device
US6968294B2 (en) 2001-03-15 2005-11-22 Koninklijke Philips Electronics N.V. Automatic system for monitoring person requiring care and his/her caretaker
US6622045B2 (en) 2001-03-29 2003-09-16 Pacesetter, Inc. System and method for remote programming of implantable cardiac stimulation devices
EP1397068A2 (en) 2001-04-02 2004-03-17 Therasense, Inc. Blood glucose tracking apparatus and methods
US6574490B2 (en) 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans
US7916013B2 (en) 2005-03-21 2011-03-29 Greatbatch Ltd. RFID detection and identification system for implantable medical devices
GR1003802B (en) 2001-04-17 2002-02-08 Micrel �.�.�. ������� ��������� ��������������� ��������� Tele-medicine system
US6698269B2 (en) 2001-04-27 2004-03-02 Oceana Sensor Technologies, Inc. Transducer in-situ testing apparatus and method
US7395214B2 (en) 2001-05-11 2008-07-01 Craig P Shillingburg Apparatus, device and method for prescribing, administering and monitoring a treatment regimen for a patient
US6932894B2 (en) 2001-05-15 2005-08-23 Therasense, Inc. Biosensor membranes composed of polymers containing heterocyclic nitrogens
US6549796B2 (en) 2001-05-25 2003-04-15 Lifescan, Inc. Monitoring analyte concentration using minimally invasive devices
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US7179226B2 (en) 2001-06-21 2007-02-20 Animas Corporation System and method for managing diabetes
EP2319400B1 (en) 2001-06-22 2012-08-22 Nellcor Puritan Bennett Ireland Wavelet-based analysis of pulse oximetry signals
WO2003000127A2 (en) 2001-06-22 2003-01-03 Cygnus, Inc. Method for improving the performance of an analyte monitoring system
US20030208113A1 (en) 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US6754516B2 (en) 2001-07-19 2004-06-22 Nellcor Puritan Bennett Incorporated Nuisance alarm reductions in a physiological monitor
US6788965B2 (en) 2001-08-03 2004-09-07 Sensys Medical, Inc. Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes
US20040260478A1 (en) 2001-08-03 2004-12-23 Schwamm Lee H. System, process and diagnostic arrangement establishing and monitoring medication doses for patients
WO2003015629A1 (en) 2001-08-20 2003-02-27 Inverness Medical Limited Wireless diabetes management devices and methods for using the same
DE60238202D1 (en) 2001-08-22 2010-12-16 Instrumentation Lab Co METHOD AND DEVICE FOR CALIBRATING SENSORS
EP1433032A4 (en) 2001-08-27 2010-09-15 Informmed Inc Handheld medication dosage calculator
US7096064B2 (en) 2001-08-28 2006-08-22 Medtronic, Inc. Implantable medical device for treating cardiac mechanical dysfunction by electrical stimulation
US6827702B2 (en) 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
US6740072B2 (en) 2001-09-07 2004-05-25 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
JP2003084101A (en) 2001-09-17 2003-03-19 Dainippon Printing Co Ltd Resin composition for optical device, optical device and projection screen
US20030055380A1 (en) 2001-09-19 2003-03-20 Flaherty J. Christopher Plunger for patient infusion device
US7052591B2 (en) 2001-09-21 2006-05-30 Therasense, Inc. Electrodeposition of redox polymers and co-electrodeposition of enzymes by coordinative crosslinking
US6830562B2 (en) 2001-09-27 2004-12-14 Unomedical A/S Injector device for placing a subcutaneous infusion set
US20050137480A1 (en) 2001-10-01 2005-06-23 Eckhard Alt Remote control of implantable device through medical implant communication service band
US6731985B2 (en) 2001-10-16 2004-05-04 Pacesetter, Inc. Implantable cardiac stimulation system and method for automatic capture verification calibration
US7854230B2 (en) 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
EP1448489B1 (en) 2001-11-16 2010-08-25 Stefan Ufer Flexible sensor and method of fabrication
US7204823B2 (en) 2001-12-19 2007-04-17 Medtronic Minimed, Inc. Medication delivery system and monitor
US7729776B2 (en) 2001-12-19 2010-06-01 Cardiac Pacemakers, Inc. Implantable medical device with two or more telemetry systems
US7082334B2 (en) 2001-12-19 2006-07-25 Medtronic, Inc. System and method for transmission of medical and like data from a patient to a dedicated internet website
US7399277B2 (en) 2001-12-27 2008-07-15 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US20080255438A1 (en) 2001-12-27 2008-10-16 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US7022072B2 (en) 2001-12-27 2006-04-04 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US20050027182A1 (en) 2001-12-27 2005-02-03 Uzair Siddiqui System for monitoring physiological characteristics
US6980852B2 (en) 2002-01-25 2005-12-27 Subqiview Inc. Film barrier dressing for intravascular tissue monitoring system
US6985773B2 (en) 2002-02-07 2006-01-10 Cardiac Pacemakers, Inc. Methods and apparatuses for implantable medical device telemetry power management
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
AU2003213638A1 (en) 2002-02-26 2003-09-09 Sterling Medivations, Inc. Insertion device for an insertion set and method of using the same
US20030212379A1 (en) 2002-02-26 2003-11-13 Bylund Adam David Systems and methods for remotely controlling medication infusion and analyte monitoring
US6830558B2 (en) 2002-03-01 2004-12-14 Insulet Corporation Flow condition sensor assembly for patient infusion device
US7043305B2 (en) 2002-03-06 2006-05-09 Cardiac Pacemakers, Inc. Method and apparatus for establishing context among events and optimizing implanted medical device performance
US7468032B2 (en) 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US6936006B2 (en) 2002-03-22 2005-08-30 Novo Nordisk, A/S Atraumatic insertion of a subcutaneous device
GB2388898B (en) 2002-04-02 2005-10-05 Inverness Medical Ltd Integrated sample testing meter
US7027848B2 (en) 2002-04-04 2006-04-11 Inlight Solutions, Inc. Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte
US7198606B2 (en) 2002-04-19 2007-04-03 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with analyte sensing
US7410468B2 (en) 2002-04-19 2008-08-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7153265B2 (en) 2002-04-22 2006-12-26 Medtronic Minimed, Inc. Anti-inflammatory biosensor for reduced biofouling and enhanced sensor performance
US20040153032A1 (en) 2002-04-23 2004-08-05 Garribotto John T. Dispenser for patient infusion device
EP1498067A1 (en) 2002-04-25 2005-01-19 Matsushita Electric Industrial Co., Ltd. Dosage determination supporting device, injector, and health management supporting system
GB2388715B (en) 2002-05-13 2005-08-03 Splashpower Ltd Improvements relating to the transfer of electromagnetic power
US7015817B2 (en) 2002-05-14 2006-03-21 Shuan Michael Copley Personal tracking device
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
JP2004054394A (en) 2002-07-17 2004-02-19 Toshiba Corp Radio information processing system, radio information recording medium, radio information processor and communication method for radio information processing system
AU2003302720B9 (en) 2002-07-19 2008-08-21 Smiths Detection-Pasadena, Inc. Non-specific sensor array detectors
US7278983B2 (en) 2002-07-24 2007-10-09 Medtronic Minimed, Inc. Physiological monitoring device for controlling a medication infusion device
EP1534121B1 (en) 2002-08-13 2014-01-22 University Of Virginia Patent Foundation Method, system, and computer program product for the processing of self-monitoring blood glucose(smbg)data to enhance diabetic self-management
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US6865641B2 (en) 2002-08-29 2005-03-08 International Business Machines Corporation Method and apparatus for non-volatile display of information for an electronic device
US7404796B2 (en) 2004-03-01 2008-07-29 Becton Dickinson And Company System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
US7144384B2 (en) 2002-09-30 2006-12-05 Insulet Corporation Dispenser components and methods for patient infusion device
US7128727B2 (en) 2002-09-30 2006-10-31 Flaherty J Christopher Components and methods for patient infusion device
US7192405B2 (en) 2002-09-30 2007-03-20 Becton, Dickinson And Company Integrated lancet and bodily fluid sensor
KR101226540B1 (en) 2002-10-11 2013-01-25 벡톤 디킨슨 앤드 컴퍼니 System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device
US7079977B2 (en) 2002-10-15 2006-07-18 Medtronic, Inc. Synchronization and calibration of clocks for a medical device and calibrated clock
US7029443B2 (en) 2002-10-21 2006-04-18 Pacesetter, Inc. System and method for monitoring blood glucose levels using an implantable medical device
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
US7572237B2 (en) 2002-11-06 2009-08-11 Abbott Diabetes Care Inc. Automatic biological analyte testing meter with integrated lancing device and methods of use
US7009511B2 (en) 2002-12-17 2006-03-07 Cardiac Pacemakers, Inc. Repeater device for communications with an implantable medical device
US20040122353A1 (en) 2002-12-19 2004-06-24 Medtronic Minimed, Inc. Relay device for transferring information between a sensor system and a fluid delivery system
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US7396330B2 (en) 2003-01-07 2008-07-08 Triage Data Networks Wireless, internet-based medical-diagnostic system
US7207947B2 (en) 2003-01-10 2007-04-24 Pacesetter, Inc. System and method for detecting circadian states using an implantable medical device
US20040172307A1 (en) 2003-02-06 2004-09-02 Gruber Martin A. Electronic medical record method
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
WO2004084820A2 (en) 2003-03-19 2004-10-07 Harry Hebblewhite Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
US20040199056A1 (en) 2003-04-03 2004-10-07 International Business Machines Corporation Body monitoring using local area wireless interfaces
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US20040204868A1 (en) 2003-04-09 2004-10-14 Maynard John D. Reduction of errors in non-invasive tissue sampling
CA2520880A1 (en) 2003-04-18 2004-11-04 Insulet Corporation User interface for infusion pump remote controller and method of using the same
US7103412B1 (en) 2003-05-02 2006-09-05 Pacesetter, Inc. Implantable cardiac stimulation device and method for detecting asymptomatic diabetes
US7258673B2 (en) 2003-06-06 2007-08-21 Lifescan, Inc Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
US20050016276A1 (en) 2003-06-06 2005-01-27 Palo Alto Sensor Technology Innovation Frequency encoding of resonant mass sensors
US7040139B2 (en) 2003-06-10 2006-05-09 Smiths Detection Inc. Sensor arrangement
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US20040254433A1 (en) 2003-06-12 2004-12-16 Bandis Steven D. Sensor introducer system, apparatus and method
US7155290B2 (en) 2003-06-23 2006-12-26 Cardiac Pacemakers, Inc. Secure long-range telemetry for implantable medical device
US7142911B2 (en) 2003-06-26 2006-11-28 Pacesetter, Inc. Method and apparatus for monitoring drug effects on cardiac electrical signals using an implantable cardiac stimulation device
US7510564B2 (en) 2003-06-27 2009-03-31 Abbott Diabetes Care Inc. Lancing device
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
WO2005007223A2 (en) 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
US7424318B2 (en) 2003-12-05 2008-09-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc Oxygen enhancing membrane systems for implantable devices
US7460898B2 (en) 2003-12-05 2008-12-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1649260A4 (en) 2003-07-25 2010-07-07 Dexcom Inc Electrode systems for electrochemical sensors
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US7467003B2 (en) 2003-12-05 2008-12-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
WO2007120442A2 (en) 2003-07-25 2007-10-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
WO2005019795A2 (en) 2003-07-25 2005-03-03 Dexcom, Inc. Electrochemical sensors including electrode systems with increased oxygen generation
US7366556B2 (en) 2003-12-05 2008-04-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US20050176136A1 (en) 2003-11-19 2005-08-11 Dexcom, Inc. Afinity domain for analyte sensor
EP1652088B1 (en) 2003-07-25 2017-09-13 Philips Intellectual Property & Standards GmbH Method and device for monitoring a system
US8285354B2 (en) 2003-08-01 2012-10-09 Dexcom, Inc. System and methods for processing analyte sensor data
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US8626257B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. Analyte sensor
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
DE10343863A1 (en) 2003-09-23 2005-04-14 Roche Diagnostics Gmbh Method and device for continuously monitoring the concentration of an analyte
JP3612324B1 (en) 2003-09-29 2005-01-19 株式会社日立製作所 Blood glucose level display method and apparatus
US7203549B2 (en) 2003-10-02 2007-04-10 Medtronic, Inc. Medical device programmer with internal antenna and display
PL1677668T3 (en) 2003-10-13 2010-12-31 Novo Nordisk As Apparatus and method for determining a physiological condition
US7148803B2 (en) 2003-10-24 2006-12-12 Symbol Technologies, Inc. Radio frequency identification (RFID) based sensor networks
US20050187749A1 (en) * 2003-10-24 2005-08-25 Judy Singley Method, system, and computer program for performing carbohydrate/insulin calculation based upon food weight
US20050090607A1 (en) 2003-10-28 2005-04-28 Dexcom, Inc. Silicone composition for biocompatible membrane
EP1683058A2 (en) 2003-10-29 2006-07-26 Novo Nordisk A/S Medical advisory system
EP1685258A4 (en) 2003-10-29 2007-08-29 Agency Science Tech & Res Biosensor
EP1761880B1 (en) 2003-10-29 2013-02-27 Innovision Research & Technology PLC Rfid apparatus
US6928380B2 (en) 2003-10-30 2005-08-09 International Business Machines Corporation Thermal measurements of electronic devices during operation
US20050096516A1 (en) 2003-10-30 2005-05-05 Orhan Soykan Optical detector of organic analyte
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US20090012376A1 (en) 2003-11-03 2009-01-08 Children's Medical Center Corporation Continuous Analyte Monitor and Method of Using Same
US7419573B2 (en) 2003-11-06 2008-09-02 3M Innovative Properties Company Circuit for electrochemical sensor strip
US20050113886A1 (en) 2003-11-24 2005-05-26 Fischell David R. Implantable medical system with long range telemetry
US20080197024A1 (en) 2003-12-05 2008-08-21 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8364230B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8425416B2 (en) 2006-10-04 2013-04-23 Dexcom, Inc. Analyte sensor
ATE480761T1 (en) 2003-12-05 2010-09-15 Dexcom Inc CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTICAL SENSOR
US8532730B2 (en) 2006-10-04 2013-09-10 Dexcom, Inc. Analyte sensor
US20080200788A1 (en) 2006-10-04 2008-08-21 Dexcorn, Inc. Analyte sensor
US8425417B2 (en) 2003-12-05 2013-04-23 Dexcom, Inc. Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device
ATE474219T1 (en) 2003-12-08 2010-07-15 Dexcom Inc SYSTEMS AND METHODS FOR IMPROVING ELECTROCHEMICAL ANALYT SENSORS
US7076300B1 (en) 2003-12-24 2006-07-11 Pacesetter, Inc. Implantable cardiac stimulation device and method that discriminates between and treats atrial tachycardia and atrial fibrillation
US7384397B2 (en) 2003-12-30 2008-06-10 Medtronic Minimed, Inc. System and method for sensor recalibration
US7637868B2 (en) 2004-01-12 2009-12-29 Dexcom, Inc. Composite material for implantable device
SI2611042T1 (en) 2004-01-27 2015-05-29 Altivera, Llc Immunoassay test strip integrating radio frequency identification tags (RFID)
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
WO2005079257A2 (en) 2004-02-12 2005-09-01 Dexcom, Inc. Biointerface with macro- and micro- architecture
CA2556331A1 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US20060154642A1 (en) 2004-02-20 2006-07-13 Scannell Robert F Jr Medication & health, environmental, and security monitoring, alert, intervention, information and network system with associated and supporting apparatuses
JP3590053B1 (en) 2004-02-24 2004-11-17 株式会社日立製作所 Blood glucose measurement device
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
CA2556592C (en) 2004-02-26 2014-01-28 Lars Gustaf Liljeryd Metabolic monitoring, a method and apparatus for indicating a health-related condition of a subject
DE102004011135A1 (en) 2004-03-08 2005-09-29 Disetronic Licensing Ag Method and apparatus for calculating a bolus amount
US7228182B2 (en) 2004-03-15 2007-06-05 Cardiac Pacemakers, Inc. Cryptographic authentication for telemetry with an implantable medical device
US7831828B2 (en) 2004-03-15 2010-11-09 Cardiac Pacemakers, Inc. System and method for securely authenticating a data exchange session with an implantable medical device
JP5051767B2 (en) 2004-03-22 2012-10-17 ボディーメディア インコーポレイテッド Device for monitoring human condition parameters
JP2007535974A (en) * 2004-03-26 2007-12-13 ノボ・ノルデイスク・エー/エス Display device for related data of diabetic patients
US6971274B2 (en) 2004-04-02 2005-12-06 Sierra Instruments, Inc. Immersible thermal mass flow meter
WO2005106017A2 (en) 2004-04-21 2005-11-10 University Of Virginia Patent Foundation Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices
US20050245799A1 (en) 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US7241266B2 (en) 2004-05-20 2007-07-10 Digital Angel Corporation Transducer for embedded bio-sensor using body energy as a power source
US7118667B2 (en) 2004-06-02 2006-10-10 Jin Po Lee Biosensors having improved sample application and uses thereof
CA3090413C (en) 2004-06-04 2023-10-10 Abbott Diabetes Care Inc. Glucose monitoring and graphical representations in a data management system
US7283867B2 (en) 2004-06-10 2007-10-16 Ndi Medical, Llc Implantable system and methods for acquisition and processing of electrical signals from muscles and/or nerves and/or central nervous system tissue
US20070060979A1 (en) 2004-06-10 2007-03-15 Ndi Medical, Llc Implantable pulse generator systems and methods for providing functional and / or therapeutic stimulation of muscles and / or nerves and / or central nervous system tissue
US20070100222A1 (en) 2004-06-14 2007-05-03 Metronic Minimed, Inc. Analyte sensing apparatus for hospital use
US7565197B2 (en) 2004-06-18 2009-07-21 Medtronic, Inc. Conditional requirements for remote medical device programming
DE102004031092A1 (en) 2004-06-28 2006-01-12 Giesecke & Devrient Gmbh transponder unit
US7233822B2 (en) 2004-06-29 2007-06-19 Medtronic, Inc. Combination of electrogram and intra-cardiac pressure to discriminate between fibrillation and tachycardia
US20080242961A1 (en) 2004-07-13 2008-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
US7640048B2 (en) 2004-07-13 2009-12-29 Dexcom, Inc. Analyte sensor
US7344500B2 (en) 2004-07-27 2008-03-18 Medtronic Minimed, Inc. Sensing system with auxiliary display
US8313433B2 (en) 2004-08-06 2012-11-20 Medtronic Minimed, Inc. Medical data management system and process
WO2006026741A1 (en) 2004-08-31 2006-03-09 Lifescan Scotland Limited Wearable sensor device and system
WO2006029090A2 (en) 2004-09-02 2006-03-16 Proteus Biomedical, Inc. Methods and apparatus for tissue activation and monitoring
JP2008511373A (en) 2004-09-03 2008-04-17 ノボ・ノルデイスク・エー/エス Method for calibrating a system for measuring the concentration of a body substance and apparatus for carrying out the method
CN101027674A (en) 2004-09-23 2007-08-29 诺和诺德公司 Device for self-care support
EP1845845B1 (en) 2004-11-02 2010-09-01 Medtronic, Inc. Techniques for user-activated data retention in an implantable medical device
US7237712B2 (en) 2004-12-01 2007-07-03 Alfred E. Mann Foundation For Scientific Research Implantable device and communication integrated circuit implementable therein
ATE545361T1 (en) 2004-12-13 2012-03-15 Koninkl Philips Electronics Nv MOBILE MONITORING
JPWO2006070827A1 (en) 2004-12-28 2008-06-12 新世代株式会社 Health care support system and recording medium
US20090082693A1 (en) 2004-12-29 2009-03-26 Therasense, Inc. Method and apparatus for providing temperature sensor module in a data communication system
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US20070027381A1 (en) 2005-07-29 2007-02-01 Therasense, Inc. Inserter and methods of use
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US20060166629A1 (en) 2005-01-24 2006-07-27 Therasense, Inc. Method and apparatus for providing EMC Class-B compliant RF transmitter for data monitoring an detection systems
US7502644B2 (en) 2005-01-25 2009-03-10 Pacesetter, Inc. System and method for distinguishing among cardiac ischemia, hypoglycemia and hyperglycemia using an implantable medical device
US20060173260A1 (en) 2005-01-31 2006-08-03 Gmms Ltd System, device and method for diabetes treatment and monitoring
JP2008527485A (en) 2005-01-31 2008-07-24 ノキア コーポレイション Method and apparatus for prohibiting interruption of active application due to event
US7547281B2 (en) 2005-02-01 2009-06-16 Medtronic Minimed, Inc. Algorithm sensor augmented bolus estimator for semi-closed loop infusion system
US7499002B2 (en) 2005-02-08 2009-03-03 International Business Machines Corporation Retractable string interface for stationary and portable devices
US7545272B2 (en) 2005-02-08 2009-06-09 Therasense, Inc. RF tag on test strips, test strip vials and boxes
US7390663B2 (en) 2005-02-23 2008-06-24 Streck, Inc. Process, composition and kit for providing a stable whole blood calibrator/control
KR100638727B1 (en) 2005-02-28 2006-10-30 삼성전기주식회사 Concurrent transceiver for zigbee and bluetooth
US20090076360A1 (en) 2007-09-13 2009-03-19 Dexcom, Inc. Transcutaneous analyte sensor
US20060202805A1 (en) 2005-03-14 2006-09-14 Alfred E. Mann Foundation For Scientific Research Wireless acquisition and monitoring system
US20070071681A1 (en) 2005-03-15 2007-03-29 Entelos, Inc. Apparatus and method for computer modeling type 1 diabetes
EP1863559A4 (en) 2005-03-21 2008-07-30 Abbott Diabetes Care Inc Method and system for providing integrated medication infusion and analyte monitoring system
US7889069B2 (en) 2005-04-01 2011-02-15 Codman & Shurtleff, Inc. Wireless patient monitoring system
US7270633B1 (en) 2005-04-22 2007-09-18 Cardiac Pacemakers, Inc. Ambulatory repeater for use in automated patient care and method thereof
DE102005019306B4 (en) 2005-04-26 2011-09-01 Disetronic Licensing Ag Energy-optimized data transmission of a medical device
US7590443B2 (en) 2005-04-27 2009-09-15 Pacesetter, Inc System and method for detecting hypoglycemia based on a paced depolarization integral using an implantable medical device
US8700157B2 (en) 2005-04-29 2014-04-15 Medtronic, Inc. Telemetry head programmer for implantable medical device and system and method
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US20060247985A1 (en) 2005-04-29 2006-11-02 Therasense, Inc. Method and system for monitoring consumable item usage and providing replenishment thereof
US20060264783A1 (en) 2005-05-09 2006-11-23 Holmes Elizabeth A Systems and methods for monitoring pharmacological parameters
US7604178B2 (en) 2005-05-11 2009-10-20 Intelleflex Corporation Smart tag activation
CA2612714C (en) 2005-05-13 2013-09-24 Trustees Of Boston University Fully automated control system for type 1 diabetes
US7541935B2 (en) 2005-05-19 2009-06-02 Proacticare Llc System and methods for monitoring caregiver performance
JP2008542764A (en) 2005-06-02 2008-11-27 アイセンス コーポレーション Filtering and use of multiple data points in analyte sensors
US20070033074A1 (en) 2005-06-03 2007-02-08 Medtronic Minimed, Inc. Therapy management system
US20060276771A1 (en) 2005-06-06 2006-12-07 Galley Paul J System and method providing for user intervention in a diabetes control arrangement
US7670288B2 (en) 2005-06-08 2010-03-02 Sher Philip M Fluctuating blood glucose notification threshold profiles and methods of use
US8251904B2 (en) 2005-06-09 2012-08-28 Roche Diagnostics Operations, Inc. Device and method for insulin dosing
US20070016449A1 (en) 2005-06-29 2007-01-18 Gary Cohen Flexible glucose analysis using varying time report deltas and configurable glucose target ranges
KR101136889B1 (en) 2005-07-12 2012-04-20 메사추세츠 인스티튜트 오브 테크놀로지 Wireless non-radiative energy transfer
US20070066956A1 (en) 2005-07-27 2007-03-22 Medtronic Minimed, Inc. Systems and methods for entering temporary basal rate pattern in an infusion device
US7606784B2 (en) 2005-08-02 2009-10-20 Northrop Grumman Corporation Uncertainty management in a decision-making system
US20070060869A1 (en) 2005-08-16 2007-03-15 Tolle Mike C V Controller device for an infusion pump
US20090227855A1 (en) 2005-08-16 2009-09-10 Medtronic Minimed, Inc. Controller device for an infusion pump
US7737581B2 (en) * 2005-08-16 2010-06-15 Medtronic Minimed, Inc. Method and apparatus for predicting end of battery life
US20070093786A1 (en) 2005-08-16 2007-04-26 Medtronic Minimed, Inc. Watch controller for a medical device
EP1758039A1 (en) 2005-08-27 2007-02-28 Roche Diagnostics GmbH Communication adaptor for portable medical or therapeutical devices
US9089713B2 (en) 2005-08-31 2015-07-28 Michael Sasha John Methods and systems for semi-automatic adjustment of medical monitoring and treatment
CA2620586A1 (en) 2005-08-31 2007-03-08 Boris P. Kovatchev Improving the accuracy of continuous glucose sensors
US8831735B2 (en) 2005-08-31 2014-09-09 Michael Sasha John Methods and systems for semi-automatic adjustment of medical monitoring and treatment
US8206428B2 (en) 2005-09-02 2012-06-26 Medtronic Vascular, Inc. Tabbed stent with minimum compressed profile
ES2575660T3 (en) 2005-09-09 2016-06-30 F. Hoffmann-La Roche Ag System, tools, devices and program for diabetic care
US8298389B2 (en) 2005-09-12 2012-10-30 Abbott Diabetes Care Inc. In vitro analyte sensor, and methods
US7725148B2 (en) 2005-09-23 2010-05-25 Medtronic Minimed, Inc. Sensor with layered electrodes
US9072476B2 (en) 2005-09-23 2015-07-07 Medtronic Minimed, Inc. Flexible sensor apparatus
US7846311B2 (en) 2005-09-27 2010-12-07 Abbott Diabetes Care Inc. In vitro analyte sensor and methods of use
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
EP1937135A1 (en) 2005-10-20 2008-07-02 Big Glucose Ltd. Non-invasive glucose monitoring
US20090054747A1 (en) 2005-10-31 2009-02-26 Abbott Diabetes Care, Inc. Method and system for providing analyte sensor tester isolation
US20070095661A1 (en) 2005-10-31 2007-05-03 Yi Wang Method of making, and, analyte sensor
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
EP3064236B1 (en) 2005-11-08 2020-02-05 Bigfoot Biomedical, Inc. Method and system for manual and autonomous control of an infusion pump
US20070173706A1 (en) 2005-11-11 2007-07-26 Isense Corporation Method and apparatus for insertion of a sensor
US7918975B2 (en) 2005-11-17 2011-04-05 Abbott Diabetes Care Inc. Analytical sensors for biological fluid
WO2007062173A1 (en) 2005-11-22 2007-05-31 Vocollect Healthcare Systems, Inc. Advanced diabetes management system (adms)
US7941200B2 (en) 2005-12-08 2011-05-10 Roche Diagnostics Operations, Inc. System and method for determining drug administration information
US8515518B2 (en) 2005-12-28 2013-08-20 Abbott Diabetes Care Inc. Analyte monitoring
CA2636034A1 (en) 2005-12-28 2007-10-25 Abbott Diabetes Care Inc. Medical device insertion
US8102789B2 (en) 2005-12-29 2012-01-24 Medtronic, Inc. System and method for synchronous wireless communication with a medical device
EP2004796B1 (en) 2006-01-18 2015-04-08 DexCom, Inc. Membranes for an analyte sensor
US20070179349A1 (en) 2006-01-19 2007-08-02 Hoyme Kenneth P System and method for providing goal-oriented patient management based upon comparative population data analysis
US7574266B2 (en) 2006-01-19 2009-08-11 Medtronic, Inc. System and method for telemetry with an implantable medical device
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
US7872574B2 (en) 2006-02-01 2011-01-18 Innovation Specialists, Llc Sensory enhancement systems and methods in personal electronic devices
EP3165247B1 (en) 2006-02-09 2020-10-28 DEKA Products Limited Partnership Pumping fluid delivery systems and methods using force application assembley
US20070287931A1 (en) 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
WO2007093981A2 (en) 2006-02-15 2007-08-23 Medingo Ltd. Systems and methods for sensing analyte and dispensing therapeutic fluid
EP3649925A1 (en) 2006-02-22 2020-05-13 DexCom, Inc. Analyte sensor
US7981034B2 (en) 2006-02-28 2011-07-19 Abbott Diabetes Care Inc. Smart messages and alerts for an infusion delivery and management system
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
ES2336360T3 (en) 2006-04-20 2010-04-12 Lifescan Scotland Ltd METHOD FOR TRANSMITTING DATA IN A GLUCOSE SYSTEM IN BLOOD AND GLUCOSE SYSTEM IN BLOOD CORRESPONDING.
US7359837B2 (en) 2006-04-27 2008-04-15 Medtronic, Inc. Peak data retention of signal data in an implantable medical device
US20070258395A1 (en) 2006-04-28 2007-11-08 Medtronic Minimed, Inc. Wireless data communication protocols for a medical device network
US8380300B2 (en) 2006-04-28 2013-02-19 Medtronic, Inc. Efficacy visualization
US20070253021A1 (en) 2006-04-28 2007-11-01 Medtronic Minimed, Inc. Identification of devices in a medical device network and wireless data communication techniques utilizing device identifiers
GB0608829D0 (en) 2006-05-04 2006-06-14 Husheer Shamus L G In-situ measurement of physical parameters
US7496852B2 (en) 2006-05-16 2009-02-24 International Business Machines Corporation Graphically manipulating a database
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US7796038B2 (en) 2006-06-12 2010-09-14 Intelleflex Corporation RFID sensor tag with manual modes and functions
US20080177149A1 (en) 2006-06-16 2008-07-24 Stefan Weinert System and method for collecting patient information from which diabetes therapy may be determined
US20070299617A1 (en) 2006-06-27 2007-12-27 Willis John P Biofouling self-compensating biosensor
US20090105560A1 (en) 2006-06-28 2009-04-23 David Solomon Lifestyle and eating advisor based on physiological and biological rhythm monitoring
US20090105571A1 (en) 2006-06-30 2009-04-23 Abbott Diabetes Care, Inc. Method and System for Providing Data Communication in Data Management Systems
US7866026B1 (en) 2006-08-01 2011-01-11 Abbott Diabetes Care Inc. Method for making calibration-adjusted sensors
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
US20080058678A1 (en) 2006-09-05 2008-03-06 Shinichi Miyata Kit for the determination of an analyte in a bodily fluid sample that includes a meter with a display-based tutorial module
US20080057484A1 (en) 2006-09-05 2008-03-06 Shinichi Miyata Event-driven method for tutoring a user in the determination of an analyte in a bodily fluid sample
US9056165B2 (en) 2006-09-06 2015-06-16 Medtronic Minimed, Inc. Intelligent therapy recommendation algorithm and method of using the same
US20080071328A1 (en) 2006-09-06 2008-03-20 Medtronic, Inc. Initiating medical system communications
US7779332B2 (en) 2006-09-25 2010-08-17 Alfred E. Mann Foundation For Scientific Research Rotationally invariant non-coherent burst coding
US8449464B2 (en) 2006-10-04 2013-05-28 Dexcom, Inc. Analyte sensor
US8447376B2 (en) 2006-10-04 2013-05-21 Dexcom, Inc. Analyte sensor
US8478377B2 (en) 2006-10-04 2013-07-02 Dexcom, Inc. Analyte sensor
US7831287B2 (en) 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8275438B2 (en) 2006-10-04 2012-09-25 Dexcom, Inc. Analyte sensor
US8298142B2 (en) 2006-10-04 2012-10-30 Dexcom, Inc. Analyte sensor
US8562528B2 (en) 2006-10-04 2013-10-22 Dexcom, Inc. Analyte sensor
US20080171967A1 (en) * 2006-10-17 2008-07-17 Blomquist Michael L Insulin pump having a food database
US20080092638A1 (en) 2006-10-19 2008-04-24 Bayer Healthcare Llc Wireless analyte monitoring system
AU2007308804A1 (en) 2006-10-26 2008-05-02 Abbott Diabetes Care, Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US20080119710A1 (en) 2006-10-31 2008-05-22 Abbott Diabetes Care, Inc. Medical devices and methods of using the same
EP1918837A1 (en) 2006-10-31 2008-05-07 F. Hoffmann-La Roche AG Method for processing a chronological sequence of measurements of a time dependent parameter
US8439837B2 (en) 2006-10-31 2013-05-14 Lifescan, Inc. Systems and methods for detecting hypoglycemic events having a reduced incidence of false alarms
US20080119705A1 (en) 2006-11-17 2008-05-22 Medtronic Minimed, Inc. Systems and Methods for Diabetes Management Using Consumer Electronic Devices
US20080139910A1 (en) 2006-12-06 2008-06-12 Metronic Minimed, Inc. Analyte sensor and method of using the same
WO2008071218A1 (en) 2006-12-14 2008-06-19 Egomedical Swiss Ag Monitoring device
US20080154513A1 (en) 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
US7946985B2 (en) 2006-12-29 2011-05-24 Medtronic Minimed, Inc. Method and system for providing sensor redundancy
US20080161666A1 (en) 2006-12-29 2008-07-03 Abbott Diabetes Care, Inc. Analyte devices and methods
US7999674B2 (en) 2007-01-15 2011-08-16 Deka Products Limited Partnership Device and method for food management
US7742747B2 (en) 2007-01-25 2010-06-22 Icera Canada ULC Automatic IIP2 calibration architecture
US10154804B2 (en) 2007-01-31 2018-12-18 Medtronic Minimed, Inc. Model predictive method and system for controlling and supervising insulin infusion
US9597019B2 (en) 2007-02-09 2017-03-21 Lifescan, Inc. Method of ensuring date and time on a test meter is accurate
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US20090093687A1 (en) 2007-03-08 2009-04-09 Telfort Valery G Systems and methods for determining a physiological condition using an acoustic monitor
US20080234663A1 (en) 2007-03-19 2008-09-25 Ofer Yodfat Method for Selecting Bolus Doses in a Drug Delivery System
US20080235053A1 (en) 2007-03-20 2008-09-25 Pinaki Ray Communication medium for diabetes management
US7659823B1 (en) 2007-03-20 2010-02-09 At&T Intellectual Property Ii, L.P. Tracking variable conditions using radio frequency identification
US9029157B2 (en) 2007-04-12 2015-05-12 Nipro Diagnostics, Inc. Error detection and rejection for a diagnostic testing system
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2008130896A1 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
US7768387B2 (en) 2007-04-14 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
WO2009096992A1 (en) 2007-04-14 2009-08-06 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683930A1 (en) 2007-04-14 2008-10-23 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683959C (en) 2007-04-14 2017-08-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US20080269714A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
US20080269723A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
CN101715555A (en) 2007-04-27 2010-05-26 艾伯特糖尿病护理公司 Test strip identification using conductive patterns
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
EP2156684A4 (en) 2007-05-14 2012-10-24 Abbott Diabetes Care Inc Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20080312845A1 (en) 2007-05-14 2008-12-18 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20080300572A1 (en) * 2007-06-01 2008-12-04 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
WO2008154312A1 (en) 2007-06-08 2008-12-18 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20080312518A1 (en) 2007-06-14 2008-12-18 Arkal Medical, Inc On-demand analyte monitor and method of use
EP2166929B1 (en) 2007-06-15 2012-12-19 F. Hoffmann-La Roche AG Visualization of a parameter which is measured on the human body
US9754078B2 (en) 2007-06-21 2017-09-05 Immersion Corporation Haptic health feedback monitoring
CA2690870C (en) 2007-06-21 2017-07-11 Abbott Diabetes Care Inc. Health monitor
EP3533387A3 (en) 2007-06-21 2019-11-13 Abbott Diabetes Care, Inc. Health management devices and methods
EP2562664B1 (en) 2007-06-27 2020-11-25 Roche Diabetes Care GmbH System for determining an insulin delivery and communicating a dose in automated pancreas software
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
EP2170159B8 (en) 2007-06-29 2016-09-21 Roche Diabetes Care GmbH Combination communication device and medical device for communicating wirelessly with a remote medical device
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US20090036760A1 (en) 2007-07-31 2009-02-05 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US7731658B2 (en) 2007-08-16 2010-06-08 Cardiac Pacemakers, Inc. Glycemic control monitoring using implantable medical device
US9968742B2 (en) 2007-08-29 2018-05-15 Medtronic Minimed, Inc. Combined sensor and infusion set using separated sites
US20090063402A1 (en) 2007-08-31 2009-03-05 Abbott Diabetes Care, Inc. Method and System for Providing Medication Level Determination
US20090085768A1 (en) 2007-10-02 2009-04-02 Medtronic Minimed, Inc. Glucose sensor transceiver
DE102007047351A1 (en) 2007-10-02 2009-04-09 B. Braun Melsungen Ag System and method for monitoring and controlling blood glucose levels
CA2702116C (en) 2007-10-10 2021-01-05 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US7783442B2 (en) 2007-10-31 2010-08-24 Medtronic Minimed, Inc. System and methods for calibrating physiological characteristic sensors
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
US20090164239A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Dynamic Display Of Glucose Information
US20090164190A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Physiological condition simulation device and method
US20090177147A1 (en) * 2008-01-07 2009-07-09 Michael Blomquist Insulin pump with insulin therapy coaching
DE102008008072A1 (en) 2008-01-29 2009-07-30 Balluff Gmbh sensor
US20090299155A1 (en) 2008-01-30 2009-12-03 Dexcom, Inc. Continuous cardiac marker sensor system
JP5091881B2 (en) 2008-02-20 2012-12-05 カルソニックカンセイ株式会社 Collision detection device
CA2715624A1 (en) 2008-02-20 2009-08-27 Dexcom, Inc. Continuous medicament sensor system for in vivo use
EP2252196A4 (en) 2008-02-21 2013-05-15 Dexcom Inc Systems and methods for processing, transmitting and displaying sensor data
US20090221890A1 (en) 2008-02-28 2009-09-03 Daniel Saffer Diabetes Management System
US20090242399A1 (en) 2008-03-25 2009-10-01 Dexcom, Inc. Analyte sensor
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US20090247855A1 (en) 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
NO2260423T3 (en) 2008-04-04 2018-07-28
WO2009125421A1 (en) 2008-04-11 2009-10-15 Indian Institute Of Science A sub-threshold capfet sensor for sensing analyte, a method and system thereof
US20090267765A1 (en) 2008-04-29 2009-10-29 Jack Greene Rfid to prevent reprocessing
US7938797B2 (en) 2008-05-05 2011-05-10 Asante Solutions, Inc. Infusion pump system
CA2724446C (en) 2008-05-14 2017-04-04 Espenusa Holding, Llc Physical activity monitor and data collection unit
WO2009143289A2 (en) 2008-05-20 2009-11-26 Deka Products Limited Partnership Rfid system
US7826382B2 (en) 2008-05-30 2010-11-02 Abbott Diabetes Care Inc. Close proximity communication device and methods
US8394637B2 (en) 2008-06-02 2013-03-12 Roche Diagnostics Operations, Inc. Handheld analyzer for testing a sample
US8432070B2 (en) 2008-08-25 2013-04-30 Qualcomm Incorporated Passive receivers for wireless power transmission
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
WO2010030609A1 (en) 2008-09-09 2010-03-18 Vivomedical, Inc. Sweat collection devices for glucose measurement
CA3132517A1 (en) 2008-09-15 2010-03-18 Deka Products Limited Partnership Systems and methods for fluid delivery
US20100095229A1 (en) 2008-09-18 2010-04-15 Abbott Diabetes Care, Inc. Graphical user interface for glucose monitoring system
EP2326944B1 (en) 2008-09-19 2020-08-19 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
CN102197304B (en) 2008-11-04 2013-08-28 松下电器产业株式会社 Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program
US9320470B2 (en) 2008-12-31 2016-04-26 Medtronic Minimed, Inc. Method and/or system for sensor artifact filtering
US8974439B2 (en) 2009-01-02 2015-03-10 Asante Solutions, Inc. Infusion pump system and methods
US8394246B2 (en) 2009-02-23 2013-03-12 Roche Diagnostics Operations, Inc. System and method for the electrochemical measurement of an analyte employing a remote sensor
US9446194B2 (en) * 2009-03-27 2016-09-20 Dexcom, Inc. Methods and systems for promoting glucose management
EP2413781B1 (en) 2009-03-31 2019-07-24 Abbott Diabetes Care Inc. Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model
WO2010121229A1 (en) 2009-04-16 2010-10-21 Abbott Diabetes Care Inc. Analyte sensor calibration management
EP2438527B1 (en) 2009-06-04 2018-05-02 Abbott Diabetes Care, Inc. Method and system for updating a medical device
EP3970610A3 (en) 2009-07-02 2022-05-18 Dexcom, Inc. Analyte sensors and methods of manufacturing same
US9792408B2 (en) 2009-07-02 2017-10-17 Covidien Lp Method and apparatus to detect transponder tagged objects and to communicate with medical telemetry devices, for example during medical procedures
US20120165626A1 (en) 2009-07-13 2012-06-28 Irina Finkelshtein V Devices, methods, and kits for determining analyte concentrations
WO2011014851A1 (en) 2009-07-31 2011-02-03 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
WO2011022418A2 (en) 2009-08-17 2011-02-24 The Regents Of The University Of California Distributed external and internal wireless sensor systems for characterization of surface and subsurface biomedical structure and condition
US9357951B2 (en) 2009-09-30 2016-06-07 Dexcom, Inc. Transcutaneous analyte sensor
US9949672B2 (en) 2009-12-17 2018-04-24 Ascensia Diabetes Care Holdings Ag Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels
US8579879B2 (en) 2010-02-19 2013-11-12 Medtronic Minimed, Inc. Closed-loop glucose control startup
US20110208027A1 (en) 2010-02-23 2011-08-25 Roche Diagnostics Operations, Inc. Methods And Systems For Providing Therapeutic Guidelines To A Person Having Diabetes
US9198623B2 (en) 2010-04-22 2015-12-01 Abbott Diabetes Care Inc. Devices, systems, and methods related to analyte monitoring and management
US9336353B2 (en) 2010-06-25 2016-05-10 Dexcom, Inc. Systems and methods for communicating sensor data between communication devices of a glucose monitoring system
EP2621339B1 (en) 2010-09-29 2020-01-15 Dexcom, Inc. Advanced continuous analyte monitoring system
US9241631B2 (en) 2010-10-27 2016-01-26 Dexcom, Inc. Continuous analyte monitor data recording device operable in a blinded mode
US20120165640A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Operations, Inc. Structured blood glucose testing performed on handheld diabetes management devices
WO2013022775A1 (en) 2011-08-05 2013-02-14 Dexcom, Inc. Systems and methods for detecting glucose level data patterns
US20130235166A1 (en) 2012-03-07 2013-09-12 Cambridge Silicon Radio Limited Synchronisation method

Patent Citations (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4245634A (en) * 1975-01-22 1981-01-20 Hospital For Sick Children Artificial beta cell
US4373527B1 (en) * 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
US4373527A (en) * 1979-04-27 1983-02-15 The Johns Hopkins University Implantable, programmable medication infusion system
US4425920A (en) * 1980-10-24 1984-01-17 Purdue Research Foundation Apparatus and method for measurement and control of blood pressure
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4494950A (en) * 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
US4847785A (en) * 1985-01-22 1989-07-11 International Business Machines Corp. Interactive display for trend or bar graph
US5279294A (en) * 1985-04-08 1994-01-18 Cascade Medical, Inc. Medical diagnostic system
US4890620A (en) * 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
US4995402A (en) * 1988-10-12 1991-02-26 Thorne, Smith, Astill Technologies, Inc. Medical droplet whole blood and like monitoring
US5379238A (en) * 1989-03-03 1995-01-03 Stark; Edward W. Signal processing method and apparatus
US4986271A (en) * 1989-07-19 1991-01-22 The University Of New Mexico Vivo refillable glucose sensor
US5082550A (en) * 1989-12-11 1992-01-21 The United States Of America As Represented By The Department Of Energy Enzyme electrochemical sensor electrode and method of making it
US6514718B2 (en) * 1991-03-04 2003-02-04 Therasense, Inc. Subcutaneous glucose electrode
US5285792A (en) * 1992-01-10 1994-02-15 Physio-Control Corporation System for producing prioritized alarm messages in a medical instrument
US5711001A (en) * 1992-05-08 1998-01-20 Motorola, Inc. Method and circuit for acquisition by a radio receiver
US5284425A (en) * 1992-11-18 1994-02-08 The Lee Company Fluid metering pump
US5384547A (en) * 1993-08-02 1995-01-24 Motorola, Inc. Apparatus and method for attenuating a multicarrier input signal of a linear device
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US5390671A (en) * 1994-03-15 1995-02-21 Minimed Inc. Transcutaneous sensor insertion set
US5391250A (en) * 1994-03-15 1995-02-21 Minimed Inc. Method of fabricating thin film sensors
US5711861A (en) * 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
US20040039298A1 (en) * 1996-09-04 2004-02-26 Abreu Marcio Marc Noninvasive measurement of chemical substances
US20080017522A1 (en) * 1997-02-06 2008-01-24 Therasense, Inc. Integrated Lancing and Measurement Device
US20040011671A1 (en) * 1997-03-04 2004-01-22 Dexcom, Inc. Device and method for determining analyte levels
US6028413A (en) * 1997-09-19 2000-02-22 Perdix Oy Charging device for batteries in a mobile electrical device
US6024699A (en) * 1998-03-13 2000-02-15 Healthware Corporation Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6175752B1 (en) * 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6990366B2 (en) * 1998-04-30 2006-01-24 Therasense, Inc. Analyte monitoring device and methods of use
US20080021436A1 (en) * 1998-04-30 2008-01-24 Abbott Diabetes Care, Inc. Analyte Monitoring Device and Methods of Use
US20020019022A1 (en) * 1998-09-30 2002-02-14 Cygnus, Inc. Method and device for predicting physiological values
US20060017923A1 (en) * 1999-01-22 2006-01-26 Ruchti Timothy L Analyte filter method and apparatus
US6689056B1 (en) * 1999-04-07 2004-02-10 Medtronic Endonetics, Inc. Implantable monitoring probe
US7317938B2 (en) * 1999-10-08 2008-01-08 Sensys Medical, Inc. Method of adapting in-vitro models to aid in noninvasive glucose determination
US20050010269A1 (en) * 2000-01-21 2005-01-13 Medical Research Group, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
US6687546B2 (en) * 2000-01-21 2004-02-03 Medtronic Minimed, Inc. Ambulatory medical apparatus and method using a robust communication protocol
US20040193090A1 (en) * 2000-01-21 2004-09-30 Medtronic Minimed, Inc. Ambulatory medical apparatus with handheld communication device
US6694191B2 (en) * 2000-01-21 2004-02-17 Medtronic Minimed, Inc. Ambulatory medical apparatus and method having telemetry modifiable control software
US7171274B2 (en) * 2000-01-21 2007-01-30 Medtronic Minimed, Inc. Method and apparatus for communicating between an ambulatory medical device and a control device via telemetry using randomized data
US20050004439A1 (en) * 2000-02-23 2005-01-06 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US20090005666A1 (en) * 2000-02-23 2009-01-01 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US20050027177A1 (en) * 2000-02-23 2005-02-03 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US20040034289A1 (en) * 2000-06-16 2004-02-19 Eric Teller System for monitoring health, wellness and fitness
US20020019612A1 (en) * 2000-08-14 2002-02-14 Takashi Watanabe Infusion pump
US6675030B2 (en) * 2000-08-21 2004-01-06 Euro-Celtique, S.A. Near infrared blood glucose monitoring system
US6695860B1 (en) * 2000-11-13 2004-02-24 Isense Corp. Transcutaneous sensor insertion device
US20050004494A1 (en) * 2001-01-22 2005-01-06 Perez Edward P. Lancet device having capillary action
US6983176B2 (en) * 2001-04-11 2006-01-03 Rio Grande Medical Technologies, Inc. Optically similar reference samples and related methods for multivariate calibration models used in optical spectroscopy
US6676816B2 (en) * 2001-05-11 2004-01-13 Therasense, Inc. Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes
US20030004403A1 (en) * 2001-06-29 2003-01-02 Darrel Drinan Gateway platform for biological monitoring and delivery of therapeutic compounds
US20030032874A1 (en) * 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US20030023317A1 (en) * 2001-07-27 2003-01-30 Dexcom, Inc. Membrane for use with implantable devices
US20030028089A1 (en) * 2001-07-31 2003-02-06 Galley Paul J. Diabetes management system
US20050001024A1 (en) * 2001-12-03 2005-01-06 Yosuke Kusaka Electronic apparatus, electronic camera, electronic device, image display apparatus, and image transmission system
US20040024553A1 (en) * 2002-03-08 2004-02-05 Monfre Stephen L. Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers
US20040010186A1 (en) * 2002-07-11 2004-01-15 Optical Sensors, Inc. Calibration technique for non-invasive medical devices
US20040010207A1 (en) * 2002-07-15 2004-01-15 Flaherty J. Christopher Self-contained, automatic transcutaneous physiologic sensing system
US20040015131A1 (en) * 2002-07-16 2004-01-22 Flaherty J. Christopher Flow restriction system and method for patient infusion device
US20050031689A1 (en) * 2003-05-21 2005-02-10 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US20050027180A1 (en) * 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20090012379A1 (en) * 2003-08-01 2009-01-08 Dexcom, Inc. System and methods for processing analyte sensor data
US20050027463A1 (en) * 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20080021666A1 (en) * 2003-08-01 2008-01-24 Dexcom, Inc. System and methods for processing analyte sensor data
US20050027181A1 (en) * 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20050027462A1 (en) * 2003-08-01 2005-02-03 Goode Paul V. System and methods for processing analyte sensor data
US20070016381A1 (en) * 2003-08-22 2007-01-18 Apurv Kamath Systems and methods for processing analyte sensor data
US20070032706A1 (en) * 2003-08-22 2007-02-08 Apurv Kamath Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20070007133A1 (en) * 2003-09-30 2007-01-11 Andre Mang Sensor with increased biocompatibility
US20100016698A1 (en) * 2003-11-19 2010-01-21 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US20100016687A1 (en) * 2003-12-09 2010-01-21 Dexcom, Inc. Signal processing for continuous analyte sensor
US20100010324A1 (en) * 2003-12-09 2010-01-14 Dexcom, Inc. Signal processing for continuous analyte sensor
US20100010332A1 (en) * 2003-12-09 2010-01-14 Dexcom, Inc. Signal processing for continuous analyte sensor
US20100010331A1 (en) * 2003-12-09 2010-01-14 Dexcom, Inc. Signal processing for continuous analyte sensor
US20100022855A1 (en) * 2003-12-09 2010-01-28 Dexcom, Inc. Signal processing for continuous analyte sensor
US7474992B2 (en) * 2004-01-28 2009-01-06 Honeywell International Inc. Trending system
US20090030294A1 (en) * 2004-05-03 2009-01-29 Dexcom, Inc. Implantable analyte sensor
US7651845B2 (en) * 2004-05-13 2010-01-26 The Regents Of The University Of California Method and apparatus for glucose control and insulin dosing for diabetics
US20060020300A1 (en) * 2004-06-09 2006-01-26 David Nghiem Implantable medical device package antenna
US20060004270A1 (en) * 2004-06-23 2006-01-05 Michel Bedard Method and apparatus for the monitoring of clinical states
US20060001551A1 (en) * 2004-06-30 2006-01-05 Ulrich Kraft Analyte monitoring system with wireless alarm
US20060001538A1 (en) * 2004-06-30 2006-01-05 Ulrich Kraft Methods of monitoring the concentration of an analyte
US20060015020A1 (en) * 2004-07-06 2006-01-19 Dexcom, Inc. Systems and methods for manufacture of an analyte-measuring device including a membrane system
US20060020186A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060020190A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060020191A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060020192A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060016700A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060019327A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060020188A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060020187A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20060015024A1 (en) * 2004-07-13 2006-01-19 Mark Brister Transcutaneous medical device with variable stiffness
US20060020189A1 (en) * 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US20070010950A1 (en) * 2004-12-03 2007-01-11 Abensour Daniel S Method to determine the degree and stability of blood glucose control in patients with diabetes mellitus via the creation and continuous update of new statistical indicators in blood glucose monitors or free standing computers
US7651596B2 (en) * 2005-04-08 2010-01-26 Dexcom, Inc. Cellulosic-based interference domain for an analyte sensor
US20060272652A1 (en) * 2005-06-03 2006-12-07 Medtronic Minimed, Inc. Virtual patient software system for educating and treating individuals with diabetes
US20070017983A1 (en) * 2005-07-19 2007-01-25 3M Innovative Properties Company RFID reader supporting one-touch search functionality
US20080009692A1 (en) * 2005-09-30 2008-01-10 Abbott Diabetes Care, Inc. Method and Apparatus for Providing Analyte Sensor and Data Processing Device
US20090018425A1 (en) * 2005-12-28 2009-01-15 Tianmei Ouyang Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent
US7653425B2 (en) * 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US20090018424A1 (en) * 2006-10-04 2009-01-15 Dexcom, Inc. Analyte sensor
US20080234943A1 (en) * 2007-03-20 2008-09-25 Pinaki Ray Computer program for diabetes management
US20090006034A1 (en) * 2007-05-14 2009-01-01 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US20090005665A1 (en) * 2007-05-14 2009-01-01 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US20090006133A1 (en) * 2007-06-27 2009-01-01 Roche Diagnostics Operations, Inc. Patient information input interface for a therapy system
US20100010329A1 (en) * 2008-07-14 2010-01-14 Abbott Diabetes Care Inc. Closed Loop Control System Interface and Methods

Cited By (468)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039881B2 (en) 2002-12-31 2018-08-07 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8647269B2 (en) 2003-06-10 2014-02-11 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US9730584B2 (en) 2003-06-10 2017-08-15 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8512239B2 (en) 2003-06-10 2013-08-20 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8219174B2 (en) 2003-10-31 2012-07-10 Abbott Diabetes Care Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US8219175B2 (en) 2003-10-31 2012-07-10 Abbott Diabetes Care Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US8684930B2 (en) 2003-10-31 2014-04-01 Abbott Diabetes Care Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US8116840B2 (en) 2003-10-31 2012-02-14 Abbott Diabetes Care Inc. Method of calibrating of an analyte-measurement device, and associated methods, devices and systems
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11020031B1 (en) 2003-12-05 2021-06-01 Dexcom, Inc. Analyte sensor
US11627900B2 (en) 2003-12-05 2023-04-18 Dexcom, Inc. Analyte sensor
US8942779B2 (en) 2004-02-05 2015-01-27 Early Sense Ltd. Monitoring a condition of a subject
US8731646B2 (en) 2004-02-05 2014-05-20 Earlysense Ltd. Prediction and monitoring of clinical episodes
US8603010B2 (en) 2004-02-05 2013-12-10 Earlysense Ltd. Techniques for prediction and monitoring of clinical episodes
US8992434B2 (en) 2004-02-05 2015-03-31 Earlysense Ltd. Prediction and monitoring of clinical episodes
US8840564B2 (en) 2004-02-05 2014-09-23 Early Sense Ltd. Monitoring a condition of a subject
US8679034B2 (en) 2004-02-05 2014-03-25 Earlysense Ltd. Techniques for prediction and monitoring of clinical episodes
US8679030B2 (en) 2004-02-05 2014-03-25 Earlysense Ltd. Monitoring a condition of a subject
US9131902B2 (en) 2004-02-05 2015-09-15 Earlysense Ltd. Prediction and monitoring of clinical episodes
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US11182332B2 (en) 2004-06-04 2021-11-23 Abbott Diabetes Care Inc. Systems and methods for managing diabetes care data
US10963417B2 (en) 2004-06-04 2021-03-30 Abbott Diabetes Care Inc. Systems and methods for managing diabetes care data
US11507530B2 (en) 2004-06-04 2022-11-22 Abbott Diabetes Care Inc. Systems and methods for managing diabetes care data
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US10194850B2 (en) 2005-08-31 2019-02-05 Abbott Diabetes Care Inc. Accuracy of continuous glucose sensors
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US9026199B2 (en) 2005-11-01 2015-05-05 Earlysense Ltd. Monitoring a condition of a subject
US9364149B2 (en) 2006-02-28 2016-06-14 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US10945647B2 (en) 2006-02-28 2021-03-16 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US11179072B2 (en) 2006-02-28 2021-11-23 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US10159433B2 (en) 2006-02-28 2018-12-25 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US11179071B2 (en) 2006-02-28 2021-11-23 Abbott Diabetes Care Inc Analyte sensor transmitter unit configuration for a data monitoring and management system
US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US11872039B2 (en) 2006-02-28 2024-01-16 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US10117614B2 (en) 2006-02-28 2018-11-06 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US11064916B2 (en) 2006-02-28 2021-07-20 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US8506482B2 (en) 2006-02-28 2013-08-13 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US9039975B2 (en) 2006-03-31 2015-05-26 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US9743863B2 (en) 2006-03-31 2017-08-29 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8597575B2 (en) 2006-03-31 2013-12-03 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8933664B2 (en) 2006-03-31 2015-01-13 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US9625413B2 (en) 2006-03-31 2017-04-18 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US9380971B2 (en) 2006-03-31 2016-07-05 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8593109B2 (en) 2006-03-31 2013-11-26 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US10208158B2 (en) 2006-07-10 2019-02-19 Medipacs, Inc. Super elastic epoxy hydrogel
US20190175119A1 (en) * 2006-08-07 2019-06-13 Abbott Diabetes Care Inc. Method and system for providing integrated analyte monitoring and infusion system therapy management
US9833181B2 (en) 2006-08-09 2017-12-05 Abbot Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US11864894B2 (en) 2006-08-09 2024-01-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8376945B2 (en) 2006-08-09 2013-02-19 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US9408566B2 (en) 2006-08-09 2016-08-09 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US10278630B2 (en) 2006-08-09 2019-05-07 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US10342469B2 (en) 2006-10-02 2019-07-09 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9839383B2 (en) 2006-10-02 2017-12-12 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9629578B2 (en) 2006-10-02 2017-04-25 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9357959B2 (en) 2006-10-02 2016-06-07 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US8515517B2 (en) 2006-10-02 2013-08-20 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9113828B2 (en) 2006-10-25 2015-08-25 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US11282603B2 (en) 2006-10-25 2022-03-22 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8211016B2 (en) 2006-10-25 2012-07-03 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US10194868B2 (en) 2006-10-25 2019-02-05 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US9814428B2 (en) 2006-10-25 2017-11-14 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8216137B2 (en) 2006-10-25 2012-07-10 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8135548B2 (en) 2006-10-26 2012-03-13 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US9882660B2 (en) 2006-10-26 2018-01-30 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US8718958B2 (en) 2006-10-26 2014-05-06 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US11722229B2 (en) 2006-10-26 2023-08-08 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US10903914B2 (en) 2006-10-26 2021-01-26 Abbott Diabetes Care Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US8121857B2 (en) 2007-02-15 2012-02-21 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US8676601B2 (en) 2007-02-15 2014-03-18 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US10022499B2 (en) 2007-02-15 2018-07-17 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US10617823B2 (en) 2007-02-15 2020-04-14 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US8417545B2 (en) 2007-02-15 2013-04-09 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US9095290B2 (en) 2007-03-01 2015-08-04 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US9801545B2 (en) 2007-03-01 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US9615780B2 (en) 2007-04-14 2017-04-11 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US8937540B2 (en) 2007-04-14 2015-01-20 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US10111608B2 (en) 2007-04-14 2018-10-30 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9204827B2 (en) 2007-04-14 2015-12-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US8149103B2 (en) 2007-04-14 2012-04-03 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage amplification in a medical device
US8427298B2 (en) 2007-04-14 2013-04-23 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage amplification in a medical device
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US8698615B2 (en) 2007-04-14 2014-04-15 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US8140142B2 (en) 2007-04-14 2012-03-20 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US11039767B2 (en) 2007-04-14 2021-06-22 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9743866B2 (en) 2007-04-14 2017-08-29 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US9402584B2 (en) 2007-04-14 2016-08-02 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US10349877B2 (en) 2007-04-14 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US7948369B2 (en) 2007-04-14 2011-05-24 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US10194846B2 (en) 2007-04-14 2019-02-05 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US7768387B2 (en) 2007-04-14 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US20110046498A1 (en) * 2007-05-02 2011-02-24 Earlysense Ltd Monitoring, predicting and treating clinical episodes
US8734360B2 (en) 2007-05-02 2014-05-27 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US8585607B2 (en) 2007-05-02 2013-11-19 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US8821418B2 (en) 2007-05-02 2014-09-02 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US9574914B2 (en) 2007-05-08 2017-02-21 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US9035767B2 (en) 2007-05-08 2015-05-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8149117B2 (en) 2007-05-08 2012-04-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9949678B2 (en) 2007-05-08 2018-04-24 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US9177456B2 (en) 2007-05-08 2015-11-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8362904B2 (en) 2007-05-08 2013-01-29 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9314198B2 (en) 2007-05-08 2016-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9649057B2 (en) 2007-05-08 2017-05-16 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8593287B2 (en) 2007-05-08 2013-11-26 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US10952611B2 (en) 2007-05-08 2021-03-23 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US10653317B2 (en) 2007-05-08 2020-05-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9000929B2 (en) 2007-05-08 2015-04-07 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US11696684B2 (en) 2007-05-08 2023-07-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US10178954B2 (en) 2007-05-08 2019-01-15 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US10634662B2 (en) 2007-05-14 2020-04-28 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10653344B2 (en) 2007-05-14 2020-05-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10463310B2 (en) 2007-05-14 2019-11-05 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8484005B2 (en) 2007-05-14 2013-07-09 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US10031002B2 (en) 2007-05-14 2018-07-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11828748B2 (en) 2007-05-14 2023-11-28 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9737249B2 (en) 2007-05-14 2017-08-22 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10045720B2 (en) 2007-05-14 2018-08-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10991456B2 (en) 2007-05-14 2021-04-27 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9797880B2 (en) 2007-05-14 2017-10-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10976304B2 (en) 2007-05-14 2021-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9801571B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9804150B2 (en) 2007-05-14 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10143409B2 (en) 2007-05-14 2018-12-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11300561B2 (en) 2007-05-14 2022-04-12 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US9060719B2 (en) 2007-05-14 2015-06-23 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8571808B2 (en) 2007-05-14 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10119956B2 (en) 2007-05-14 2018-11-06 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11125592B2 (en) 2007-05-14 2021-09-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10820841B2 (en) 2007-05-14 2020-11-03 Abbot Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10261069B2 (en) 2007-05-14 2019-04-16 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8612163B2 (en) 2007-05-14 2013-12-17 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11119090B2 (en) 2007-05-14 2021-09-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9558325B2 (en) 2007-05-14 2017-01-31 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8682615B2 (en) 2007-05-14 2014-03-25 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11076785B2 (en) 2007-05-14 2021-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9483608B2 (en) 2007-05-14 2016-11-01 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US11848089B2 (en) 2007-05-24 2023-12-19 Tandem Diabetes Care, Inc. Expert system for insulin pump therapy
US11257580B2 (en) 2007-05-24 2022-02-22 Tandem Diabetes Care, Inc. Expert system for insulin pump therapy
US10943687B2 (en) 2007-05-24 2021-03-09 Tandem Diabetes Care, Inc. Expert system for insulin pump therapy
US11576594B2 (en) 2007-05-30 2023-02-14 Tandem Diabetes Care, Inc. Insulin pump based expert system
US8617069B2 (en) 2007-06-21 2013-12-31 Abbott Diabetes Care Inc. Health monitor
US11276492B2 (en) 2007-06-21 2022-03-15 Abbott Diabetes Care Inc. Health management devices and methods
US11264133B2 (en) 2007-06-21 2022-03-01 Abbott Diabetes Care Inc. Health management devices and methods
US8597188B2 (en) 2007-06-21 2013-12-03 Abbott Diabetes Care Inc. Health management devices and methods
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9398872B2 (en) 2007-07-31 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US9743865B2 (en) 2007-10-23 2017-08-29 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US9804148B2 (en) 2007-10-23 2017-10-31 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US9332934B2 (en) 2007-10-23 2016-05-10 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US10173007B2 (en) 2007-10-23 2019-01-08 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US11083843B2 (en) 2007-10-23 2021-08-10 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
US9439586B2 (en) 2007-10-23 2016-09-13 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US10685749B2 (en) 2007-12-19 2020-06-16 Abbott Diabetes Care Inc. Insulin delivery apparatuses capable of bluetooth data transmission
US11302433B2 (en) 2008-01-07 2022-04-12 Tandem Diabetes Care, Inc. Diabetes therapy coaching
US10773015B2 (en) * 2008-01-09 2020-09-15 Tandem Diabetes Care, Inc. Infusion pump incorporating information from personal information manager devices
US11850394B2 (en) 2008-01-09 2023-12-26 Tandem Diabetes Care, Inc. Infusion pump with add-on modules
US20140323961A1 (en) * 2008-01-09 2014-10-30 Tandem Diabetes Care, Inc. Infusion pump incorporating information from personal information manager devices
US9770211B2 (en) 2008-01-31 2017-09-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US9320468B2 (en) 2008-01-31 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US11779248B2 (en) 2008-03-28 2023-10-10 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8718739B2 (en) 2008-03-28 2014-05-06 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9730623B2 (en) 2008-03-28 2017-08-15 Abbott Diabetes Care Inc. Analyte sensor calibration management
US10463288B2 (en) 2008-03-28 2019-11-05 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9320462B2 (en) 2008-03-28 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9883809B2 (en) 2008-05-01 2018-02-06 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US20230050496A1 (en) * 2008-05-02 2023-02-16 Tandem Diabetes Care, Inc. Display for pump
US11488549B2 (en) * 2008-05-02 2022-11-01 Tandem Diabetes Care, Inc. Display for pump
US11580918B2 (en) 2008-05-02 2023-02-14 Tandem Diabetes Care, Inc. Display for pump
US8998830B2 (en) 2008-05-12 2015-04-07 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US8882684B2 (en) 2008-05-12 2014-11-11 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US7826382B2 (en) 2008-05-30 2010-11-02 Abbott Diabetes Care Inc. Close proximity communication device and methods
US11770210B2 (en) 2008-05-30 2023-09-26 Abbott Diabetes Care Inc. Close proximity communication device and methods
US9831985B2 (en) 2008-05-30 2017-11-28 Abbott Diabetes Care Inc. Close proximity communication device and methods
US9184875B2 (en) 2008-05-30 2015-11-10 Abbott Diabetes Care, Inc. Close proximity communication device and methods
US8737259B2 (en) 2008-05-30 2014-05-27 Abbott Diabetes Care Inc. Close proximity communication device and methods
US8509107B2 (en) 2008-05-30 2013-08-13 Abbott Diabetes Care Inc. Close proximity communication device and methods
US8795252B2 (en) 2008-08-31 2014-08-05 Abbott Diabetes Care Inc. Robust closed loop control and methods
US9610046B2 (en) 2008-08-31 2017-04-04 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US10188794B2 (en) 2008-08-31 2019-01-29 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US9572934B2 (en) 2008-08-31 2017-02-21 Abbott DiabetesCare Inc. Robust closed loop control and methods
US11679200B2 (en) 2008-08-31 2023-06-20 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US20100064257A1 (en) * 2008-09-05 2010-03-11 Roche Diagnostics Operations, Inc. Insulin pump configuration programming invalid settings notification and correction
US8231562B2 (en) * 2008-09-05 2012-07-31 Roche Diagnostics Operations, Inc. Insulin pump configuration programming invalid settings notification and correction
US8744547B2 (en) 2008-09-30 2014-06-03 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US11484234B2 (en) 2008-09-30 2022-11-01 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US9662056B2 (en) 2008-09-30 2017-05-30 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US11202592B2 (en) 2008-09-30 2021-12-21 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US10045739B2 (en) 2008-09-30 2018-08-14 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US11013439B2 (en) 2008-09-30 2021-05-25 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US11464434B2 (en) 2008-09-30 2022-10-11 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US20230310744A1 (en) * 2008-10-15 2023-10-05 Insulet Corporation Infusion pump system and methods
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US11678848B2 (en) 2008-11-10 2023-06-20 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US9730650B2 (en) 2008-11-10 2017-08-15 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US11272890B2 (en) 2008-11-10 2022-03-15 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US20100125183A1 (en) * 2008-11-17 2010-05-20 Honeywell International Inc. System and method for dynamically configuring functionality of remote health monitoring device
US10368745B2 (en) 2008-12-23 2019-08-06 Roche Diabetes Care Inc Systems and methods for optimizing insulin dosage
US10915505B2 (en) 2008-12-23 2021-02-09 Roche Diabetes Care, Inc. Management method and system implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US11350822B2 (en) 2008-12-23 2022-06-07 Roche Diabetes Care, Inc. Status reporting of a structured collection procedure
US11382507B2 (en) 2008-12-23 2022-07-12 Roche Diabetes Care, Inc. Structured tailoring
US9918635B2 (en) 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
US8849458B2 (en) 2008-12-23 2014-09-30 Roche Diagnostics Operations, Inc. Collection device with selective display of test results, method and computer program product thereof
US10216767B2 (en) 2008-12-23 2019-02-26 Roche Diabetes Care, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US9117015B2 (en) 2008-12-23 2015-08-25 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US10733154B2 (en) 2008-12-23 2020-08-04 Roche Diabetes Care Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US11327931B2 (en) 2008-12-23 2022-05-10 Roche Diabetes Care, Inc. Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
US10565170B2 (en) 2008-12-23 2020-02-18 Roche Diabetes Care, Inc. Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
US11907180B2 (en) 2008-12-23 2024-02-20 Roche Diabetes Care, Inc. Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
US10437962B2 (en) 2008-12-23 2019-10-08 Roche Diabetes Care Inc Status reporting of a structured collection procedure
US10456036B2 (en) 2008-12-23 2019-10-29 Roche Diabetes Care, Inc. Structured tailoring
US9659037B2 (en) 2008-12-23 2017-05-23 Roche Diabetes Care, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US8103456B2 (en) * 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8676513B2 (en) * 2009-01-29 2014-03-18 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US20140200427A1 (en) * 2009-01-29 2014-07-17 Abbott Diabetes Care Inc. Method and Device for Early Signal Attenuation Detection Using Blood Glucose Measurements
US9066709B2 (en) * 2009-01-29 2015-06-30 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8532935B2 (en) 2009-01-29 2013-09-10 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US11464430B2 (en) 2009-01-29 2022-10-11 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US10089446B2 (en) 2009-01-29 2018-10-02 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US20120123691A1 (en) * 2009-01-29 2012-05-17 Abbott Diabetes Care Inc. Method and Device for Early Signal Attenuation Detection Using Blood Glucose Measurements
US8473220B2 (en) * 2009-01-29 2013-06-25 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US11006870B2 (en) 2009-02-03 2021-05-18 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11006872B2 (en) 2009-02-03 2021-05-18 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11006871B2 (en) 2009-02-03 2021-05-18 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11213229B2 (en) 2009-02-03 2022-01-04 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11202591B2 (en) 2009-02-03 2021-12-21 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US11166656B2 (en) 2009-02-03 2021-11-09 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US20100198142A1 (en) * 2009-02-04 2010-08-05 Abbott Diabetes Care Inc. Multi-Function Analyte Test Device and Methods Therefor
US10009244B2 (en) 2009-04-15 2018-06-26 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8730058B2 (en) 2009-04-15 2014-05-20 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US9178752B2 (en) 2009-04-15 2015-11-03 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9693688B2 (en) 2009-04-29 2017-07-04 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8483967B2 (en) 2009-04-29 2013-07-09 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US9088452B2 (en) 2009-04-29 2015-07-21 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US10172518B2 (en) 2009-04-29 2019-01-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8368556B2 (en) 2009-04-29 2013-02-05 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US9310230B2 (en) 2009-04-29 2016-04-12 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US9949639B2 (en) 2009-04-29 2018-04-24 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US10617296B2 (en) 2009-04-29 2020-04-14 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US9451044B2 (en) 2009-05-02 2016-09-20 Citrix Systems, Inc. Methods and systems for providing a consistent profile to overlapping user sessions
US8725791B2 (en) * 2009-05-02 2014-05-13 Citrix Systems, Inc. Methods and systems for providing a consistent profile to overlapping user sessions
US20110004649A1 (en) * 2009-05-02 2011-01-06 Nord Joseph Methods and systems for providing a consistent profile to overlapping user sessions
US10225363B2 (en) 2009-05-02 2019-03-05 Citrix Systems, Inc. Methods and systems for providing a consistent profile to overlapping user sessions
US11793936B2 (en) 2009-05-29 2023-10-24 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
US11872370B2 (en) 2009-05-29 2024-01-16 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
US20110022981A1 (en) * 2009-07-23 2011-01-27 Deepa Mahajan Presentation of device utilization and outcome from a patient management system
EP3173014A1 (en) * 2009-07-23 2017-05-31 Abbott Diabetes Care, Inc. Real time management of data relating to physiological control of glucose levels
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US10872102B2 (en) 2009-07-23 2020-12-22 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US11234625B2 (en) 2009-07-31 2022-02-01 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring and therapy management system accuracy
US8718965B2 (en) 2009-07-31 2014-05-06 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US9936910B2 (en) 2009-07-31 2018-04-10 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring and therapy management system accuracy
US10660554B2 (en) 2009-07-31 2020-05-26 Abbott Diabetes Care Inc. Methods and devices for analyte monitoring calibration
US8993331B2 (en) 2009-08-31 2015-03-31 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
US10881355B2 (en) 2009-08-31 2021-01-05 Abbott Diabetes Care Inc. Displays for a medical device
US10456091B2 (en) 2009-08-31 2019-10-29 Abbott Diabetes Care Inc. Displays for a medical device
US10123752B2 (en) 2009-08-31 2018-11-13 Abbott Diabetes Care Inc. Displays for a medical device
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US9226714B2 (en) 2009-08-31 2016-01-05 Abbott Diabetes Care Inc. Displays for a medical device
US10492685B2 (en) 2009-08-31 2019-12-03 Abbott Diabetes Care Inc. Medical devices and methods
US10136816B2 (en) 2009-08-31 2018-11-27 Abbott Diabetes Care Inc. Medical devices and methods
US11045147B2 (en) 2009-08-31 2021-06-29 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US10918342B1 (en) 2009-08-31 2021-02-16 Abbott Diabetes Care Inc. Displays for a medical device
US11635332B2 (en) 2009-08-31 2023-04-25 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
US9814416B2 (en) 2009-08-31 2017-11-14 Abbott Diabetes Care Inc. Displays for a medical device
US8514086B2 (en) 2009-08-31 2013-08-20 Abbott Diabetes Care Inc. Displays for a medical device
US9186113B2 (en) 2009-08-31 2015-11-17 Abbott Diabetes Care Inc. Displays for a medical device
USD1010133S1 (en) 2009-08-31 2024-01-02 Abbott Diabetes Care Inc. Analyte sensor assembly
US11150145B2 (en) 2009-08-31 2021-10-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
US10429250B2 (en) 2009-08-31 2019-10-01 Abbott Diabetes Care, Inc. Analyte monitoring system and methods for managing power and noise
US9968302B2 (en) 2009-08-31 2018-05-15 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US8816862B2 (en) 2009-08-31 2014-08-26 Abbott Diabetes Care Inc. Displays for a medical device
US11730429B2 (en) 2009-08-31 2023-08-22 Abbott Diabetes Care Inc. Displays for a medical device
US10772572B2 (en) 2009-08-31 2020-09-15 Abbott Diabetes Care Inc. Displays for a medical device
US11241175B2 (en) 2009-08-31 2022-02-08 Abbott Diabetes Care Inc. Displays for a medical device
US11202586B2 (en) 2009-08-31 2021-12-21 Abbott Diabetes Care Inc. Displays for a medical device
US9549694B2 (en) 2009-08-31 2017-01-24 Abbott Diabetes Care Inc. Displays for a medical device
USRE47315E1 (en) 2009-08-31 2019-03-26 Abbott Diabetes Care Inc. Displays for a medical device
US20160206817A1 (en) * 2009-09-10 2016-07-21 Medipacs, Inc Low profile actuator and improved method of caregiver controlled administration of therapeutics
US9750439B2 (en) 2009-09-29 2017-09-05 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US10349874B2 (en) 2009-09-29 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9750444B2 (en) 2009-09-30 2017-09-05 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US10765351B2 (en) 2009-09-30 2020-09-08 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US11259725B2 (en) 2009-09-30 2022-03-01 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US8185181B2 (en) 2009-10-30 2012-05-22 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US10117606B2 (en) 2009-10-30 2018-11-06 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US9050041B2 (en) 2009-10-30 2015-06-09 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US11207005B2 (en) 2009-10-30 2021-12-28 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US11769589B2 (en) * 2010-02-12 2023-09-26 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US20220101995A1 (en) * 2010-02-12 2022-03-31 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US11061491B2 (en) 2010-03-10 2021-07-13 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US10078380B2 (en) 2010-03-10 2018-09-18 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US9326709B2 (en) 2010-03-10 2016-05-03 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
WO2011112974A1 (en) * 2010-03-11 2011-09-15 University Of Virginia Patent Foundation Method and system for the safety, analysis and supervision of insulin pump action and other modes of insulin delivery in diabetes
CN102892895A (en) * 2010-03-11 2013-01-23 弗吉尼亚大学专利基金会 Method and system for the safety, analysis and supervision of insulin pump action and other modes of insulin delivery in diabetes
US11069434B2 (en) * 2010-03-11 2021-07-20 University Of Virginia Patent Foundation Method and system for the safety, analysis and supervision of insulin pump action and other modes of insulin delivery in diabetes
US9198623B2 (en) 2010-04-22 2015-12-01 Abbott Diabetes Care Inc. Devices, systems, and methods related to analyte monitoring and management
WO2011133768A1 (en) * 2010-04-22 2011-10-27 Abbott Diabetes Care Inc. Devices, systems, and methods related to analyte monitoring and management
US9339219B2 (en) 2010-04-22 2016-05-17 Abbott Diabetes Care Inc. Devices, systems, and methods related to analyte monitoring and management
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US11478173B2 (en) 2010-06-29 2022-10-25 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US20120046962A1 (en) * 2010-08-20 2012-02-23 James Andrew Fant System and method for glucose monitoring and analysis
US11213226B2 (en) 2010-10-07 2022-01-04 Abbott Diabetes Care Inc. Analyte monitoring devices and methods
US8761940B2 (en) 2010-10-15 2014-06-24 Roche Diagnostics Operations, Inc. Time block manipulation for insulin infusion delivery
US11147476B2 (en) 2010-12-07 2021-10-19 Hill-Rom Services, Inc. Monitoring a sleeping subject
US10292625B2 (en) 2010-12-07 2019-05-21 Earlysense Ltd. Monitoring a sleeping subject
US10522247B2 (en) 2010-12-29 2019-12-31 Roche Diabetes Care, Inc. Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels
US9532737B2 (en) 2011-02-28 2017-01-03 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US11534089B2 (en) 2011-02-28 2022-12-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US10624568B2 (en) 2011-04-15 2020-04-21 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10835162B2 (en) 2011-04-15 2020-11-17 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10561354B2 (en) 2011-04-15 2020-02-18 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10610141B2 (en) 2011-04-15 2020-04-07 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10555695B2 (en) 2011-04-15 2020-02-11 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10682084B2 (en) 2011-04-15 2020-06-16 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10722162B2 (en) 2011-04-15 2020-07-28 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US8766803B2 (en) 2011-05-13 2014-07-01 Roche Diagnostics Operations, Inc. Dynamic data collection
US8755938B2 (en) 2011-05-13 2014-06-17 Roche Diagnostics Operations, Inc. Systems and methods for handling unacceptable values in structured collection protocols
CN103889317A (en) * 2011-06-23 2014-06-25 弗吉尼亚大学专利基金会 Unified platform for monitoring and control of blood glucose levels in diabetic patients
US11406331B2 (en) 2011-10-31 2022-08-09 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9069536B2 (en) 2011-10-31 2015-06-30 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
US9913619B2 (en) 2011-10-31 2018-03-13 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9465420B2 (en) 2011-10-31 2016-10-11 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US10939859B2 (en) 2011-11-23 2021-03-09 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9743872B2 (en) 2011-11-23 2017-08-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9289179B2 (en) 2011-11-23 2016-03-22 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US10136847B2 (en) 2011-11-23 2018-11-27 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US10082493B2 (en) 2011-11-25 2018-09-25 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US11391723B2 (en) 2011-11-25 2022-07-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
WO2013150523A1 (en) * 2012-04-01 2013-10-10 Earlysense Ltd. Monitoring, predicting and treating clinical episodes
US11676694B2 (en) 2012-06-07 2023-06-13 Tandem Diabetes Care, Inc. Device and method for training users of ambulatory medical devices
WO2014018797A1 (en) * 2012-07-26 2014-01-30 Rimidi Diabetes Improved glucose management through cloud-based modeling of circadian profiles
US8756043B2 (en) 2012-07-26 2014-06-17 Rimidi Diabetes, Inc. Blood glucose meter and computer-implemented method for improving glucose management through modeling of circadian profiles
WO2014018788A1 (en) * 2012-07-26 2014-01-30 Rimidi Diabetes Improved glucose management through modeling of circadian profiles
US8768673B2 (en) 2012-07-26 2014-07-01 Rimidi Diabetes, Inc. Computer-implemented system and method for improving glucose management through cloud-based modeling of circadian profiles
US8744828B2 (en) 2012-07-26 2014-06-03 Rimidi Diabetes, Inc. Computer-implemented system and method for improving glucose management through modeling of circadian profiles
US10942164B2 (en) 2012-08-30 2021-03-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10345291B2 (en) 2012-08-30 2019-07-09 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US10656139B2 (en) 2012-08-30 2020-05-19 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US20140068487A1 (en) * 2012-09-05 2014-03-06 Roche Diagnostics Operations, Inc. Computer Implemented Methods For Visualizing Correlations Between Blood Glucose Data And Events And Apparatuses Thereof
US11612363B2 (en) 2012-09-17 2023-03-28 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US11896371B2 (en) 2012-09-26 2024-02-13 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US10842420B2 (en) 2012-09-26 2020-11-24 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9907492B2 (en) 2012-09-26 2018-03-06 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US10463282B2 (en) * 2012-10-04 2019-11-05 Roche Diabetes Care, Inc. System and method for assessing risk associated with a glucose state
US11406296B2 (en) * 2012-10-04 2022-08-09 Roche Diabetes Care, Inc. System and method for assessing risk associated with a glucose state
US20140100435A1 (en) * 2012-10-04 2014-04-10 Roche Diagnostics Operations, Inc. System and method for assessing risk associated with a glucose state
JP2015532138A (en) * 2012-10-04 2015-11-09 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト System and method for assessing risks associated with glucose status
RU2665157C2 (en) * 2012-10-04 2018-08-28 Ф.Хоффманн-Ля Рош Аг System and method for assessing risk associated with glycemic state
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9801577B2 (en) 2012-10-30 2017-10-31 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US10188334B2 (en) 2012-10-30 2019-01-29 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US10874336B2 (en) 2013-03-15 2020-12-29 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US11324898B2 (en) 2013-06-21 2022-05-10 Tandem Diabetes Care, Inc. System and method for infusion set dislodgement detection
US11229382B2 (en) 2013-12-31 2022-01-25 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US11717225B2 (en) 2014-03-30 2023-08-08 Abbott Diabetes Care Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems
US20160030670A1 (en) * 2014-08-01 2016-02-04 The General Hospital Corporation Blood Glucose and Insulin Control Systems and Methods
US11812936B2 (en) 2014-09-03 2023-11-14 Hill-Rom Services, Inc. Apparatus and methods for monitoring a sleeping subject
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
EP3319511A4 (en) * 2015-08-07 2019-03-20 Trustees of Boston University Glucose control system with automatic adaptation of glucose target
US11744945B2 (en) 2015-08-07 2023-09-05 Trustees Of Boston University Glucose control system with automatic adaptation of glucose target
US10842934B2 (en) 2015-08-07 2020-11-24 Trustees Of Boston University Glucose control system with automatic adaptation of glucose target
EP3957233A3 (en) * 2015-08-07 2022-05-11 Trustees of Boston University Glucose control system with automatic adaptation of glucose target
WO2017027459A1 (en) 2015-08-07 2017-02-16 Trustees Of Boston University Glucose control system with automatic adaptation of glucose target
US10835671B2 (en) 2016-01-14 2020-11-17 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
US10780223B2 (en) 2016-01-14 2020-09-22 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
US10806859B2 (en) 2016-01-14 2020-10-20 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
US10307538B2 (en) * 2016-01-14 2019-06-04 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
US11857763B2 (en) 2016-01-14 2024-01-02 Insulet Corporation Adjusting insulin delivery rates
US11147921B2 (en) 2016-01-14 2021-10-19 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
US20180089395A1 (en) * 2016-09-27 2018-03-29 Bigfoot Biomedical, Inc. Personalizing preset meal sizes in insulin delivery system
US11229751B2 (en) * 2016-09-27 2022-01-25 Bigfoot Biomedical, Inc. Personalizing preset meal sizes in insulin delivery system
US20180085532A1 (en) * 2016-09-27 2018-03-29 Bigfoot Biomedical, Inc. Medicine injection and disease management systems, devices, and methods
US11806514B2 (en) 2016-09-27 2023-11-07 Bigfoot Biomedical, Inc. Medicine injection and disease management systems, devices, and methods
US10426896B2 (en) * 2016-09-27 2019-10-01 Bigfoot Biomedical, Inc. Medicine injection and disease management systems, devices, and methods
US20180099092A1 (en) * 2016-10-06 2018-04-12 Medtronic Minimed, Inc. Infusion systems and methods for automated exercise mitigation
US10561788B2 (en) * 2016-10-06 2020-02-18 Medtronic Minimed, Inc. Infusion systems and methods for automated exercise mitigation
US11096624B2 (en) 2016-12-12 2021-08-24 Bigfoot Biomedical, Inc. Alarms and alerts for medication delivery devices and systems
CN108261591A (en) * 2016-12-30 2018-07-10 上海移宇科技股份有限公司 A kind of closed loop control algorithm of artificial pancreas
US10758675B2 (en) 2017-01-13 2020-09-01 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US11027063B2 (en) 2017-01-13 2021-06-08 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US10610644B2 (en) 2017-01-13 2020-04-07 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US11446439B2 (en) 2017-01-13 2022-09-20 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US11033682B2 (en) 2017-01-13 2021-06-15 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US10881793B2 (en) 2017-01-13 2021-01-05 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10583250B2 (en) 2017-01-13 2020-03-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10881792B2 (en) 2017-01-13 2021-01-05 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US11511039B2 (en) 2017-01-13 2022-11-29 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US10500334B2 (en) 2017-01-13 2019-12-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US11565045B2 (en) 2017-01-13 2023-01-31 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
US11706876B2 (en) 2017-10-24 2023-07-18 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US20220044785A1 (en) * 2018-04-23 2022-02-10 Medtronic Minimed, Inc. Determination of adjustments to fluid delivery settings
US11158413B2 (en) * 2018-04-23 2021-10-26 Medtronic Minimed, Inc. Personalized closed loop medication delivery system that utilizes a digital twin of the patient
USD1014513S1 (en) 2018-08-20 2024-02-13 Tandem Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
USD918227S1 (en) 2018-08-20 2021-05-04 Tandem Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
USD980232S1 (en) 2018-08-20 2023-03-07 Tandem Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
US11224693B2 (en) 2018-10-10 2022-01-18 Tandem Diabetes Care, Inc. System and method for switching between medicament delivery control algorithms
US11135365B2 (en) 2019-07-16 2021-10-05 Beta Bionics, Inc. Ambulatory medicament device with security override passcode
US10960137B2 (en) 2019-07-16 2021-03-30 Beta Bionics, Inc. Blood glucose control system with automated backup therapy protocol generation
US11103638B2 (en) * 2019-07-16 2021-08-31 Beta Bionics, Inc. Ambulatory medicament device with gesture-based control of medicament delivery
US11116902B2 (en) 2019-07-16 2021-09-14 Beta Bionics, Inc. Blood glucose control system with control parameter modification
US11744947B2 (en) 2019-07-16 2023-09-05 Beta Bionics, Inc. Glucose control system with control parameter modification
US11766518B2 (en) 2019-07-16 2023-09-26 Beta Bionics, Inc. Glucose level control system with control parameter modification
US10940267B2 (en) 2019-07-16 2021-03-09 Beta Bionics, Inc. Blood glucose control system with real-time glycemic control optimization
US11154656B2 (en) 2019-07-16 2021-10-26 Beta Bionics, Inc. Blood glucose control system with medicament bolus recommendation
USD931306S1 (en) 2020-01-20 2021-09-21 Tandem Diabetes Care, Inc. Display screen or portion thereof with graphical user interface
USD980857S1 (en) 2020-03-10 2023-03-14 Beta Bionics, Inc. Display screen with graphical user interface
USD981439S1 (en) 2020-03-10 2023-03-21 Beta Bionics, Inc. Display screen with animated graphical user interface
USD980858S1 (en) 2020-03-10 2023-03-14 Beta Bionics, Inc. Display screen with transitional graphical user interface
US11581080B2 (en) 2020-12-07 2023-02-14 Beta Bionics, Inc. Ambulatory medicament pump voice operation
US11688501B2 (en) 2020-12-07 2023-06-27 Beta Bionics, Inc. Ambulatory medicament pump with safe access control
US11610661B2 (en) 2020-12-07 2023-03-21 Beta Bionics, Inc. Ambulatory medicament pump with safe access control
WO2023036878A1 (en) 2021-09-08 2023-03-16 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Use of diazirine linker for drug conjugates
US11925788B2 (en) 2022-03-02 2024-03-12 Beta Bionics, Inc. Ambulatory medicament device with motion detection and gesture-based control
US11918783B2 (en) * 2023-04-20 2024-03-05 Insulet Corporation Infusion pump system and methods

Also Published As

Publication number Publication date
US20160106919A1 (en) 2016-04-21
WO2010039743A1 (en) 2010-04-08
US11749410B2 (en) 2023-09-05
US10685749B2 (en) 2020-06-16
US20170193184A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
US11749410B2 (en) Dynamic display of glucose information
US20090164251A1 (en) Method and apparatus for providing treatment profile management
US8732188B2 (en) Method and system for providing contextual based medication dosage determination
US20190175119A1 (en) Method and system for providing integrated analyte monitoring and infusion system therapy management
US10448834B2 (en) Smart messages and alerts for an infusion delivery and management system
US11445910B2 (en) Method and system for providing data management in integrated analyte monitoring and infusion system
JP4997248B2 (en) System and method for determining drug administration information
KR101793015B1 (en) Graphical user interface pertaining to a bolus calculator residing on a handheld diabetes management device
US20160203275A1 (en) Systems, devices, and methods for analyte monitoring and/or drug delivery
JP5112301B2 (en) System and method for intervening a user in a diabetes control device
JP2010508097A (en) Method for processing temporal sequences of measurements of time-dependent parameters
US20230154625A1 (en) Dynamic display of glucose information

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABBOTT DIABETES CARE, INC.,CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAYTER, GARY;DUNN, TIMOTHY CHRISTIAN;REEL/FRAME:022451/0453

Effective date: 20090313

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION